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Abstract
Phosphatidylinositol 3-kinase (PI3K)/Akt Signaling Pathway and Angiogenesis
Zongxian Cao
Angiogenesis, the formation of new blood vessels from preexisting ones, is tightly controlled
under physiological conditions, and deregulated angiogenesis contributes to many pathological
situations. This study investigates the role of PI3K/Akt pathway in both physiological and
pathological angiogenesis. Angiopoietin-1 (Ang1) is an endothelial specific growth factor that
plays a critical role in vessel maturation and stabilization during angiogenesis. We found that
Ang1 potently induced p70S6K1 activation in human umbilical vein endothelial cells (HUVECs).
p70S6K1 is a downstream target of PI3K, but its role in angiogenesis has not be defined. In the
work shown in Chapter 2, p70S6K1 activity in HUVECs was modified by adenovirus-mediated
gene transfer, and we provided first evidence that p70S6K1 is directly involved in Ang1-induced
angiogenic endothelial responses, including cell migration, invasion, survival, and capillary
morphogenesis. We also examined the effect and mechanisms of action of insulin-like growth
factor-I (IGF-I) on the expression of cyclooxygenase-2 (COX-2), which is a crucial player in
angiogenesis and tumorigenesis. In Chapter 3, we showed that IGF-I efficiently upregulated
COX-2 expression in human ovarian cancer cells, which was differentially regulated by PI3K,
MAPK, and PKC signaling pathways at transcriptional and/or post-transcriptional levels. In the
study shown in Chapter 4, we selectively modulated PI3K/Akt signaling in either human
microvascular endothelial cells or cancer cells, and examined the effects on tumor angiogenesis
using a chimeric tumor model. We found that PI3K and Akt activities in both endothelial cells
and tumor cells contributed to tumor growth and angiogenesis, suggesting that targeting
PI3K/Akt signaling in both cellular compartments may be more effective for anti-cancer therapy.
In Chapter 5, we demonstrated that resveratrol has a strong inhibitory effects on hypoxiainducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF) expression in
human ovarian cancer cells. The effects are associated with suppression of PI3K/Akt and MAPK
pathways, interference with protein translational machinery, and enhancement of HIF-1α protein
degradation through the proteasome. This work provides a better understanding of the molecular
basis of angiogenesis, which we hope may facilitate the identification of novel therapeutic targets
in the future.
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Chapter 1

Introduction and Literature Review
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1. Phosphatidylinositiol 3-kinase (PI3K)/Akt signaling pathway

Phosphatidylinositiol 3-kinase (PI3K) was initially found to form complexes with some viral
oncoproteins such as v-Src and v-Ros, and attracted considerable scientific attention because of
its involvement in malignant transformation (1-4). PI3K is a heterodimer composed of a
regulatory subunit (p85) and a catalytic (p110) subunit, and appears to possess both lipid kinase
and protein kinase activity (5;6). p85 subunit negatively regulates the catalytic activity of its
associated p110 subunit, and this inhibition is alleviated by binding of the p85 SH2 domain to
specific phosphotyrosine sequences generated by receptor or nonreceptor tyrosine kinases, and
thereby leads to enzymatic activation of PI3K (7;8). GTP-associated Ras can directly bind to
p110 catalytic subunit and stimulates the catalytic activity of PI3K (9). Upon activation, PI3K
phosphorylates

phosphatidylinositol

at

the

3’-OH

of

the

inositol

ring,

producing

phosphatidylinositol (3,4,5) trisphosphate (PIP3), which functions as lipid second messenger. The
tumor suppressor PTEN is a phosphoinositide 3-phosphatase that specifically removes the
phosphate group from the D3 position and thereby antagonizes the PI3K activity (10;11). A
number of pleckstrin (PH) domain-containing proteins, including the serine/thrionine kinase Akt,
bind to PIP3 and are recruited to the inner surface of plasma membrane. PIP3 also recruits
phosphoinositide dependent kinase 1 (PDK1) to the plasma membrane. Full activation of Akt
requires phosphorylation of the T308 and S473 residues by PDK1 and a still controversial PDK2,
respectively (12;13). Akt is the key downstream target of PI3K that transmits most, if not all, the
signals from PI3K. A large number of Akt downstream effectors have been identified, such as
Bad, caspase-9, Forkhead (FH) trsanscription factors, IκB kinases (IKKs), eNOS, BRCA1,
mTOR, p70S6K1, GSK-3β, IRS-1, Glut4, E2F, p21, MDM2, and hTERT (14;15). PI3K also
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directly affects cytoskeletal dynamics through activation of Rac and Rho GTPases (16;17). The
activation of TEC family of tyrosine kinases (Btk, Itk, and Tec), which have an N-terminal PH
domain, is also mediated by PI3K (18). Therefore, PI3K/Akt pathway has been emerging as one
of the most important signal events involved in a variety of key cellular processes, including cell
survival, cell proliferation, protein synthesis, glucose metabolism, and cell motility (19).

2. PI3K signaling and angiogenesis

Blood vessels are first formed by the process of vasculogenesis, which involves in situ
differentiation of endothelial cells from mesodermal precursors and their organization into a
primary vascular plexus. This primary capillary plexus is extended by a process called
angiogenesis, in which new blood vessels are formed from the pre-existing vasculature (20).
Vasculogenesis occurs only during early embryogenesis, whereas angiogenesis is required for
the normal growth of both embryonic and postnatal tissues. Angiogenesis is a complex process,
involving a high degree of spatial and temporal coordination between different cell types.
Vascular endothelial cells play a pivotal role in new blood vessel formation. The process of
angiogenesis requires that endothelial cells detach from pericytes (PC) and extracellular matrix
(ECM); proliferate, migrate and form endothelial tubes; and recruit peri-endothelial supporting
cells (pericytes for small capillaries; smooth muscle cells for larger vessels) to encase the
endothelial tubes. Angiogenesis is crucial in many physiological processes, including embryonic
development, female reproductive cycle, wound healing, tissue repair and organ regeneration. It
also contributes to several pathological situations such as diabetic retinopathy, rheumatoid
arthritis, and tumor progression and metastasis.
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The process of angiogenesis can be considered to have two phases: the induction and
response phases. The former includes the production of angiogenic cytokines by host or/and
tumor cells, and the latter refers to the functional responses of endothelial cells to these stimuli.
PI3K signaling pathway appears to play a key role in both aspects of angiogenesis.

2. 1. Role of PI3K/Akt signaling in the induction of angiogenic factors
Under physiological conditions, angiogenesis is tightly regulated through a local balance
between angiogenic stimulators (e.g., VEGF, bFGF, TGF-beta, PDGF) and angiogenic inhibitors
(e.g., thrombospondin-1 (TSP-1), tissue inhibitor of MMP-1, angiostatin, endostatin). The robust
formation of new blood vessels in many pathological settings is due to either a decrease in levels
of inhibitors, an increase in levels of inducers, or a combination of both (21). VEGF is the most
powerful and selective angiogenic inducers. VEGF is expressed by many types of cells
surrounding the area of angiogenesis, including the activated endothelial cells themselves. A
majority of malignant tumors overexpress VEGF, and tumor cell-derived VEGF was considered
to be the primary stimulus for tumor angiogenesis (22). One of the major stimuli for VEGF
expression in tumor cells is intratumoral hypoxia, a characteristic property of advanced solid
tumors, which is caused by the structural and functional abnormalities of the tumor
microvasculature, rapid expansion of tumor mass, and tumor-associated anemia (23;24).
Hypoxia induces VEGF expression primarily through the induction of hypoxia-inducible factor-1
(HIF-1) (25;26). HIF-1 is a heterodimeric transcriptional factor composed of HIF-1α and HIF-1ß
subunits (27). HIF-1α is rapidly accumulated under hypoxia conditions due to the inhibition of
ubiquitin-mediated degradation, and subsequently dimerizes with the constitutively expressed
HIF-1β, and activates transcription of target genes, including VEGF (23). HIF-1α also regulates
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VEGF expression under normoxic conditions. Many growth factors and oncogenic proteins can
induce HIF-1α-mediated VEGF expression in a PI3K/Akt-dependent manner (28-31). Forced
expression of PI3K or Akt was shown to sufficiently induce VEGF expression in fibroblasts and
endothelial cells (32). Consistently, it was found that loss of PTEN upregulates VEGF
production in prostate cancer cells, and reintroduction of PTEN decreases VEGF production (33).
The PI3K specific inhibitor LY294002 reduces both constitutive and hypoxia-induced VEGF
expression in ovarian cancer cells (34). In addition, PI3K controls hepatocyte growth factor
(HGF)-induced production of IL-8, which is another important angiogenic cytokine (35). In a
mouse glioma tumor model, overexpression of PTEN suppresses tumor angiogenesis, which
correlates with increased TSP-1 expression in the tumor cells (36). PTEN and PI3K inhibitor
LY294002 were shown to be able to induce transactivation of p53 in glioma tumor cells, and
systemic administration of LY294002 significantly decreases tumor-induced angiogenesis and
tumor growth in vivo (37). A more recent study demonstrated that activation of integrin-linked
kinase (ILK) resulted in HIF-1α-mediated VEGF expression in prostate cancer cells, which
contributed to tumor growth and tumor angiogenesis in vivo (38).

2. 2. Role of PI3K/Akt signaling in endothelial responses to angiogenic factors
Vascular endothelial cells play a central role during angiogenesis. A single layer of
endothelial cells (termed endothelium) lines the lumen surface of mature capillaries. Basement
membrane and a layer of cells called pericytes surround the endothelium and maintain the
integrity of the vessels. Endothelial cells are the biological target of most angiogenic factors.
Upon stimulation by angiogenic factors, endothelial cells become activated and secrete proteases
that digest the basement membrane and break the cell-cell junctions between endothelial cells.
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The cells then migrate, proliferate and form sprouts towards the source of the angiogenic stimuli.
Neighboring blind-ended sprouts then join together to form a capillary loop, which eventually
matures into functional blood vessels. During the process of angiogenesis, the continuous
presence of angiogenic factors is the prerequisite for endothelial cell proliferation, migration,
survival, and differentiation into tube structures. The PI3K/Akt signaling pathway has been
recognized as the key signaling event involved in the regulation of these angiogenic endothelial
responses.

2. 2. 1. Akt directly mediates the activation of endothelial nitric oxide synthase (eNOS)
It is well established that endothelial-derived nitric oxide (NO) plays an essential role in
postnatal neovascularization (39;40). NO production in endothelial cells is catalyzed by
endothelial nitric oxide synthase (eNOS). Akt was shown to phosphorylate eNOS at Ser1177,
leading to a persistent, calcium-independent eNOS activation (41;42). The activity of eNOS is
also regulated by subcellular localization and protein-protein interactions. eNOS has been shown
to localize in caveolae and to interact with caveolin-1, which inhibits eNOS activity (43-45).
eNOS was also shown to interact with heat shock protein 90 (Hsp90) upon stimulation with
VEGF or shear stress, and this interaction enhances eNOS activity (46). Interestingly, Akt also
interacts with Hsp90 upon stimulation and this interaction enhances Akt enzymatic activity (47).
It was suggested that Hsp90 may serve as a scaffold protein for the efficient phosphorylation of
eNOS by Akt at caveolae (48)
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2. 2. 2. Role of PI3K/Akt signaling in VEGF-induced endothelial responses
Binding of growth factors to the cognate tyrosine kinase receptors represents the
prototypical model of PI3K activation. As an endothelial-specific growth factor, VEGF binds to
its receptor KDR and induces positive angiogenic responses. In cultured human umbilical vein
endothelial cells (HUVECs), the p85 subunit of PI3K was shown to constitutively associate with
KDR (49). VEGF induces phosphorylation of p85 and subsequent PI3K activation, which is
required for VEGF-induced EC proliferation(49;50). VEGF/KDR-induced anti-apoptotic effect
is also PI3K and Akt dependent (51;52). VEGF-induced EC migration was inhibited by
overexpression of a dominant-negative Akt. Conversely, introduction of a constitutively active
Akt initiated cell migration in the absence of VEGF (53). In an in vivo model, transduction of a
dominant-negative Akt was shown to block VEGF-induced vascular permeability, whereas
expression of an active form of Akt mimicked the effect of VEGF (54). Forced expression of
PTEN in HUVECs inhibited VEGF-induced cell migration and proliferation. In contrast,
expression of a dominant-negative PTEN enhanced VEGF-mediated cell migration, proliferation
and tube formation (55). Interestingly, activation of PI3K/Akt signaling can in turn increase
VEGF expression (56-58). It is plausible that VEGF-induced PI3K/Akt signaling mediates an
autocrine expression of VEGF that amplifies VEGF functions.

2. 2. 3. Role of PI3K/Akt signaling in angiopoietin-1-induced endothelial responses
Angiopoietin-1 (Ang1) was identified in 1996 as a ligand for receptor Tie2, which is
expressed almost exclusively in endothelial cells (59;60). As an endothelial specific growth factor,
Ang1 plays a very important role in angiogenesis. Ang1 is critical for vessel maturation and
stabilization at the later stages of angiogenesis by recruiting mural cells to support the primitive
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endothelial tubes (61;62). Ang1 does not stimulate endothelial cell proliferation, rather it is a
potent factor for endothelia cell survival (63-66), and can induce endothelial cell migration (67),
sprouting (68;69), and tube formation (70-72). Binding of Ang1 to its receptor Tie2 activates PI3K
/Akt signaling pathway (73). Tyrosine 1101 of Tie2 receptor was shown to associate with the p85
subunit of PI3K, inducing PI3K and Akt activation (74). PI3K/Akt signaling plays an essential role
in Ang1/Tie2-induced angiogenic responses in endothelial cells, such as cell survival, migration,
sprouting, and tube formation (75-80). The anti-apoptosis protein survivin has recently been shown
to regulate Ang1-mediated endothelial cell survival in a PI3K/Akt-dependent manner (81). In
addition, PI3K/Akt pathway modulates Ang1-induced increased nitric oxide release and activation
of matrix metalloproteinase-2 (MMP-2) in endothelial cells (82;83).

3. Vascular endothelial growth factor, angiopoietin-1 and angiogenesis

Many angiogenic factors such as bFGF, PDGF, and TGF-beta have profound effects in
endothelial cells. However, such factors also act on other cells, and these nonspecific growth
factors are not the ideal targets for the treatment of angiogenesis-related diseases. Vascular
endothelial growth factor (VEGF) and angiopoietin-1 (Ang1) are the only growth factors proven
to be specific for endothelial cells and are critical for angiogenesis both in vitro and in vivo.
VEGF is absolutely required for the vascular morphogenesis during the early stages of blood
vessel formation, whereas Ang1 is essential for vessel maturation and stabilization at the later
stages of vascular development. VEGF and Ang1 have been shown to be useful in inducing
functional neovascularization for therapeutic angiogenesis (84-86).
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3. 1. VEGF and angiogenesis
VEGF was identified independently as vascular permeability factor (VPF) and vascular
endothelial cell-specific growth factor in 1980s (87;88). There are at least six isoforms of human
VEGF resulting from alternative mRNA splicing, of which VEGF121, VEGF165 and VEGF189 are
the three predominant variants (89). VEGF binds to endothelial cell–specific tyrosine kinase
receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR, also known as Flk-1 in mice). Although
VEGFR-1 has the highest affinity for VEGF, VEGF binding does not activate the receptor and
does not induce any positive endothelial cell responses (90). VEGFR-2 is tyrosinephosphorylated efficiently upon VEGF binding and mediates major positive signals from VEGF
(89;90).

The lack of significant cellular responses to VEGFR-1 stimulation has led to

speculation that VEGFR-1 acts as a decoy receptor that sequesters VEGF from signaling through
VEGFR-2 (89). VEGF165 also binds to endothelial cell surface molecule neuropilin-1 (NRP1).
NRP1 acts as a co-receptor for binding of VEGF165 to KDR, increasing the affinity to about 10fold, making VEGF165 the strongest signaling molecule among the VEGF subtypes (91).
Extensive research over the last decade has elucidated the pivotal role of VEGF and its receptors
in the regulation of angiogenesis. VEGF induces pronounced angiogenic responses in a variety
of in vitro and in vivo models (92). VEGF has multiple effects on endothelial cells: it stimulates
cell proliferation, migration, survival, activation of eNOS, release of matrix metalloproteinases
(MMPs) and plasminagen activators (PAs) (92-94), all of these cellular events are critical for
angiogenesis. Furthermore, targeted disruption of VEGF and its receptors results in murine
embryonic lethality that correlated with remarkable vascular defects. VEGFR-2 knockout mice
lack both endothelial cells and hematopoietic precursors, and die by embryonic day 8.5 (E8.5)
due to lack of vasculogenesis and very low hematopoiesis (95). VEGFR-1 knockout mice also
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die around E8.5. However, these mice have normal hematopoietic progenitors and abundant
endothelial cells but fail to assemble into tubes and functional vessels (96). Disruption of even a
single VEGF allele results in mouse embryo death between days 11 and 12 due to abnormal
vessel and blood island formation (97;98). The VEGF deficient mice have delayed endothelial
differentiation and impaired endothelial cell sprouting and lumen formation, suggesting that
VEGF is required for early vascular development (97;98). VEGF also plays an important role in
tumor-induced angiogenesis. A majority of malignant tumor cells overexpress VEGF, and tumor
cells-derived VEGF is believed to be the primary stimulus for tumor angiogenesis (22).
Inhibition of VEGF function shows potent anti-tumor effects in experimental and clinical studies,
and VEGF is therefore considered as one of the primary targets for anti-angiogenic therapy of
cancer (99).

3. 2. Angiopoietin-1 and angiogenesis
Receptor Tie1 (tyrosine kinase with immunoglobulin and epidermal growth factor
homology domain) and Tie2 (also known as Tek) represent another family of receptor tyrosine
kinases (RTKs) that are selectively expressed on vascular endothelial cells (59;60). So far, four
ligands, Ang1 to Ang4, have been identified for Tie2 receptor, whereas Tie1 is still an orphan
receptor (100;101). Ang1 and Ang2 are the best-characterized angiopoietins. They have similar
binding affinities for Tie2, but only Ang1 induces Tie2 receptor activation (102). Tie2 knockout
mice die around E9.5~10.5. In Tie2-/- mice, endothelial cells are present in normal numbers and
can be assembled into tubes, but the vessels are immature, lacking branching networks and periendothelial supporting cells (103). Ang1 knockout mice have largely similar phenotypes
(103;104). Mice overexpressing Ang2 have similar vascular defects to Ang1 and Tie2 knockout

10

mice, supporting the idea that Ang2 is an antagonist for the Ang1/Tie2 system (102). In vitro
studies showed that Ang1 has no effect on endothelial cell proliferation, rather it is a strong
survival factor for endothelial cells (105-108). Ang1 is also involved in endothelial cell
migration and sprouting to form tube-like structures in vitro (109;110). Ang1/Tie2 system seems
to play a crucial role in recruitment of periendothelial cells (also termed mural cells) during
angiogenesis. It has been recognized that interactions between endothelial cells (ECs) and mural
cells (MCs) are critical for vessel stability and integrity maintenance: ECs and MCs form tight
contacts by interdigitations and gap junctions; MCs inhibit EC proliferation and migration in part
due to the activation of TGF-β1; paracrine expression of VEGF and Ang1 is essential for vessel
stability by providing continous survival signals to ECs (62;111;112). Transgenic overexpression
of Ang1 in vivo increases vascularization (113-115). Importantly, blood vessels induced by Ang1
are leakage-resistant (116). Ang1 has therapeutic potential for diseases with increased vascular
leakage, e.g., diabetic retinopathy (117), and appears to be of benefit in inducing functional
neovascularization when it is co-administered with VEGF (118-120).
The role of Ang1 in tumor angiogenesis is not clear. Expression levels of Ang1 vary
among different tumor types (121). Interestingly, despite the stimulatory role in physiological
angiogenesis, ectopic overexpression of Ang1 in several types of cancer cells decreases tumor
angiogenesis in xenograft tumor models, suggesting an inhibitory role of Ang1 in tumor
angiogenesis (121). By contrast, high levels of Ang2 are frequently detected in a variety of
highly vascularized human tumors, and elevated Ang2 expression was shown to correlate with
poor prognosis (121). It is believed that Ang2 plays an important role in the initiation of tumor
angiogenesis.
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3. 3. Complementary actions of VEGF and Ang1 in angiogenesis
There appears to be an elaborate collaboration between VEGF, Ang1 and Ang2 in the
process of angiogenesis. In the absence of VEGF, Ang2 induces vessel regression by
antagonizing Ang1/Tie2 signaling. In the presence of VEGF, however, Ang2 enhances
angiogenesis presumably by blocking Ang1/Tie2 function and destabilizing the vascular
structure and thereby exposing the endothelial cells to VEGF stimulation (62;111;112). Blood
vessels induced by VEGF are inherently leaky (122). In contrast, Ang1-induced blood vessels
are

leakage-resistant

(123).

Co-administration

of

Ang1

counteracts

VEGF-induced

hyperpermeability of blood vessels and augments VEGF-induced angiogenesis (124-126).

4. Role of cyclooxygenase-2 in angiogenesis and human cancer

Cyclooxygenases (COXs) are the rate-limiting enzymes for prostaglandin (PG) biosynthesis.
Three isoforms of cyclooxygenases have been identified so far, termed COX-1, COX-2, and
COX-3. COX-1 is constitutively expressed in most human tissues, and appears to be responsible
for the production of PGs that modulate physiological functions. COX-3 is a variant of COX-1
and is abundant in cerebral cortex (127). In contrast to COX-1, COX-2 is expressed at low or
undetectable levels in most normal tissues, but can be rapidly induced by inflammatory stimuli
(128;129). The first step of PG synthesis is hydrolysis of membrane phospholipids by
phospholipase A2 (PLA2) to produce free arachidonic acid. COXs catalyze a reaction by which
oxygen is inserted into arachidonic acid to form PGG2. PGG2 is an unstable intermediate and is
rapidly converted to PGH2 by the peroxidase activity of COXs. Finally, several specific
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synthases/isomerases convert PGH2 into thromboxane A2 (TXA2) and a series of PGs (PGE2,
PGI2, PGD2, etc.) (130-132). Prostaglandins mediate acute and chronic inflammation and have
important homeostatic functions, e.g., the maintenance of gastric mucosal integrity. COXs are of
particular clinical significance because they are the main target for nonsteroidal antiinflammatory drugs (NSAIDs) such as aspirin. Recently, a growing body of evidence suggests
that COXs are also critically involved in the process of angiogenesis and the development and
progression of human cancer.

4. 1. Cyclooxygenase-2 and angiogenesis
Inflammatory stimuli can acutely induce COX-2 expression. It is known that many
inflammatory mediators (e.g., IL-1ß, TNF-α) are potent inducers for angiogenesis (133). Indeed,
COX-2 was shown to play a pivotal role in angiogenesis at site of inflammation (134).
Importantly, the classical angiogenic factor VEGF- and bFGF-induced angiogenesis appears to
require the induction of COX-2 (135-137). The proangiogenic effects of COX-2 are mediated
primarily by three products of arachidonic metabolism: TXA2, PGE2, and PGI2, which are
involved in multiple key points of angiogenesis (138). Downstream proangiogenic actions of
these eicosanoid products include: (a) production of vascular endothelial growth factor; (b)
promotion of vascular sprouting, migration, and tube formation; (c) inhibition of endothelial cell
apoptosis by stimulation of Bcl-2 or Akt activation; (d) induction of matrix metalloproteinases;
and (e) activation of epidermal growth factor receptor-mediated angiogenesis. Recent studies
indicated that COX-2 plays a critical role in tumor-induced angiogenesis as well (139). High
levels of COX-2 were detected in the area of invading neovasculature of various human cancers
(140). COX-2 overexpressing colon cancer cells produce large amounts of proangiogenic factors,

13

including VEGF, bFGF, TGF-β, PDGF, and endothelin-1 (141). Furthermore, PGE2 can induce
hypoxia-inducible factor-1 expression in human prostate cancer cells (142). The dual COX-1/-2
inhibitor diclofenac was shown to inhibit colorectal cancer growth via the suppression of
angiogenesis (143). Also, tumors implanted in COX-2 (-/-) mice display a reduction in vascular
density and tumor growth (144).

4. 2. Cyclooxygenase-2 and human cancer
Multiple lines of evidence support that COX-2 plays a crucial role in tumor development and
progression. Many human cancers produce higher levels of COX-2 and PGE2 than the normal
tissues (145). Overexpression of COX-2 in human cancer is a consequence of deregulated
transcriptional and posttranscriptional control (146;147). COX-2 expression can be induced by
inflammatory cytokines and by growth factors as well as by activation of oncogenes and
inactivation of tumor suppressor genes (148). Genetic studies showed that transgenic mice that
overexpressed

COX-2 in various types of tissues developed malignant tumors (149;150).

Conversely, the development and growth of tumors were markedly retarded in COX-2 knockout
mice (151;152). The role of COX-2 in carcinogenesis is further supported by recent experimental
and clinical studies which demonstrated the effectiveness of selective COX-2 inhibitors in the
prevention and treatment of human cancers (153;154). The biological effects of COX-2 are
mediated by its prostanoid products that affect multiple mechanisms implicated in carcinogenesis.
For example, PGE2 can stimulate cell proliferation and motility while inhibiting apoptosis and
immune surveillance (155). Importantly, COX-2-derived prostanoids are critically involved in
tumor angiogenesis as mentioned above.
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5. Anti-angiogenic therapy for cancer

It is a well established notion that solid tumor growth is angiogenesis dependent (156). The
progression of tumors can be divided into two phases: the pre-vascular (avascular) and the
vascular phase (157). Tumors may persist in situ for a long period of time (from months to years)
in an avascular, quiescent status. In this phase, the size of the tumor usually does not exceed a
few cubic millimeters because of the limited supply of nutrients and oxygen through passive
diffusion from the host vasculature. Once a tumor switches to an angiogenic phenotype, the
tumor grows rapidly and acquires an increased metastatic potential (157). After the recognition
of angiogenesis being absolutely required for solid tumor expansion, it was hypothesized that the
process of angiogenesis might be an attractive target for developing a novel anti-cancer strategy.
To date, anti-angiogenesis therapy is being considered a very promising approach for cancer
therapy based on the exciting results obtained from experimental animal models, and intense
clinical trials are ongoing to evaluate and validate this novel therapeutic tool.

5. 1. Biological rationale for anti-angiogenesis therapy
It has been recognized for a long time that tumor vessels are phenotypically different from
normal vessels with respect to organization, structure and function (158;159). Tumor vasculature
is structurally irregular and heterogeneous with arterovenous shunts, multiple loops, and spiral
motifs (158;159). They are also very leaky and less efficient for oxygen delivery, leading to
typical hypoxic characteristics (160). Importantly, tumor vessels are lined by actively dividing
endothelial cells, which overexpress some specific molecules such as endoglin, E-selectin,
endosialin, and VEGF receptors (161). Human tumor-derived endothelial cells show enhanced
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survival and proadhesive properties, and have increased angiogenic potential (162). The Akt
activity was found to be up-regulated and PTEN expression was decreased in tumor-derived
endothelial cells (162). The “activated” endothelial cells in tumor vessels are the primary target
for anti-angiogenic therapy. Endothelial cells in normal vessels are quiescent under physiological
conditions, and angiogenesis in adults is normally restricted. Therefore, the side effects of antiangiogenesis therapy is considered to be negligible (161). In addition, microvascular endothelial
cells are genetically stable as compared to tumor cells (163;164), so the potential of drug
resistance to anti-angiogenic therapy might be very low. Indeed, acquired resistance to antiangiogenesis drugs has not been clearly demonstrated in preclinical studies. Anti-angiogenic
therapy presents several other advantages over conventional therapy: (i) Intratumoral
endothelium overexpresses selective molecules that may be harnessed as more specific
therapeutic targets; (ii) Endothelial cells are easily accessible from the circulation; (iii) Some
anti-angiogenic compounds have synergistic effects when combined with cytotoxic drugs and
radiation therapy (165).

5. 2. Approaches to interfere with tumor angiogenesis
Anti-angiogenic agents can be divided into two classes: direct and indirect angiogenesis
inhibitors (166). Direct inhibitors target tumor vascular endothelial cells, inhibiting their ability
to proliferate, migrate, or survive in response to a spectrum of pro-angiogenic factors. Indirect
angiogenesis inhibitors inhibit the tumor production of pro-angiogenic factors or block the
expression of its receptor on endothelial cells. More and more anti-angiogenic compounds are
available for clinical evaluation in cancer patients, and many of these drugs target the VEGF
pathway. Actually, the VEGF system is considered to be the primary target for anti-angiogenic
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therapy of cancer. There are multiple possible strategies to inhibit VEGF function, including the
use of monoclonal antibodies against VEGF protein or receptors, VEGF receptor tyrosine kinase
inhibitors (TKRIs) and VEGF receptor targeted ribozymes. Other therapeutic targets include
matrix metalloproteinase inhibitors (MMPIs), and natural inhibitors, such as endostatin,
angiostatin, and thromobspondin-1 (TSP-1).

5. 2. 1. Monoclonal antibodies against VEGF protein or receptors
Bevacizumab (Avastin®; Genentech, Inc.) is a humanized monoclonal antibody directed
against VEGF-A. It has been tested in phase I studies in combination with chemotherapy with a
good safety profile (167;168). In phase II studies, the combination of bevacizumab and
chemotherapy resulted in an increased response rate and prolonged progression-free survival in
metastatic colon cancer, stage IIIB–IV non-small cell lung cancer (NSCLC), and advanced breast
cancer (161;169). Several phase III studies of bevacizumab treatment combined with
chemotherapy are ongoing, and the results for the treatment of colorectal cancer are quite
promising. Monoclonal antibodies against the extracellular domain of VEGF receptor have also
been developed, and shown effectiveness in inhibiting tumor growth in animal models (170). So
far, no clinical data are available for these VEGF receptor neutralizing antibodies.

5. 2. 2. VEGF receptor tyrosine kinase inhibitors
Another class of angiogenesis inhibitors currently under development is the smallmolecules that inhibit VEGF receptor tyrosine kinase. Semaxanib(SU5416) is an inhibitor of
VEGF-R2 (KDR), VEGF-R1 (Flt) and c-kit (171). SU5416 inhibits growth and metastasis of
lung, colon, breast, prostate cancers, melanoma, glioma and sarcoma xenografts (172-174). In a
Phase I clinical trial for patients with gastrointestinal, breast, or lung cancer, a weekly scheduled
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dose of SU5416 showed signs of clinical benefit as defined by tumor regression or disease
stabilization for at least 12 weeks (175). The most common serious drug-related toxicity was
headache, often associated with nausea and vomiting (175). However, in a randomized phase II
study, no significant disease-modifying effects of SU5416 were observed in prostate cancer
patients (176). In a phase III study of 737 untreated metastatic colorectal cancer patients,
SU5416 resulted in severe toxicity, and showed no improvement in response rate, time to
progression, and overall survival (161). Therefore, SU5416 was not recommended for additional
study in cancer patients. Vatalanib (PTK787/ZK-222584) is a potent inhibitor of VEGFR-1 and
VEGFR-2 with good oral bioavailability (177). Phase II/III trials with vatalanib (PTK787) in
colorectal cancer are ongoing. ZD6474 is another oral compound that inhibits VEGFR-2,
VEGFR-3, and EGFR (178). Clinical evaluation of ZD6474 is still in early phases for cancer
patients refractory to conventional treatments.
Another strategy to block VEGF function is the administration of soluble VEGF
receptors. A soluble VEGF receptor was constructed by fusing the entire extracellular domain of
murine flk-1 to a six-histidine tag at the C-terminus (ExFlk.6His) (179). In vitro, recombinant
ExFlk.6His protein binds VEGF with high affinity, blocks the receptor activation, and inhibited
VEGF-induced endothelial cell migration and proliferation. In vivo, ExFlk.6His potently
inhibited corneal neovascularization induced by conditioned media prepared from a rat
mammary carcinoma cell line (179).

5. 2. 3. Natural peptide inhibitors of angiogenesis
Angiostatin and endostatin are potent endogenous inhibitors of angiogenesis. Angiostatin
is a 38-kD of plasminogen fragment generated by proteolytic cleavage. This circulating inhibitor
of angiogenesis interacts with vascular endothelial cells through at least 3 potential receptors:
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ATP synthase, angiomotin and αvβ3 integrin (180). Angiostatin inhibits endothelial growth in
vitro, and angiogenesis in vivo, and induces tumor dormancy in both primary and metastatic
tumors in mice (181;182). Endostatin is a 20 kD C-terminal fragment of collagen XVIII by the
action of elastase and other proteases (183). Endostatin specifically inhibits endothelial
proliferation, and induces endothelial cell apoptosis more potently than angiostatin (184).
Endostatin also acts on endothelial precursor cells that contribute to the de novo vessel formation
in tumors (185). Results from phase I studies are available for both agents, and have shown no
drug related toxicity.

5. 2. 4. Specific inhibitors of endothelial cell growth
One of the first compounds identified to specifically inhibit endothelial cell growth was
O-chloroacetylcarbamoyl fumagillol or AGM-1470/TNP-470, an analog of the fungus-derived
antibiotic fumagillin (186). TNP-470 was found to prevent endothelial cells from entering G1
phase of the cell cycle, and thereby decreasing cell proliferation (187). TNP-470 inhibits both
tumor growth and metastasis in animal models (186;188). Mild toxicity and high incidence of
apparent prolonged progression-free survival were reported in phase I/II clinical studies (189).
Several other endogenous molecules were found to directly inhibit endothelial cell growth,
including thrombospondin-1, platelet factor-4, and interferon-inducible protein-10 (189).
Some other novel approaches are emerging to interfere with tumor blood supply. Tumor
vasculature targeting aims to block tumor blood flow by a direct damage of endothelium within
the tumor, without affecting normal endothelium (190). This approach requires an absolutely
specific marker for tumor vasculature, and a variety of potential target candidates are under
investigation (191).
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6. Significance and relevance

Angiogenesis is a complex process that is tightly controlled by pro- and anti-angiogenic factors,
and involves the interaction and coordination between different cell types within the host
microenvironment. Deregulated angiogenesis contributes to many pathological situations
including tumor progression and metastasis. The proposed studies in this dissertation are
expected to provide better understanding of the molecular mechanisms of angiogenesis, which
would be of benefit for the development of novel strategies for anti-angiogenic therapy.
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Chapter 2

Modulation of Angiopoietin-1-induced Angiogenic Effects by p70S6K1
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Abstract
Angiopoietin-1 (Ang1) is an endothelial specific growth factor that is critical for vessel
maturation and stabilization during angiogenesis. We found that Ang1 markedly induces the
activation of p70S6K1 in human umbilical vein endothelial cells (HUVECs). p70S6K1 is a
downstream target of PI3K signaling and has emerged as an important regulator of cell cycle
progression and cell growth. However, little is known about the role of p70S6K1 in angiogenesis.
Here, we showed that inhibition of endogenous p70S6K1 activity in HUVECs by adenovirusmediated overexpression of a dominant-negative p70S6K1 mutant (p70S6K-KD) caused
remarkable changes in cell morphology, characterized by disruption of stress fiber formation,
cell rounding, and loss of cell polarity and motile structures. Overexpression of p70S6K-KD
completely blocked Ang1-induced cell migration. In contrast, expression of a constitutively
active p70S6K1 (p70S6K-CA) enhanced Ang1-induced cell migration. Ang1 significantly
reduced serum deprivation-induced cell death. p70S6K-KD completely abrogated the effect of
Ang1 on cell viability, whereas p70S6K-CA enhanced Ang1-mediated cell survival. Ang1
treatment also significantly increased cell invasion through the Matrigel. Inhibition of p70S6K1
activity markedly reduced Ang1-induced cell invasion. Correlated with its effect on cell invasion,
p70S6K1 also regulated Ang1-induced MMP-2 secretion and activation. Moreover, p70S6K-KD
significantly inhibited endothelial tube formation, whereas cells transduced with p70S6K-CA
form more tube structures in the presence or absence of Ang1. Taken together, this study
provides evidence that p70S6K1 is directly involved in Ang1-mediated angiogenic responses,
including endothelial cell migration, invasion, survival, and capillary morphogenesis, implying
an important role of p70S6K1 in angiogenesis.
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Introduction

Angiopoietin-1 (Ang1) is a ligand of the receptor tyrosine kinase Tie2, which is expressed
predominantly on endothelial cells (ECs) (1;2). Gene knockout studies suggested that Ang1 is
involved in the recruitment of mural cells to support the primitive endothelial tubes, thereby
contributes to vessel maturation and stabilization at the later stages of angiogenesis (3). Ang1
does not stimulate EC proliferation (3), rather it is a potent factor for EC survival (4-7), and
Ang1 can induce EC migration (8), sprouting (9;10), and tube formation (5;11;12). Transgenic
overexpression of Ang1 increases vascularization in vivo, and the blood vessels induced by Ang1
are leakage-resistant (13-15). Ang1 has therapeutic potential for diseases with increased vascular
leakage, e.g., diabetic retinopathy (16), and appears to be of benefit in inducing functional
neovascularization when it is co-administered with vascular endothelial growth factor (VEGF) to
produce therapeutic angiogenesis (17-19).
Binding of Ang1 to its receptor Tie2 activates phosphatidylinositol 3-kinase (PI3K) /Akt
signaling pathway (20). The PI3K/Akt signaling pathway has been recognized as the key signaling
event of Tie2 activation to regulate the angiogenic functions of Ang1. PI3K/Akt signaling plays
important roles in mediating Ang1-induced EC survival, migration, sprouting, and tube formation
(6;10;12;21-23). The anti-apoptotic protein survivin has recently been shown to regulate Ang1mediated EC survival in a PI3K/Akt-dependent manner (24). In addition, PI3K/Akt pathway
modulates nitric oxide release and activation of matrix metalloproteinase-2 (MMP-2) in human
endothelial cells in response to Ang1 stimulation (10;12).
The 70 kD ribosomal S6 kinase (p70S6K1) plays a critical role in the initiation of protein
synthesis. p70S6K1 phosphorylates the S6 ribosomal protein and stimulates the translation of a
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subset of mRNAs with a 5'-oligopyrimidine tract that encode major components of the protein
synthesis apparatus (25). p70S6K1 is activated by numerous mitogens, growth factors and
hormones. Activation of p70S6K1 occurs through a complex series of phosphorylation events on
several serine and threonine residues, which are mediated by PI3K, mTOR, and other kinases
(25;26). In addition to S6 ribosomal protein, many other substrates or downstream effectors of
p70S6K1 have been identified, and p70S6K1 has emerged as an important regulator of cell cycle
progression, cell growth, and cell motility (25-27). However, the role of p70S6K1 in
angiogenesis remains largely unclear. It is reported that VEGF induced a PI3K-dependent
activation of p70S6K1, and that inactivation of p70S6K1 by rapamycin inhibited VEGFstimulated HUVEC proliferation (28). A more recent study suggested that the PDGFRαp70S6K1 signaling in mesenchymal cells might be a target for rapamycin to suppress tumor
angiogenesis (29). In both studies, the pharmaceutical inhibitor rapamycin was utilized to inhibit
p70S6K1 activity. However, the target of rapamycin is the serine/threonine kinase mTOR
(mammalian target of rapamycin), which has other downstream effectors besides p70S6K1. In
the present study, we directly modified p70S6K1 activity in human endothelial cells using
adenoviral vector-mediated gene transfer, and aimed to define the role of p70S6K1 in Ang1induced angiogenic responses in human endothelial cells.

Materials and Methods

Cell Culture and Reagents
HUVECs were cultured in MCDB131 medium (Sigma, St. Louis, MO) supplemented with 10%
fetal bovine serum (FBS), 15 µg/ml EC growth supplement (ECGS, Upstate, Lake Placid, NY), 1
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ng/ml bFGF, 10 ng/ml EGF, 50 µg/ml heparin, 1 µg/ml hydrocortisone, 100 units/ml penicillin,
and 100μg/ml streptomycin. The cells were maintained at 37°C and 5% CO2 in a humid
environment. Cells at 4-6 passage were used in this study.
Recombinant human Ang1 was purchased from R & D Systems (Minneapolis, MN).
LY294002, PD98059, and rapamycin were from Calbiochem (La Jolla, CA). Antibodies against
phosphorylated S6 ribosomal protein (Ser235/236), phosphorylated p70S6K1 (Thr412/Ser424,
and Thr389), total p70S6K1, phosphorylated Akt (Ser473), total Akt, phosphorylated Erk1/2
(Thr202/Tyr204), and HA tag were obtained from Cell Signaling Technology (Beverly, MA).
Total Erk1/2 antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody against
β–actin was from Sigma (St. Louis, MO). Monoclonal antibody against poly(ADP-ribose)
polymerase (PARP) was purchased from R & D Systems (Minneapolis, MN). Growth factorreduced Matrigel was from BD Biosciences (San Jose, CA).

Adenovirus Preparation and Cell Infection
The construction of constitutively active p70S6K1 and kinase-dead p70S6K1 has been described
previously (30). Recombinant adenoviruses were generated using the AdEasy system as
previously described (31). A control virus carrying the green fluorescent protein (Ad-GFP) was
derived from the same vector system. The virus stock was purified by cesium chloride gradient
centrifugation. Viral titers were determined by using the BD Adeno-X™ Rapid Titer Kit (BD
Biosciences Clontech, Mountain View, CA). 10 multiplicity of infection (MOI) was used for
HUVEC infection, which consistently achieved more than 90% of transduction and no apparent
cell toxicity was observed.
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Western Blotting
Cell lysates were fractionated by SDS-PAGE and transferred to nitrocellulose membranes
(Schleicher & Schuell Biosciences, Keene, NH). The Blots were incubated with appropriately
diluted primary antibodies, followed by incubation with corresponding horseradish peroxidaseconjugated secondary antibody and visualized by enhanced chemiluminescence reagent (Pierce
Biotechnology, Rockford, IL).

Immunofluorescence Staining
HUVECs were seeded onto glass coverslips and cultured in normal growth medium. Cells were
fixed in 3.7% formaldehyde, washed in PBS, and permealized with 0.4% Triton-X100. Actin
filaments were stained with TRITC-phalloidin diluted to 1:1000 in 3% BSA in PBS. The
coverslips were washed and mounted on slides with Fluormount (Fisher, Pittsburgh, PA). A
Zeiss LSM 510 confocal microscope was used to capture the images.

p70S6K1 Kinase Activity Assay
In vitro p70S6K1 kinase assay was carried out using a S6 Kinase Assay Kit (Upstate
biotechnology, Lake Placid, NY) according to the manufacturer’s instructions. Briefly, p70S6K1
was precipitated from 200 μg of cell lysates by a monoclonal anti-p70S6K1 antibody (49D7,
Cell Signaling Technology, Beverly, MA). Immunoprecipitates were washed and then incubated
at 30°C for 10 min in the kinase assay cocktail containing a substrate peptide and 10 μCi [γ32

P]dATP. The reaction was transferred onto a P81 phosphocellulose filter and the residual [γ-

32

P]dATP was washed off. The radioactivity of the phosphorylated substrate bound to the filter

was quantified by using a liquid scintillation counter.
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Cell Migration Assay
Migration of HUVECs was assayed using a 6.5 mm Transwell device with polycarbonate filters
of 8.0 µM pore size (Corning Incorporated, Corning, NY). Cells were trypsinized and
resuspended in basal medium as 2.5×105 cells/ml and 200 µl of the cell suspension was added
onto the upper chamber. Ang1 was added into the lower chamber as a chemotractant. The
chamber was incubated at 37°C for 6 h. The filter was carefully removed, and cells attached on
the upper side were wiped off. The cells migrating through the filter to the lower side were fixed
with methanol and stained with Diff-Quik solution.

Cell Invasion Assay
The in vitro cell invasion assay was performed using BD Biocoat™ Matrigel™ invasion
chamber with 6.5-mm diameter polycarbonate filters with 8.0 µm pore size (BD Biosciences, San
Jose, CA). HUVECs were resuspended at 5×105 cells/ml in basal medium containing 1%FBS.
Ang1 (250 ng/ml) or BSA was added into the cell suspension and 200 µl of the cell suspension
was loaded onto the upper chamber. The lower wells were filled with basal medium containing
1%FBS with or without 250 ng/ml of Ang1. The chamber was incubated at 37°C for 24 h. The
Matrigel and nonmigrating cells on the upper surface of the filter were removed by wiping with a
cotton swab, and the filter was then fixed with methanol and stained with Diff-Quik solution.
Invasive activity was quantified by counting the cells that migrated to the lower side of the filter.
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Gelatin Zymography Assay
For MMP-2 zymography, equal aliquots of conditioned cell culture medium were separated in
9% SDS-PAGE containing 0.1% gelatin. Samples were prepared in a nonreducing loading buffer.
After electrophoresis, SDS was removed by 2.5% Triton X-100 to renature gelatinases. The gels
were washed in a buffer (0.1 mol/L Tris-HCl, pH 8.0, 0.5 mol/L NaCl, 2.5% Triton X-100), and
were then incubated at 37°C for 24 h in a reaction buffer (50 mmol/L Tris-HCl, pH 8.0, 20
mmol/L CaCl2). The gels were stained with 0.25% Coomassie Blue R250, followed by
destaining in a buffer containing 10% methanol and 10% acetic acid.

Cell Survival Assay
HUVECs were seeded in triplicate at the density of 1×105 cells per well in 6-well plates. Cells
were infected with adenovirus vectors for 24 h in normal growth medium, then washed with
1×PBS and incubated in serum-free medium with or without 250 ng/ml Ang1. After 24 h, cell
viability was determined by trypan blue dye exclusion. Viable cells were counted on a
hemocytometer.

Tube Formation Assay
HUVECs were infected with adenovirus vectors for 24 h, serum-starved and then trypsinized and
resuspended in basal medium containing 0.5% FBS. Cells (1×104cells per well) were plated in
triplicate wells of 96-well plates pre-coated with growth factor-reduced Matrigel. The cells were
incubated for 16 h at 37°C, and tubule structures were photographed by phase-contrast
microscopy using an Olympus IX-71 microscope (100 × magnification) connected to a digital
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camera. Total tube length per field was measured using the Olympus MicroSuite™ Basic
program.

Statistical Analysis
All results were expressed as the mean ± SD. Statistical analysis was performed using the onetailed Student's t test (two sample, unequal variance) or one-way ANOVA (Tukey’s honestly
significance difference test was used for post-hoc comparisons). Significance level was set at
p<0.05. SPSS software (SPSS® for Windows Student Version, SPSS Inc., Chicago, IL, USA)
was used for all statistical analyses.

Results

Ang1 Induces p70S6K1 Activation through PI3K and MAPK Signaling Pathways
To determine whether Ang1 induces p70S6K1 activation, we examined the effects of Ang1 on
the phosphorylation of p70S6K1 at Thr421/Ser424 and Thr389 residues, which are critical
phosphorylation sites for maximal activation of p70S6K1. Ang1 significantly induced p70S6K1
phosphorylation, which was blocked by LY294002, rapamycin, or PD98509 (Figure 1A). We
also examined the effect of Ang1 on the phosphorylation of S6 ribosomal protein, which is an
endogenous substrate of p70S6K1. Stimulation of serum-starved HUVECs with recombinant
Ang1 led to a marked increase in S6 ribosomal protein phosphorylation (Figure 1A). Ang1induced phosphorylation of S6 ribosomal protein was inhibited by PI3K inhibitor LY294002,
mTOR inhibitor rapamycin, or MAPK inhibitor PD98509 (Figure 1A). Ang1 stimulation caused
dramatic increases in Akt and ERK1/2 MAPK phosphorylation that were specifically inhibited
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by LY294002 and PD98509, respectively (Figure 1A). These data demonstrate that Ang1
stimulates p70S6K1 activation via PI3K and MAPK signaling cascades in HUVECs.

p70S6K1 modulates Actin Cytoskeleton Remodeling and Ang1-mediated EC Migration
To study the role of p70S6K1 in Ang1-mediated angiogenic effects, we altered p70S6K1 activity
in HUVECs by adenovirus-mediated expression of either a constitutively active p70S6K1 mutant
(p70S6K-CA) or a catalytically inactive mutant (p70S6K-KD). Ang1 treatment significantly
stimulated p70S6K1 kinase activity in HUVECs (Figure 1B). Overexpression of p70S6K-KD
blocked Ang1-induced p70S6K1 activation, indicating that p70S6K-KD functions dominantnegatively in the cells. In contrast, transduction of p70S6K-CA resulted in marked increases in
p70S6K1 activity even in unstimulated cells (Figure 1B). After adenoviral infection, we noticed
pronounced morphologic changes of the cells. The cells transduced with p70S6K-KD were
relatively larger in size and became rounded up, whereas cells transduced with p70S6K-CA or
Ad-GFP did not show apparent morphologic changes as observed under phase-contrast
microscope (Figure 2A). The distinct changes in cell morphology prompted us to examine the
alterations in cell cytoskeleton. We found that, in untransduced HUVECs, bundled actin stress
fibers were formed throughout the cells, both lamelipodia and philopodia structures were
apparent, and the cells were polarized (Figure 2B). Infection of the cells with Ad-GFP or Adp70S6K-CA did not cause significant changes in actin cytoskeleton architecture (Figure 2B). In
contrast, cells infected with Ad-p70S6K-KD displayed remarkable morphological changes,
characterized by disruption of stress fiber formation, cell rounding, and loss of cell polarity and
motile structures (Figure 2B). These results suggested that p70S6K1 may be important for cell
migration. To test this hypothesis, we performed transwell cell migration assay using a modified
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Boyden chamber system. As previously documented, Ang1 treatment significantly increased EC
migration (Figure 2C). Overexpression of p70S6K-KD completely blocked Ang1-induced cell
migration, whereas expression of p70S6K-CA enhanced both basal and Ang1-induced cell
migration (Figure 3C). Taken together, these results indicate that p70S6K1 modulates the
cytoskeletal architecture of endothelial cells and controls Ang1-mediated cell migration.

Role of p70S6K1 in Ang1-mediated EC Survival
Compelling evidence indicates that EC apoptosis plays a major regulatory role in angiogenesis
(32). Ang1 has been shown to have strong antiapoptotic effect on ECs (4-7;11). Mechanistically,
the anti-apoptotic effect of Ang1 is dependent on PI3K/Akt signaling pathway (6;24). We have
shown that Ang1-induced p70S6K1 activation is downstream of PI3K/Akt signaling (Figure 1).
In addition, p70S6K1 was shown to regulate cell survival in rat fibroblasts (33). Therefore, we
hypothesized that p70S6K1 might be involved in the regulation of Ang1-mediated EC survival.
To test this, we performed a cell viability assay in HUVECs cultured in serum-free medium for
24 h. Consistent with previous studies, Ang1 treatment significantly reduced cell death induced
by serum deprivation (Figure 3A). Overexpression of p70S6K-KD completely abolished the
cytoprotective effect of Ang1, whereas p70S6K-CA enhanced cell survival (Figure 3A). To
further confirm the effect of p70S6K1 on cell apoptosis, we evaluated PARP cleavage in
HUVECs upon serum deprivation. PARP is a substrate of caspases, and cleaved PARP fragments
mediate the apoptotic effects (34). In control groups, Ang1 treatment inhibited serum
deprivation-induced PARP cleavage (Figure 3B). Overexpression of p70S6K-KD increased
PARP cleavage and reduced Ang1-mediated cell survival. In contrast, very low levels of cleaved
PARP were detected in cells overexpressing p70S6K-CA either with or without Ang1 treatment
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(Figure 3B). These results indicate that p70S6K1 is downstream of Ang1 to modulate the antiapoptotic effects.

p70S6K1 Regulates EC Invasion and MMP-2 Activation Induced by Ang1
EC invasion, the ability of ECs to degrade and penetrate the basement membrane and the
extracellular matrix, is critical for angiogenesis. To determine whether Ang1 regulates EC
invasion, we performed cell invasion assay using a Matrigel-coated transwell system. Ang1
treatment significantly increased invasion of HUVECs through the Matrigel (Figure 4A).
Inhibition of p70S6K1 activity by overexpressing p70S6K-KD significantly reduced cell
invasion both at basal level and after Ang1 treatment (Figure 4A). In contrast, transduction of the
cells with the empty vector or p70S6K-CA did not significantly alter Ang1-induced EC invasion
(Figure 4A).
Matrix metalloproteinases (MMPs) are important for degradation of extracellular matrix
components during cell invasion, and ECs can synthesize and release MMPs, especially MMP-2
(35;36). Here, we performed gelatin zymography assay to determine whether p70S6K1
modulates the secretion and activation of MMP-2 in ECs. We found that Ang1 treatment resulted
in marked increases in both proMMP-2 and active MMP-2 secretion in HUVECs (Figure 4B).
Expression of p70S6K-KD dramatically inhibited both basal level and Ang1-induced MMP-2
secretion and activation, whereas p70S6K-CA did not exhibit significant effect (Figure 4B).
These results indicate that p70S6K1 is necessary for Ang1-induced MMP-2 secretion and
activation, which might be an underlying mechanism for the involvement of p70S6K1 in Ang1mediated EC invasion.
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p70S6K1 Controls Ang1-induced endothelial cell tube formation
We have demonstrated that p70S6K1 is important for Ang1-induced EC migration, survival, and
invasion, which are critical cellular events for angiogenesis. We next evaluated the effect of
p70S6K1 in Ang1-induced EC differentiation into capillary structures by performing endothelial
tube formation assay in Matrigel, which is a commonly-used in vitro assay to study angiogenesis.
HUVECs were infected with adenoviruses and then seeded on growth factor-reduced Matrigel
and treated with or without Ang1. Within 16 h, the cells formed an organized network of tubelike structures, and this effect was enhanced by Ang1 treatment (Figure 5). Overexpression of
p70S6K-KD significantly inhibited EC tube formation in the absence or presence of Ang1
(Figure 5). Conversely, the cells infected with p70S6K-CA formed more tube structures, and the
ability of Ang1 to induce EC tube formation was further enhanced by expression of p70S6K-CA
(Figure 5). These data indicate that p70S6K1 activation is important for Ang1-induced EC
capillary morphogenesis.

Discussion

This study examined the regulation and functional significance of p70S6K1 in ECs in response
to Ang1 stimulation. We showed that p70S6K1 is directly involved in the regulation of Ang1mediated EC migration, survival, invasion, and capillary morphogenesis, implying an important
role of p70S6K1 in angiogenesis.
This study revealed that p70S6K1 modulates the reorganization of actin cytoskeleton and
EC migration induced by Ang1. Our results were consistent with recent observations that
p70S6K1 plays a role in actin filament remodeling and cell motility in other cultured cells
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(25;37). The mechanisms by which p70S6K1 controls cell migration remain unclear. The
remarkable effects of p70S6K1 on actin cytoskeleton remodeling and EC migration suggest that
p70S6K1 may modulate the activities of Rho family small GTPases, which are key regulators of
cell motility (38). In addition, p70S6K1 has been found to colocalize with actin cytoskeleton and
the leading edges of motile cells (25). Therefore, it was speculated that p70S6K1 may enhance
localized synthesis of key protein regulators of the motility structures (25).
EC survival is important for angiogenesis and vessel integrity (32). Ang1 is a strong
antiapoptotic factor for ECs (4;5;11). In the present study, we demonstrated that p70S6K1 plays
an important role in controlling Ang1-mediated EC survival. The effect of Ang1 on cell survival
is dependent on the PI3K/Akt signaling pathway (6;24). We have shown that Ang1-induced
p70S6K1 activation is downstream of PI3K/Akt signaling. Therefore, p70S6K1 appears to act
downstream of PI3K/Akt pathway to transmit Ang1-induced survival signal. Other Akt-regulated
proteins, such as BAD, eNOS, and survivin, have been shown to be important for the
cytoprotective effects of many angiogenic factors including Ang1 (32). The mechanisms by
which p70S6K1 regulates Ang1-mediated EC survival are unknown. p70S6K1 might modulate
cell survival by acting closely with the above-mentioned Akt downstream proteins. Indeed, a
recent study reported that p70S6K1 is capable of phosphorylating and inactivating the proapoptotic protein BAD, and thereby promotes cell survival (33). The precise mechanisms by
which p70S6K1 controls Ang1-mediated EC survival remain to be elucidated.
EC sprouting is a critical initial step in angiogenesis (39). Ang1 has been shown to be a
potent inducer for EC sprouting in vitro (9;10), suggesting that Ang1 may directly regulate EC
invasion because EC sprouting requires the migratory and invasive activities of EC. Here, we
demonstrated that Ang1 treatment indeed significantly increased EC invasion in an in vitro
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invasion assay. We further showed that p70S6K1 plays an important role in Ang1-induced EC
invasion. Previous work showed that Ang1 was able to stimulate MMP-2 secretion by ECs (10).
Here, we found that activation of p70S6K1 is essential for Ang1-induced MMP-2 secretion and
activation, which may be responsible for its involvement in Ang1-mediated EC invasion. The
detailed mechanisms by which p70S6K1 regulates MMP-2 secretion and activation remain to be
defined. The in vitro cell invasion and MMP-2 zymography assays were performed for 24 h after
cell quiescence in serum-free medium, and cell apoptosis can be initiated under this experimental
setting. Therefore, the effects of p70S6K1 on Ang1-mediated cell invasion and MMP-2 secretion
might be, at least partly, due to the alterations in cell survival. In addition, overexpression of
p70S6K-CA failed to further enhance the effect of Ang1 on EC invasion, suggesting that
activation of p70S6K1 alone was not sufficient to induce EC invasion.
Based on the wide range of cellular effects of p70S6K1 on ECs, we anticipated that
p70S6K1 might have significant effects on angiogenesis. Indeed, overexpression of p70S6K-KD
markedly inhibited EC tube formation, whereas p70S6K-CA enhanced Ang1-induced EC tube
formation. The effects of p70S6K1 on EC capillary formation may result from the combined
effects of p70S6K1 on EC survival, migration and invasion. Notably, modulation of p70S6K1
activity in ECs has significant effects on basal EC behavior in addition to the effects on Ang1induced EC responses. Furthermore, Ang1 induces p70S6K1 activation through PI3K and
MAPK signaling pathways. These two signaling cascades, which are critical regulators of the
angiogenic phenotypes in ECs, can also be initiated by many other angiogenic factors, such as
basic fibroblast growth factor (bFGF) and VEGF. We also found that VEGF treatment potently
induces p70S6K1 activation (data not shown). Therefore, p70S6K1 may influence EC responses
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to other angiogenic factors as well. In summary, our data suggest that p70S6K1 functions at a
converging point of multiple signaling pathways to modulate the EC responses to Ang1.

Acknowledgements

This work was supported by National Cancer Institute Grant R01CA109460, and by American
Cancer Society Research Scholar Grant 04-076-01-TBE (to B.H. Jiang). We thank Dr. Bert
Vogelstein (Howard Hughes Medical Institute and Johns Hopkins University) for providing the
AdEasy adenoviral vector system.

52

Figures and Figure Legends
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Figure 1. Ang1 induces p70S6K1 activation in HUVECs. A, Serum-starved HUVECs were
pretreated with solvent (DMSO), LY294002 (LY), rapamycin (RAP), or PD98059 (PD), followed
by treatment with 250 ng/ml of Ang1 for 30 min. Phosphorylation of S6 ribosomal protein,
p70S6K1, Akt, and ERK1/2 was assessed with phosphospecific antibodies as indicated. B,
Modulation of p70S6K1 activity in HUVECs by adenovirus-mediated gene transfer. Upper panel:
p70S6K1 kinase activity assay. HUVECs were infected with 10 MOI of adenoviruses for 24 h
followed by serum-starvation and subsequent treatment with solvent (1% BSA in 1×PBS) or 250
ng/ml of Ang1 for 30 min. The kinase activity of p70S6K1 was assayed as described in Methods.
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p70S6K1 kinase activity was presented as CPM incorporated/min/200 μg protein. (* indicates
significant different when the value was compared to that of mock or Ad-GFP-infected cells
treated with BSA solvent, p<0.05;

&

indicates significant different compared to mock or Ad-

GFP-infected cells treated with Ang1, p<0.05; # indicates significant different when the value
was compared to that of mock or Ad-GFP-infected cells treated with BSA solvent, p<0.05;

§

indicates significant different compared to mock or Ad-GFP-infected cells treated with Ang1,
p<0.05). Lower panel: cell lysates prepared from the cells treated as described above were
subjected to immunoblotting analysis using antibodies against total p70S6K1, HA, or β–actin.
Only p70S6K1 constructs have the HA tag.
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Figure 2.
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Figure 2. p70S6K1 Regulates actin cytoskeleton remodeling and Ang1-induced cell
migration. A, HUVECs were cultured in complete growth medium in plastic petri dish. Cell
morphology was photographed by phase-contrast microscope 24 h after infection with indicated
adenoviruses. Original magnification: 200×. B, HUVECs were cultured in complete growth
medium on glass coverslips and infected with adenoviruses for 24 h. F-actin was visualized by
immunofluorescence staining with rhodamine-conjugated phalloidin. (Red: F-actin; Green: GFP
expressed from adenovirus vectors). C, Transwell cell migration assay. HUVECs were infected
with adenoviruses for 24 h, then cultured in serum-free medium for 24 h, followed by the
chemotaxis assay in the presence or absence of 250 ng/ml of Ang1 for 6 h. Upper panel,
representative photographs of the transwell assays. Lower panel: quantification of cell migration
by counting the cell number in high-power fields (100×) under a microscope. Data represent
mean±SD from three random fields. The experiments were repeated three times with similar
results. (* indicates significant different when the value was compared to that of mock or AdGFP-infected cells treated with BSA solvent, p<0.05;
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to mock or Ad-GFP-infected cells treated with Ang1, p<0.05;
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when the value was compared to that of mock or Ad-GFP-infected cells treated with BSA
solvent, p<0.05).
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Figure 3. p70S6K1 regulates Ang1-mediated EC survival. A, HUVECs were infected with 10
MOI of adenoviruses for 24 h, the cells were then switched to serum-free medium in the
presence or absence of 250 ng/ml Ang1. Cell viability was determined by trypan blue staining 24
h after serum-deprivation. (* indicates significant different when the value was compared to that
of mock or Ad-GFP-infected cells treated with BSA solvent, p<0.05; ** indicates significant
different compared to mock or Ad-GFP-infected cells treated with BSA, p<0.05;

&

indicates

significant different compared to mock or Ad-GFP-infected cells treated with Ang1, p<0.05;

#

indicates significant different when the value was compared to that of mock or Ad-GFP-infected
cells treated with BSA solvent, p<0.05). B, After the same treatments as described above,
HUVECs were collected and cell lysates were subjected to Western blotting using antibodies
against PARP and β-actin, respectively.
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Figure 4.
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Figure 4. p70S6K1 modulates Ang1-induced EC invasion. A, HUVECs (1×105 cells) were
loaded to Transwell chamber precoated with Matrigel, and treated with or without 250 ng/ml
Ang1 for 24 h. Invaded cells on the opposite side of the filter were stained with Quik-diff. Upper
panel,

representative photographs of invasion assays. Lower panel: quantification of cell
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invasion by counting the cell number in high-power fields (100×) under a microscope. Data
represent mean±SD from three random fields. The experiments were repeated twice with similar
results. (* indicates significant different compared to mock or Ad-GFP-infected cells treated with
BSA solvent, p<0.05;

**

indicates significant different when the value was compared to that of

mock or Ad-GFP-infected cells treated with BSA solvent, p<0.05; # indicates significant different
compared to mock or Ad-GFP-infected cells treated with Ang1, p<0.05). B, MMP-2 gelatin
zymography assay. HUVECs were either uninfected (mock), or infected with adenovirus
expressing GFP, p70S6K-KD, or p70S6K-CA for 24 h, then incubated in serum-free medium for
24 h in the absence or presence of 250 ng/ml Ang1. The culture medium was collected and
analyzed by gelatin zymography.
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Figure 5.
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Figure 5. p70S6K1 modulates Ang1-induced EC tube formation. A, HUVECs were either
uninfected (mock), or infected with adenovirus expressing GFP, p70S6K-KD, or p70S6K-CA for
24 h, then plated on growth factor-reduced Matrigel in the wells of 96-well plate and treated with
BSA or Ang1 for 16 h. EC capillary structures were photographed by phase-contrast microscopy.
Original magnification: 100×. B, Quantification of total tube length per high-power field. Data
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are mean ± SD of 3 random fields of each experiment that was repeated 3 times. (* indicates
significant different when the value was compared to that of mock or Ad-GFP-infected cells
treated with BSA solvent, p<0.05; **indicates significant different when the value was compared
to that of mock or Ad-GFP-infected cells treated with BSA solvent, p<0.05;

&

indicates

significant different compared to mock or Ad-GFP-infected cells treated with Ang1, p<0.05;

#

indicates significant different when the value was compared to that of mock or Ad-GFP-infected
cells treated with BSA solvent, p<0.05; § indicates significant different compared to mock or AdGFP-infected cells treated with Ang1, p<0.05).
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ABSTRACT

Elevated levels of insulin-like growth factor-I (IGF-I) are associated with ovarian carcinogenesis
and progression. However, the molecular mechanisms by which IGF-I contributes to ovarian
cancer development remain to be elucidated. Cyclooxygenase-2 (COX-2) is a crucial player in
the pathogenesis of human malignancies. Herein we showed that IGF-I efficiently induced COX2 expression and PGE2 biosynthesis at physiologically relevant concentrations in human ovarian
cancer cells. IGF-I treatment significantly increased COX-2 transcriptional activation. IGF-I also
stabilized COX-2 mRNA through the COX-2 3’-untranslated region (3’-UTR), which appeared
independent of the conserved AU-rich elements. We next investigated the signaling pathways
involved in IGF-I-induced COX-2 expression. We found that PI3K inhibitor wortmannin or
LY294002 blocked COX-2 expression induced by IGF-I. Wortmannin treatment or a dominant
negative PI3K mutant significantly inhibited IGF-I-induced COX-2 mRNA stabilization, but
only slightly decreased COX-2 transcriptional activation. We showed that ERK1/2 and p38
MAPKs were required for IGF-I-induced COX-2 expression and that activation of both pathways
by IGF-I increased COX-2 transcriptional activation and its mRNA stability. IGF-I stimulated
PKC activation in the cells and pretreatment with PKC inhibitor bisindolylmaleimide prevented
IGF-I-induced COX-2 transcriptional activation and mRNA stabilization, and inhibited COX-2
mRNA and protein expression. Taken together, our data demonstrate that IGF-I induces COX-2
expression in human ovarian cancer cells, which is mediated by three parallel signaling cascades
— PI3K, MAPK, and PKC pathways that differentially regulate COX-2 expression at
transcriptional and post-transcriptional levels.
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INTRODUCTION

The type I insulin-like growth factor receptor (IGF-IR) and its ligand IGF-I have been implicated
in the development and progression of human cancer (1-3). An accumulating body of
epidemiological evidence suggests that high levels of circulating IGF-I are associated with the
risk of a number of human malignancies, such as breast, prostate, colorectal, pancreas, lung, and
ovarian cancer (1). Insulin-like growth factors (IGF-I and IGF-2) are small polypeptides
structurally related to insulin and exert their mitogenic effects mainly through IGF-IR. IGF-2 is
considered as the major IGF isoform in fetal development, whereas IGF-I plays a more important
role in adults (1). The bioactivities of IGFs are regulated by a family of IGF binding proteins (i.e.,
from IGFBP-1 to IGFBP-6) and a group of IGFBP proteases (1;2;4). Activation of IGF-IR by
ligand binding initiates the mitogen-activated protein kinase (MAPK) and phosphatidylinositol
3-kinase (PI3K) pathways, which are the major signaling cascades that mediate the mitogenic
and antiapoptotic actions of IGFs (1-3). The IGF-IR is frequently overexpressed in several
human cancers. The combination of the mitogenic and antiapoptotic effects of IGF-IR activation
has a profound impact on tumor growth. In addition, IGF-IR is involved not only in the induction
of cell transformation, but also in the maintenance of the transformed phenotype (5).
Furthermore, IGF-I has been implicated in tumor neo-vascularization by increasing the
expression of hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor
(VEGF) (6-9). Despite these findings, however, the molecular mechanisms by which IGF-I
contributes to cancer progression remain to be elucidated.
The conversion of arachidonic acid to prostaglandins (PGs) is catalyzed by two isoforms
of cyclooxygenases, COX-1 and COX-2. COX-1 is constitutively expressed in most human
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tissues, and appears to be responsible for the production of PGs that modulate physiological
functions. In contrast, COX-2 is expressed at low or undetectable levels in most normal tissues.
COX-2 can be rapidly induced by inflammatory stimuli, and is frequently overexpressed in many
human cancers (10-13). Genetic studies showed that transgenic mice overexpressing COX-2 in
various types of tissues developed malignant tumors (10;11). Conversely, the development and
growth of tumors were markedly retarded in COX-2 knockout mice (10;11). The role of COX-2
in carcinogenesis is further supported by experimental and clinical studies which demonstrate the
effectiveness of selective COX-2 inhibitors in the prevention and treatment of human cancers
(10;11). The biological effects of COX-2 are mediated by its prostanoid products that affect
multiple mechanisms implicated in carcinogenesis. For example, prostaglandin E2 (PGE2) can
stimulate cell proliferation and motility while inhibiting apoptosis and immune surveillance (10).
Importantly, COX-2-derived prostanoids are involved in multiple key points of tumor
angiogenesis, including enhancing VEGF production (12).
Expression of COX-2 in human cancer is regulated at both transcriptional and
posttranscriptional levels by multiple signaling pathways (14).

COX-2 expression can be

induced by inflammatory cytokines and by growth factors (13). COX-2 expression can also be
induced by activation of oncogenes and inactivation of tumor suppressor genes (13). However,
little is known about the precise factors and molecular mechanisms regulating COX-2 gene
expression in human ovarian cancer. The novel findings of this study are: (a) COX-2, but not
COX-1 expression in human ovarian cancer cells can be potently induced by IGF-I stimulation;
(b) IGF-I activates PI3K, MAPK as well as PKC signaling cascades in the cells, and all these
pathways are required for IGF-I-induced COX-2 expression; (c) PI3K, MAPK and PKC
pathways are differentially involved in transcriptional and post-transcriptional regulation of IGF-
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I-induced COX-2 expression in the cells; (d) PKC is independent of Erk1/2 MAPK in the
mediation of IGF-I-induced COX-2 expression. Our data suggest that increased COX-2
expression may be important for IGF-I involvement in ovarian cancer development and
progression.

Materials and Methods

Cell Culture and Reagents

A2780 and OVCAR-3 human ovarian cancer cells were cultured in RPMI Medium 1640 (Life
Technologies, Grand Island, NY), supplemented with 10% fetal bovine serum, 50 nM insulin
(Sigma), 100 units/ml penicillin, and 100 µg/ml streptomycin. The cells were maintained at
37°C and 5% CO2 in a humid environment. Actinomycin D, PD98059, bisindolylmaleimide, and
recombinant human IGF-I were purchased from Sigma (St Louis, MO). LY294002, wortmannin
and SB203580 were purchased from Calbiochem (La Jolla, CA). Monoclonal antibodies against
COX-2 and COX-1, and selective COX-2 inhibitor NS398 were obtained from Cayman
Chemical Company (Ann Arbor, MI). Antibodies against phosphorylated AKT (Ser473) or total
AKT, phosphorylated ERK1/2 (Thr202/Tyr204), and phosphorylated MAPKAPK2 (Thr334)
were purchased from Cell Signaling Technology (Beverly, MA). Antibody against total p44/p42
MAPK was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal antibody
against β-actin was from Sigma.
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Immunoblotting
After appropriate treatments, cells were washed with ice-cold PBS, and collected by
centrifugation. Cell lysates were prepared using RIPA buffer supplemented with protease
inhibitors (100 mM Tris, PH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1%
deoxycholate acid, 0.1% SDS, 2 mM phenylmethylsulfonyl fluoride, 1 mM sodium
orthovanadate, 2 mM DTT, 20 µg/ml leupeptin, 20 µg/ml pepstatin). Aliquots of protein lysates
(50 µg) were fractionated by SDS-PAGE, transferred to a nitrocellulose membrane (Schleicher
& Schuell Biosciences, Keene, NH), and subjected to immunoblotting according to the
manufacturer’s instructions. Immunoreactivity was visualized with chemiluminescence detection
reagent (Pierce Biotechnology, Rockford, IL).

RT-PCR
Total cellular RNAs were prepared using Trizol reagent (Invitrogen) according to the
manufacturer’s instructions. Aliquots of total RNAs (1 µg) were used as templates to synthesize
the first strand cDNA using reverse transcriptase (Promega). The following primers were used
for PCR amplification: human COX-2: sense 5’-TTCAAATG AGATTGTGGGAAAATTGCT3’,

antisense

5’-AGATCATCTCTGCCTGAGTATCTT-3’;

GAPDH:

sense

5’-

ACCACAGTCCATGCCATCAC -3’, antisense 5’-TCCACCACCCTGTTGCTGTA-3’. PCR
was performed for 30 cycles, with each cycle at 95°C for 1 min, 56°C for 1 min, and 72°C for 1
min. PCR products were separated on a 2% agarose gel and visualized with ethidium bromide
and photographed using an EagleEye II system (Stratagene, La Jolla, CA).
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PGE2 ELISA assay

Cells were seeded at 2×105 cells/well in 12-well plates, and cultured to 80% confluence in
normal growth medium. The cells were cultured in serum-free medium overnight, then changed
to fresh basal medium containing various concentrations of IGF-I in the presence or absence of
25 µM NS398 for 24 h. Levels of PGE2 released by the cells were measured using an ELISA kit
(R&D systems, Minneapolis, MN) according to the manufacturer’s instructions.

Transient transfection and luciferase reporter assay

A reporter construct containing the 5'-flanking region of the human COX-2 gene (phPES21432/+59) was used to study transcriptional activation of the COX-2 promoter (15). The COX-2
3'-UTR reporter luciferase construct Luc-3’UTR contains the full-length human COX-2 3’-UTR
region; Luc-3’UTRΔARE contains the 3’-UTR region with the deletion of a conserved 116nucleotide AU-rich sequence element as described previously (16). Cells were seeded at a
density of 2×105 cells/well in 12-well plates. The next day, 1 µg of plasmid DNA was transfected
into the cells using 2 µl of Lipofectamine (Invitrogen) as per manufacturer's instructions. After
the transfection, the cells were cultured overnight, changed to fresh basal medium with different
treatments for 16 h. Luciferase and β–galactosidase activities were assayed in the cell lysates,
and relative luciferase activity was the ratio of luciferase/β–galactosidase activity which was
normalized to the control.
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PKC Kinase Activity Assay

The activity of PKC was measured as described previously with modifications (17). Briefly, cells
were lysed in a PKC extraction buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Tween
20, 1 mM EDTA, 2.5 mM EGTA, 10% glycerol) supplemented with protease inhibitors
(10 µg/ml of aprotinin, 10 µg/ml of leupeptin, 0.1 mM phenylmethylsulfonyl fluoride) and
phosphatase inhibitors (1 mM NaF, 0.1 mM Na3VO4). PKC proteins were immunoprecipitated
from 200 µg of the cellular extracts with 2 µg of the anti-phospho-PKC (pan) antibody (beta II,
Ser660) (Cell Signaling Technology, Beverly, MA). The kinase assay was performed in 40 µl of
PKC reaction buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 2.5 mM
EGTA, 1 mM NaF, 0.1 mM Na3VO4, 10 µM ATP) containing 1 µg of the substrate myelin basic
protein and 5 µCi of [γ-32P]ATP.

The reactions were performed at 30°C for 20 min, and

terminated by adding SDS-PAGE sample buffer. Reaction products were analyzed by SDSPAGE and visualized by autoradiography. The radioactive bands were excised and quantified by
liquid scintillation counting. The activity of PKC is expressed as counts per min with each µg of
protein.

Statistics

Comparisons between treatments were made by the Student's t test. A difference between the
treatments was considered significant at p < 0.05.
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RESULTS

IGF-I stimulates COX-2 mRNA and protein expression, and induces PGE2 biosynthesis in
human ovarian cancer cells
To examine whether IGF-I was able to induce COX-2 expression, human ovarian cancer cells
A2780 were incubated with various concentrations of IGF-I, and COX-2 mRNA levels were
analyzed by RT-PCR. At the range of physiologically relevant concentrations, IGF-I induced
COX-2 mRNA expression in a dose-dependent manner (Fig. 1A). Similar results were obtained
using another human ovarian cancer cell line, OVCAR-3 (Fig. 1A). We next examined the timedependent effect of IGF-I on COX-2 expression in the cells. A2780 and OVCAR-3 cells were
incubated with IGF-I for 0, 0.5, 1, 2, 4, 6, 12, or 24 h; and COX-2 mRNA expression was
examined. IGF-I increased COX-2 expression within 1 h, and the induction reached the
maximum at 6 h (Fig. 1B). COX-2 protein levels were examined to determine whether the
elevated COX-2 mRNA levels correlated with increased COX-2 protein expression. As shown in
Fig. 2A, IGF-I greatly upregulated COX-2 protein expression in a dose-dependent fashion in
both cell lines. COX-2 protein expression was gradually increased and peaked by 6-8 h, and
remained elevated for up to 24 h (Fig. 2B). By contrast, both cell lines expressed constitutive
levels of COX-1 that were not increased by IGF-I treatment (Figs. 2A and 2B). We further
examined whether IGF-I-induced COX-2 protein expression was associated with induction of
PGE2 biosynthesis. As shown in Fig. 2C, treatment of the cells with IGF-I increased PGE2
biosynthesis, and pretreatment of the cells with the COX-2 selective inhibitor NS398 completely
inhibited the induction. These data show that COX-2 expression and activity were upregulated
by IGF-I in human ovarian cancer cells.
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IGF-I increases COX-2 transcriptional activation and its mRNA stability
To study the mechanism underlying the induction of COX-2 by IGF-I, A2780 cells were
transfected with a COX-2 promoter luciferase reporter phPHES2(-1432/+59), which carries the
full-length promoter region of human COX-2 gene (15). Treatment of the cells with IGF-I
significantly increased COX-2 promoter activity (Fig. 3A), suggesting that IGF-I was able to
stimulate COX-2 transcriptional activation.
Post-transcriptional stabilization of COX-2 mRNA plays an important role in the
regulation of COX-2 expression. To determine whether IGF-I affects the stability of COX-2
mRNA, the rate of COX-2 mRNA decay was examined in A2780 cells. In the absence of IGF-I
treatment, the half-life (t1/2) of COX-2 mRNA in the cells was 60 min. IGF-I treatment increased
the stability of COX-2 mRNA and extended the t1/2 to 215 min (Fig. 3B). It is known that the 3’untranslated region (3’-UTR) of COX-2 mRNA is involved in promoting its mRNA decay (16).
We therefore asked whether IGF-I treatment affected COX-2 3’-UTR activity. We found that
treatment of cells with IGF-I caused up to 2-fold increase of COX-2 3’-UTR reporter activity,
suggesting that IGF-I increased COX-2 mRNA stability (Fig. 3C). Within the proximal end of
COX-2 3’-UTR, there is a highly conserved AU-rich mRNA decay sequence element (ARE)
(16). To determine whether the stabilization of COX-2 mRNA by IGF-I was dependent on the
conserved ARE sequence, luciferase reporter assays were performed by using the Luc-3’UTR
and Luc-3’UTRΔARE constructs. We found that the luciferase activity was dramatically
increased when the ARE region was deleted from the full-length COX-2 3’-UTR (Fig. 3D). This
result suggested that in human ovarian cancer cells, the COX-2 ARE facilitated COX-2 mRNA
decay. Interestingly, IGF-I treatment similarly increased luciferase reporter activity when the
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ARE was deleted (Fig. 3D), implying that IGF-I promoted COX-2 mRNA stabilization through
other regions of the 3'UTR. Taken together, these results showed that IGF-I upregulated COX-2
expression through both transcriptional activation and post-transcriptional mechanisms.

PI3K signaling pathway is involved in IGF-I-induced COX-2 expression
We next investigated the signaling pathways that are required for IGF-I-induced COX-2
expression. PI3K signaling is a major pathway initiated by growth factor receptors including
IGF-IR. To determine whether PI3K regulates IGF-I-induced COX-2 expression, the cells were
treated with PI3K selective inhibitors. As shown in Fig. 4A and 4B, PI3K inhibitors wortmannin
and LY294002 inhibited IGF-I-induced COX-2 protein and mRNA expression, indicating that
PI3K activation plays an important role in IGF-I-mediated COX-2 expression. We next
examined whether PI3K is involved in IGF-I-induced COX-2 transcriptional activation or posttranscriptional mRNA stability. As shown in Fig. 4C, wortmannin treatment slightly reduced
COX-2 promoter activity (up to 15% reduction) in IGF-I-treated cells. In contrast, wortmannin
completely inhibited IGF-I-induced increase of the COX-2 3’-UTR activity (Fig. 4D). Similar
results were observed by using a dominant-negative PI3K construct (Figs. 4E and 4F). These
data indicate that PI3K activation regulates IGF-I-induced COX-2 expression in human ovarian
cancer cells primarily through increasing stabilization of COX-2 mRNA.

ERK1/2 and p38 MAP kinases are important for COX-2 induction by IGF-I at both
transcriptional and post-transcriptional levels
IGF-I treatment induced the activation of Erk1/2 and p38 MAPKs in human ovarian cancer cells,
and treatment with MEK1 inhibitor PD98059 or p38 inhibitor SB203580 inhibited IGF-I-
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induced COX-2 expression, which correlated with the inhibition of Erk1/2 and p38 kinase
activation (Figs. 5A and 5B). Consistent with their effects on COX-2 protein expression, the
MAPK inhibitors completely prevented IGF-I-induced COX-2 mRNA expression (Fig. 5C). To
test whether ERK1/2 and p38 regulate COX-2 transcriptional activation, COX-2 promoter
reporter activity was analyzed in the cells treated by PD98509 and SB203580. As shown in Figs.
5D and 5E, PD98509 and SB203580 treatment significantly inhibited IGF-I-induced COX-2
promoter reporter activity in a dose-dependent manner, indicating that ERK1/2 and p38 activities
are required for COX-2 transcriptional activation. PD98509 and SB203580 similarly inhibited
the COX-2 3’-UTR reporter activity, suggesting that ERK1/2 and p38 also regulate IGF-Iinduced COX-2 expression by increasing COX-2 mRNA stabilization.

PKC activation is required for IGF-I-mediated COX-2 expression
To determine whether IGF-I stimulates PKC activation, PKC kinase activity was analyzed in
human ovarian cancer cells. We found that IGF-I treatment significantly increased PKC activity
which was inhibited by PKC inhibitor bisindolylmaleimide (Fig. 6A). We next determined
whether IGF-I-induced PKC activation contributed to COX-2 induction. Treatment of the cells
with bisindolylmaleimide inhibited COX-2 protein and mRNA expression induced by IGF-I
(Figs. 6B and 6C). Blockade of PKC activity also significantly inhibited IGF-I-induced COX-2
promoter and 3’-UTR reporter activities (Figs. 6D and 6E), indicating that PKC activation was
important for IGF-I-mediated COX-2 transcriptional activation and mRNA stabilization. PKC
was shown to regulate IL-1β-induced COX-2 expression through ERK1/2 activation in
astrocytes (18). However, we found that pretreatment with the PKC inhibitor did not alter IGF-Iinduced ERK1/2 activation in the human ovarian cancer cells (Fig. 6F), suggesting that
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regulation of IGF-I-induced COX-2 expression by PKC is independent of ERK1/2 activation in
the cells.

DISCUSSION

The exact roles of IGF-I in regulating COX-2 expression are not well understood. The findings
in this study demonstrated that IGF-I induced COX-2 expression and prostaglandin synthesis in
human ovarian cancer cells. A recent study showed that enhanced autocrine expression of IGF-II
up-regulated COX-2 mRNA expression in Caco-2 human colon cancer cells (19). In human
keratinocytes, COX-2 mRNA and protein expression was stimulated by exogenous IGF-II (20).
It was recently reported that local IGF-I expression in colorectal cancer tissue was associated
with COX-2 mRNA levels (21). IL-1β–induced COX-2 expression was enhanced by IGF-I
treatment in rat renal mesangial cells (22). However, other recent studies showed that IGF-I
failed to induce COX-2 expression in HT-29 colon cancer cells, hepatic stellate cells, and human
vein vascular endothelial cells (23-25), and IGF-I treatment even decreased COX-2 expression in
osteoblasts (26). Thus, the effects of IGF-I on COX-2 expression appear to be cell-type specific,
which may reflect its ability to promote organ-specific tumorigenesis (1;2;4).
Recent studies showed that COX-2 was overexpressed in ovarian cancer, and that COX-2
overexpression correlated with a more aggressive phenotype and a worse clinical outcome
(27;28). In addition, some studies showed that COX-1 was overexpressed in ovarian cancer
(29;30). The discrepancy of COX isoform expression in ovarian cancer may be due to the
differences in patient population and detection methodology. In this study, we found that both
COX-1 and COX-2 are expressed in A2780 and OVCAR-3 ovarian cancer cells, and that basal
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levels of COX-1 are relatively high in the cells. IGF-1 treatment dramatically increases COX-2
expression, but not COX-1 expression in the cells. These data suggest that, in addition to
inhibiting COX-1, COX-2 activity should also be targeted for ovarian cancer patients with
elevated levels of IGF-1. Recent studies show that high levels of COX-2 and PGE2 expression
are associated with cancer progression and angiogenesis in other human cancers such as colon,
gastric, and breast cancers (12;13;31;32). Since IGF-I and its receptor IGF-IR are frequently
overexpressed in human ovarian cancer (1;2;4), the induction of COX-2 expression by IGF-I
may play an important role in the angiogenesis switch during ovarian cancer development and
progression.

In addition, PGE2 is a signaling molecule which may be involved in tumor

development and angiogenesis through autocrine effect by binding to its cognate E-prostanoid
receptors or paracrine effect by acting on the neighboring cells through the induction of growth
factors including VEGF and bFGF (33;34). Thus, IGF-I-induced expression of COX-2 and PGE2
may have profound impacts on ovarian cancer development, progression, and angiogenesis.
Overexpression of COX-2 in human cancer is due to deregulated transcriptional and posttranscriptional control (10;11;14). Here we have shown that IGF-I was able to stimulate both
COX-2 transcriptional activation and mRNA stability, which correlated with elevated COX-2
mRNA and protein expression. Increasing evidence indicates that post-transcriptional regulation
via the stabilization of COX-2 mRNA plays an important role in the COX-2 expression (10;14).
We found that the conserved ARE sequence in COX-2 3’-UTR attenuates COX-2 expression in
human ovarian cancer cells. The data are consistent with several recent studies showing that the
3’-UTR of COX-2 mRNA and its ARE sequence are important for regulating COX-2 mRNA
stability (16;35;36). Interestingly, the stabilization of COX-2 mRNA induced by IGF-I was
independent of the ARE region in the COX-2 3’-UTR. Recently other cis-acting regions were
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identified within the COX-2 3'-UTR that are important for the post-transcriptional regulation of
COX-2 (37;38). It would be of interest to identify these mRNA regions that are regulated by
IGF-I to induce COX-2 expression in human ovarian cancer cells in the future study.
We found that treatment of the cells with PI3K inhibitors blocked both COX-2 protein and
mRNA expression induced by IGF-I, indicating that PI3K signaling plays an important role in
IGF-I-induced COX-2 expression. Our results are in agreement with several recent reports that
PI3K positively regulates COX-2 expression induced by other factors. PI3K/Akt activation was
shown to be required for K-Ras-induced COX-2 expression in rat intestinal epithelial cells
(39;40). PI3K activity also mediates COX-2 expression in response to LPS, interferon-γ, UVB
treatment, and high glucose stimulation (41-44). Our data indicate that PI3K regulates IGF-Iinduced COX-2 expression predominantly by modulating the stability of COX-2 mRNA. In
addition, we recently showed that IGF-I induced PI3K-dependent phosphorylation of several key
components of protein translational apparatus, including p70S6K1, S6 ribosomal protein, 4EBP1, and eIF4E in human ovarian cancer cells (9). Thus, it is possible that PI3K/Akt pathway
may also regulate COX-2 protein translation in response to IGF-I treatment.
Many factors known to induce COX-2 expression also activate MAPK signaling pathway.
Our findings indicate that ERK1/2 and p38 MAPKs are involved in the regulation of IGF-Iinduced COX-2 expression in human ovarian cancer cells. We found that inhibition of MEK1/ERK1/2 by PD98509 completely blocked IGF-I-induced COX-2 protein and mRNA
expression, and that ERK1/2 activation was involved in both transcriptional and posttranscriptional regulation of COX-2 expression in response to IGF-I treatment. Similarly, IGF-Iinduced activation of the p38 MAPK pathway was shown to regulate COX-2 expression on these
levels. We found that the p38 selective inhibitor SB203580 suppressed IGF-I-induced activation
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of COX-2 promoter activity and mRNA stabilization. This is consistent with previous findings
showing that p38 MAPK was involved in COX-2 transcription presumably through increasing
AP-1 activity (41;45-47), and that p38 MAPK regulated COX-2 mRNA stabilization by its
downstream kinase MK-2 (36;47;48).
PKC activity regulated COX-2 expression induced by inflammatory stimuli and stress
signals (15;18;47;49;50). Activation of PKC promotes COX-2 gene transcription through the
transcription factors NF-κB and C/EBP (15;49). PKC also regulates the stability of COX-2
mRNA (47). In this study, we showed that IGF-I was able to stimulate PKC activation in human
ovarian cancer cells. We further demonstrated that PKC was involved in both transcriptional and
post-transcriptional regulation of COX-2 expression. It was observed that MAPK could be a
downstream signal of PKC for regulating COX-2 expression (18;47). However, we found that in
ovarian cancer cells, blockade of PKC activity did not inhibit IGF-I-induced ERK1/2 activation,
suggesting that induction of COX-2 expression by PKC is independent of MAPK in human
ovarian cancer cells.
In summary, the present study provides first evidence that IGF-I upregulates COX-2
expression and the associated PGE2 biosynthesis in human ovarian cancer cells, and this effect is
mediated by PI3K, MAPK, and PKC signaling cascades which are differentially involved in the
transcriptional and posttranscriptional regulation of COX-2 expression (Fig. 7). Emerging
evidence indicates that COX-2 is important in multiple steps of malignant transformation and
tumor progression (10;11). Our data suggest that increased COX-2 expression may be important
for ovarian cancer development, progression, and angiogenesis in patients associated with high
levels of IGF-I.
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Figures and figure legends
Fig. 1.
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Fig. 1. IGF-I upregulates COX-2 mRNA expression. (A) A2780 and OVCAR-3 cells were
cultured in serum-free medium for 16 h, and then treated with the indicated concentrations of
IGF-I for 6 h. COX-2 and GAPDH mRNA levels in the cells were detected by RT-PCR. (B) The
cells were treated with 200 ng/ml IGF-I for 0 to 24 h as indicated. COX-2 and GAPDH mRNA
expression was analyzed by RT-PCR.

82

Fig. 2.
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Fig. 2. IGF-I induces COX-2 protein expression and PGE2 biosynthesis. (A) The serumstarved cells were treated with the indicated concentrations of IGF-I for 8 h. Total cellular lysates
were subjected to immunoblotting using antibodies against COX-2, COX-1, or β-actin. (B) The
serum-starved cells were treated with 200 ng/ml IGF-I for 0 to 24 h as indicated. COX-2, COX-1,
and β-actin protein levels were analyzed by immunobloting. (C) The cells were incubated in
basal medium containing the indicated concentrations of IGF-I in the presence or absence of 25
μM NS398 for 24 h. PGE2 levels in the medium were determined by ELISA assay. * indicates
that the value is significantly different when compared to that of the control (p<0.05).
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Fig. 3.
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Fig. 3. IGF-I treatment induces COX-2 transcriptional activation and mRNA stability. (A)
A2780 cells were co-transfected with a COX-2 promoter reporter construct phPHES2(-1432/+59)
and pCMV-β-gal, and incubated overnight. The cells were treated with the indicated
concentrations of IGF-I for 16 h. Relative luciferase activity was presented as the ratio of
luciferase to β-gal activity that was normalized to that of the control. (B) The cells were treated
with solvent (control) or 200 ng/ml IGF-I for 1 h, and then treated with 5 μg/ml actinomycin D
(Act D) to stop the transcription. The cells were harvested at the indicated time after the addition
of Act D, and the levels of COX-2 mRNA were detected by RT-PCR. The densitometry
intensity of COX-2 signal was normalized to that of GAPDH levels, and the half-life (t1/2) of
COX-2 mRNA was calculated using the regression program of Microsoft Excel 2000. (C) The
cells were transfected with a luciferase reporter construct containing full-length COX-2 3’-UTR
region (Luc-3’UTR). Relative luciferase activity was analyzed in the cells as described above
after the cells were treated for 16 h with the indicated concentrations of IGF-I. (D) The cells
were transfected with Luc-3’UTR or Luc-3’UTRΔARE (the deletion of AU-rich sequence
element from 3’-UTR region). Luciferase activity was assayed after the treatment of the cells
with 200 ng/ml IGF-I for 16 h. The data were presented as mean ±SD. All transient transfection
assays were performed in triplicate and repeated at least three times. *indicates that the value is
significantly different when compared to that of the control (p<0.05).
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Fig. 4.
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Fig. 4. PI3K signaling is required for IGF-I-induced COX-2 expression. (A) Serum-starved
A2780 cells were pretreated with wortmannin (WT), LY294002 (LY) or the solvent DMSO
followed by the incubation with 200 ng/ml IGF-I for 8 h. COX-2, phospho-Akt (p-Akt, Ser473),
total Akt, and β–actin protein levels were analyzed by immunoblotting. (B) The cells were
pretreated with wortmannin (WT), LY294002 (LY) or solvent (DMSO) followed by incubation
with 200 ng/ml IGF-I for 6 h. COX-2 and GAPDH mRNA levels were detected by RT-PCR. (C
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and D) The cells were transfected with phPHES2(-1432/+59) and Luc-3’UTR, respectively; and
cultured overnight. The cells were switched to serum-free medium in the absence or presence of
wortmannin or 200 ng/ml IGF-I for 16 h. Luciferase activity was assayed and was presented as
mean ± SD from three independent experiments. * indicates that the value is significantly
different when compared to that of the control (p<0.05); # indicates that the value is significantly
different when compared to that of IGF-I treatment alone (p<0.05). (E) A2780 cells were cotransfected with phPHES2(-1432/+59), pCMV-βgal, empty vector, or a vector expressing
dominant-negative PI3K construct (p85 DN); and cultured overnight. The cells were switched to
serum-free medium, and incubated in the absence or presence of 200 ng/ml IGF-I for 16 h.
Relative luciferase activity was analyzed. (F) The cells were co-transfected with Luc-3’UTR,
pCMV-βgal, empty vector, or a vector expressing p85 DN. The cells were switched to serumfree medium and incubated in the absence or presence of 200 ng/ml IGF-I for 16 h. Relative
luciferase activity was analyzed as described above. *indicates that the value is significantly
different when compared to that of the control (p<0.05); # indicates that the value is significantly
different when compared to that of the vector-transfected cells treated with IGF-I alone (p<0.05).
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Fig. 5.
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Fig. 5. IGF-I-induced COX-2 expression is dependent on MAPK activation. (A and B)
A2780 cells were pretreated with the solvent (-), PD98059 (PD) or SB203580 (SB) for 1 h, then
treated with 200 ng/ml IGF-I for 8 h. Specific protein levels were analyzed by immunoblotting
using antibodies against COX-2, phospho-Erk1/2 (p-Erk1/2, Thr202/Tyr204), total Erk1/2,
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phospho-MK2 (p-MK2,Thr33), and β–actin, respectively. (C) The cells were pretreated with PD,
SB, or DMSO for 1 h, followed by incubation with 200 ng/ml IGF-I for 6 h. COX-2 and
GAPDH mRNA levels were analyzed by RT-PCR. (D and E) The cells were transfected with
phPHES2(-1432/+59) and Luc-3’UTR plasmids, respectively; and cultured overnight. The cells
were switched to serum-free mdium, and incubated in the absence or presence of DMSO, PD, or
SB with 200 ng/ml IGF-I as indicated for 16 h. Relative luciferase activity was analyzed as
described in Fig. 3. Data are mean + SD from five independent experiments. * indicates that the
value is significantly different when compared to that of the control (p<0.05); # indicates that the
value is significantly different when compared to that of IGF-I treatment alone (p<0.05).
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Fig. 6.
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Fig. 6. PKC activity is important for IGF-I-induced COX-2 expression. (A) Serum-starved
A2780 cells were pretreated with PKC inhibitor bisindolylmaleimide (BIS) for 30 min, followed
by incubation with 200 ng/ml IGF-I for 6 h. Total PKC activity was measured using myelin
basic protein as a substrate as described in Experimental Procedures. (B) The serum-starved
cells were pretreated with BIS and treated with 200 ng/ml IGF-I for 6 h. COX-2 and β–actin
protein levels were analyzed by immunoblotting. (C) The cells were treated as above. COX-2
and GAPDH mRNA levels in the cells were analyzed by RT-PCR. (D and E) The cells were
transfected with phPHES2 (-1432/+59) and Luc-3’UTR reporter constructs, respectively. The
cells were cultured overnight after the transfection, then switched to serum-free medium in the
absence or presence of BIS and 200 ng/ml IGF-I for 16 h. Relative luciferase activity was
analyzed in the cells. Data represent mean + SD from five independent experiments. * indicates
that the value is significantly different when compared to that of the control (p<0.05); # indicates
that the value is significantly different when compared to that of IGF-I treatment alone (p<0.05).
(F) The serum-starved cells were pretreated with BIS, followed by incubation with 200 ng/ml
IGF-I for 4 h. Specific protein levels were analyzed by immunoblotting using antibodies against
phospho-Erk1/2 (p-Erk1/2, Thr202/Tyr204), and total Erk1/2, respectively.
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Fig. 7.
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Schematic representation of the mechanism by which IGF-I induces COX-2

expression in human ovarian cancer cells.
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Abstract

We modulated PI3K/Akt signaling specifically in either human microvascular endothelial cells
(HMVECs) or cancer cells, and investigated their roles in tumor angiogenesis using a chicken
chimeric tumor model system. We found that inhibition of PI3K or Akt activity in HMVECs
significantly decreased angiogenesis and tumor growth in vivo, whereas upregulation of
endothelial PI3K or Akt activity greatly induced tumor angiogenesis and tumor growth in vivo.
In cancer cells, PI3K/Akt signaling regulated HIF-1α-mediated VEGF expression. Inhibition of
PI3K or Akt activity in cancer cells markedly suppressed tumor angiogenesis and tumor growth
in vivo. Knockdown of HIF-1α or VEGF expression by Si-RNA had similar effects. We thus
demonstrated the important roles of PI3K/Akt signaling pathway in both human endothelial cells
and cancer cells for regulating tumor angiogenesis.

Significance
Cancer cells and vascular endothelial cells are the key cell types for tumor angiogenesis.
Accumulating evidence suggests that PI3K/Akt signaling pathway plays an important role in
both cell types. Here we demonstrated that PI3K and Akt activities in endothelial cells are
important for tumor angiogenesis and tumor growth in vivo. In human ovarian cancer cells,
PI3K/Akt regulates HIF-1α-mediated VEGF expression; PI3K/Akt signaling and its downstream
effectors HIF-1α and VEGF are essential for tumor angiogenesis and tumor growth in vivo. Thus
PI3K/Akt signaling pathway plays important roles in both tumor and endothelial cells during
tumor angiogenesis, suggesting that targeting PI3K-Akt signaling in both cellular compartments
may be more effective to control angiogenesis and tumor growth.
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Introduction

Angiogenesis, the development of new blood vessels from the pre-existing vasculature, is
essential for tumor growth and metastasis (1;2). Anti-angiogenic therapy is an attractive new
strategy for cancer treatment, which has some advantages over conventional therapies, such as a
potential low rate of drug resistance, direct accessibility from the circulation, and negligible side
effects on normal tissues (3-6). Angiogenesis is tightly regulated by the balance of positive and
negative angiogenic factors. A variety of angiogenic factors have been identified as potential
targets for anti-angiogenesis therapy (7). One of the key inducers of angiogenesis is vascular
endothelial growth factor (VEGF), which is a very promising target for anti-angiogenic therapy
(6).
VEGF binds to endothelial cell (EC)–specific tyrosine kinase receptors, VEGFR-1 and
VEGFR-2. VEGFR-2 is tyrosine-phosphorylated efficiently upon VEGF binding and mediates
major positive signals from VEGF in ECs (8). VEGF has multiple effects on ECs: it stimulates
cell migration, proliferation, survival, activation of endothelial nitric oxide synthase (eNOS),
release of matrix metalloproteinases (MMPs) and plasminogen activators (PAs) (9;10), all of
these are critical cellular events during the process of angiogenesis. Considerable evidence
suggests that phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is the predominant
signaling event in VEGF-induced angiogenic responses in ECs. Blockade of PI3K/Akt signaling
in ECs inhibits VEGF-induced endothelial cell proliferation, survival, migration, vascular
permeability, and angiogenesis (11-15).
VEGF is expressed by many types of cells surrounding the area of angiogenesis,
including the activated ECs themselves. A majority of malignant tumors overexpress VEGF, and
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tumor cell-derived VEGF is considered as the primary stimulus for tumor angiogenesis (16). One
of the major stimuli for VEGF expression in tumor cells is intratumoral hypoxia, a characteristic
property of advanced solid tumors, which is caused by the structural and functional abnormalities
of tumor microvasculature, rapid expansion of tumor mass, and tumor-associated anemia (17;18).
Hypoxia induces VEGF expression primarily through hypoxia-inducible factor 1 (HIF-1) (19;20).
HIF-1 is a heterodimeric transcriptional factor, composed of HIF-1α and HIF-1ß subunits (21).
HIF-1α is rapidly accumulated under hypoxia conditions due to the inhibition of ubiquitinmediated degradation, and subsequently dimerizes with the constitutively expressed HIF-1β, and
activates transcription of its target genes, including VEGF (22). HIF-1α also regulates VEGF
expression under normoxic conditions. Previous work done by our laboratory and others has
shown that, under normoxic conditions, HIF-1α expression can be induced by growth factors and
oncogenic proteins, which depends on the PI3K/Akt pathway (23-26). In addition, activation of
PI3K or Akt is sufficient to induce VEGF expression (14). The PI3K pathway has inherent
oncogenic properties (27;28), and constitutive activation of PI3K is present in many human
cancers (29). Multiple mechanisms are involved in the activation of PI3K in human cancers, e.g.
amplification or activating mutations of p110α gene, mutational inactivation or loss of the tumor
suppressor PTEN, which is the antagonist for PI3K (29).
Tumor angiogenesis is a complex process, involving the interaction and coordination
between different cell types within the tumor microenvironment. Among these cell types, the
tumor cells and vascular endothelial cells are especially important for tumor angiogenesis. As
described above, PI3K/Akt signaling pathway appears to play important roles in both cell types.
Recently, PI3K/Akt pathway was found to be up-regulated in tumor-derived endothelial cells
(30). However, there is no direct evidence about the functional significance of the enhanced
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endothelial PI3K/Akt signaling in tumor angiogenesis in vivo. In this study, we aimed to define
the specific role of PI3K/Akt signaling pathway in endothelial cells or cancer cells in tumorinduced angiogenesis and progression in vivo. We developed a chicken chorioallantoic
membrane (CAM) tumor model system based on a recently reported nude mouse model, in
which human cancer cells were co-implanted subcutaneously with microvascular endothelial
cells by using a biodegradable poly(lactic-co-glycolic acid) (PLGA) sponge as a scaffold (31).
The implanted human ECs will form microvessels that anastomose with the host vasculature and
transport host blood to support tumor growth (31). In this model system, tumor angiogenesis and
growth will be predominantly determined by the direct interactions between cancer cells and the
implanted human endothelial cells within the defined space of the biodegradable sponge. The
CAM model has the advantages of easy manipulation, low cost, and allowing large–scale
treatments in a relatively short time. By using this unique model, we were able to specifically
modulate the PI3K-Akt signaling in either endothelial cells or cancer cells in culture, and then
evaluate their contributions to tumor neovascularization and tumor growth in vivo. We found
that modulation of endothelial PI3K or Akt activity significantly affected tumor-induced
angiogenesis and tumor growth in vivo. Blockade of PI3K or Akt activation in cancer cells
inhibited HIF-1α-mediated VEGF expression, and resulted in dramatic inhibition of tumor
growth and angiogenesis in vivo. Downregulation of HIF-1α and VEGF expression in cancer
cells similarly inhibited tumor growth and angiogenesis in vivo. Our results demonstrated the
important roles of PI3K/Akt signaling pathway in endothelial cells and cancer cells for tumor
angiogenesis, suggesting that targeting PI3K/Akt signaling in both tumor cells and endothelial
cells may be more effective to control tumor angiogenesis and tumor progression.
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Materials and methods

Cell culture
Human ovarian cancer cells A2780 were cultured in RPMI Medium 1640 (Life Technologies
Inc., Grand Island, NY), supplemented with 10% fetal bovine serum (FBS), 50 nM insulin
(Sigma), 100 units/ml penicillin, and 100 μg/ml streptomycin. Human dermal microvascular
endothelial cells (HMVEC, Cambrex BioScience , Walkersville, MD) were cultured in
endothelial cell growth medium (EGM-2 MV, Cambrex ), and were used at passage 6 or less. All
cultures were maintained in a humid environment containing 5% CO2 at 37°C.

Adenovirus preparation and transduction efficiency
The construction of constitutively active Akt (myrislated Akt), dominant-negative Akt (AktK179M), p110α, wild-type PTEN, and phosphatase mutant PTEN (PTEN C124S) has been
described previously (14). Recombinant adenoviruses were made using the AdEasy system (32).
Briefly, the constructs were subcloned into the shuttle vector pAdTrack-CMV, then transferred
to AdEasy-1 plasmid through homologous recombination as described previously (32). The viral
vectors were then transfected into 293 cells to generate viruses. A control virus which carries the
green fluorescent protein (Ad-GFP) was derived from the same vector system. Viral titres were
determined using the BD Adeno-X™ Rapid Titer Kit (BD Biosciences Clontech, Mountain
View, CA) per the manufacturer’s instructions. Adenoviral transduction efficiency for the cell
lines was determined using the adenoviral vector Ad-GFP. To achieve more than 90% of
transduction, 50 and 100 multiplicity of infection (MOI) was used for HMVEC and A2780 cells,
respectively.
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Collection of cancer cell conditioned medium and VEGF ELISA assays
Human ovarian cancer cells A2780 were cultured in normal growth medium to 80% confluence.
The cells were washed twice with PBS, and incubated in serum-free medium for 24 h.
Conditioned medium (CM) was collected, centrifuged to remove any cellular debris and stored at
-80°C until use. VEGF levels in the CM were determined using an ELISA assay kit (R&D
systems, Minneapolis, MN) according to the manufacturer’s instruction.

Endothelial cell tube formation assay
HMVECs were cultured to about 80% confluence. The cells were either left untreated or infected
with 50 MOI of relevant adenoviruses for 24 h and were then washed and serum-starved in basal
EBM2 medium overnight. After trypsinization, cells were resuspended in basal EBM2 at a
concentration of 2 ×105 cells/ml. An aliquot of the cell suspension (50 µl) was mixed with an
equal volume of cancer cell conditioned medium or basal RPMI1640 medium. The cells were
seeded in a 96-well tissue culture plate that had been evenly coated with growth factor-reduced
Matrigel (BD Labware, Bedford, MA). Seeded cells were incubated at 37°C in a 5% CO2
incubator for 16 h, and tube formation was examined under a phase-contrast microscope
(Olympus IX-71) connected to a digital camera. Tube formation was quantified by calculating
the length of the tubular network in five randomly selected fields under 200× magnification.

Immunoblotting
After appropriate treatments, the cells were washed with ice-cold phosphate-buffered saline (140
mM NaCl, 3 mM KCl, 6 mM Na2HPO4, 1 mM KH2PO4, PH 7.4), scraped, and pelleted by
centrifugation. Whole cellular extracts were prepared using modified radioimmune precipitation
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buffer (100 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% deoxycholate acid,
0.1% SDS, 2 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 2 mM DTT, 20
μg/ml leupeptin, 20 μg/ml pepstatin. pH 7.4). Protein concentrations of the lysates were assayed
using a protein assay reagent (Bio-Rad). Aliquots (50 μg) of the protein samples were
fractionated by SDS-PAGE and transferred to a nitrocellulose membrane (Schleicher & Schuell
Biosciences, Keene, NH). The blots were blocked in 1×TBS-T solution containing 5% nonfat
dry milk for 2 h at room temperature, followed by incubation with primary antibodies overnight
at 4°C. Immunoreactivity was visualized with appropriate horseradish peroxidase-conjugated
secondary antibodies and enhanced chemiluminescence (PerkinElmer Life Sciences, Boston,
MA).

Biodegradable Sponge Fabrication
The bioabsorbable polymer scaffolds were prepared as previously described (31;33). Briefly,
PLGA (85% d,l-lactide/15%glycolide, Medisorb, Cincinnati, Ohio) was dissolved in chloroform
to yield a solution of 5% polymer. The solution was loaded into Teflon dishes packed with
sodium chloride particles which was sieved to a size between 250 and 500 μm. The solvent was
allowed to evaporate and the salt was leached by immersing films in distilled water with several
changes. Sponges were subsequently coated with polyvinyl alcohol (PVA, Aldrich Chem. Co.,
Milwaukee, WI) by immersing them for 16 h in an aqueous solution containing 10 mg/mL of
PVA in PBS. The sponges were removed from the solution, dried, and cut to 6×6×1 mm in size.
The day before implantation, sponges were soaked in 100% ethanol for 2 hours, washed twice in
PBS, and then left overnight in fresh PBS.
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Implantation of HMVEC and human tumor cells into nude mice
Just before implantation, 0.9 x 106 HMVECs infected with relevant adenoviruses or parental
HMVECs (untransduced) were mixed with 0.1 x 106 A2780 cells, and resuspended in a 1:1
mixture of EBM-MV and growth factor-reduced Matrigel (BD Labware, Bedford, MA) and
seeded into the PLGA sponges. The sponges were incubated for 30 min at 37°C to allow for
gelation of the Matrigel. Female nude mice (3 to 4 weeks old, CB.17. nude, Taconic,
Germantown, NY) were anesthetized with pentobarbital, and two sponges were surgically
implanted subcutaneously on the right and left flank regions of each mouse. Mice were
euthanized 21 days after transplantation, and the implants were retrieved, immediately measured
with calipers, and weighed in an electronic balance. The tumor tissues were fixed overnight in
Bouin’s solution, and processed for histological examination. The care and treatment of
experimental animals was in accordance with West Virginia University Animal Care and Use
Committee Policy for Survival Surgery on Rodents.

Implantation of HMVEC and Human Tumor Cells into Chicken Chorioallantoic
Membrane (CAM)
Fertilized chicken eggs (standard pathogen free grade; SPAFAS, Preston, CT) were incubated for
7 d at 37°C in a humidified atmosphere. An artificial air sac was created over the well-formed
chicken chorioallantoic membrane (CAM) as described (14). A 1.0 × 1.0-cm square window was
cut in the shell over the artificial air sac and sealed with Scotch® tape. On the next day, a piece of
PLGA sponge loaded with the cell mixture as described was put onto the exposed CAM. The
eggshell window was resealed and the embryo was maintained at 37°C in a humidified
atmosphere. the chick embryos were opened11 days after implantation, and the implants were

111

removed, immediately measured with calipers, and weighed in an electronic balance. The tumor
tissues were fixed in Bouin’s solution overnight, and processed for histological examination.

Immuonohistochemical Staining of CD31 and Quantification of Microvessel Density
Neovascularization were evaluated in human tumors grown in nude mice and on the CAM by
immuonohistochemical staining of the vascular endothelial marker CD31. Tissue sections were
deparaffinized and rehydrated and antigen retrieval was performed by heating in a microwave
oven to 89ºC for 10 min in BD PharmingenTM Retrievagen A solution (pH 6.0). Human
microvessels were visualized by incubating sections at 4ºC overnight with 1:40 dilution of
monoclonal mouse antihuman CD31 antibody (Clone JC/70A, DakoCytomation California,
Carpinteria, CA). Sections were incubated with appropriate secondary antibodies, and
visualization of the complex was accomplished using an ABC staining kit (Santa Cruz
Biotechnology, Santa Cruz, CA). The sections were counterstained with haematoxylin,
dehydrated and mounted. The same procedure without primary antibody was included as a
negative control.
Microvessel density was determined as described (34). Since microvessels are distributed
heterogeneously throughout the tumor, two to four sections from each tumor were scanned under
low-power magnification (40×) to identify areas of highest CD31-positive vessel density (hotspots). Then 5 high-power fields (400×) were randomly chosen from each section to count for
the number of CD31-positive microvessels. All of the areas in which cells were stained with the
endothelial cell marker CD31 were considered as a microvessel, in spite of their size or
morphology. Data were collected by two independent observers without knowledge of which

112

tumors were viewed.

Microvessel Density (MVD) was defined as the total number of

microvessels per 200x field (mean± SE).

Generation of A2780 cells stably expressing Si-RNA against HIF-1α or VEGF
The hairpin siRNA-encoding DNA oligonucleotides were prepared by Ambion (Austin, TX).
The

targeting

sequences

used

to

silence

HIF-1α

and

VEGF

were:

5'-

GTGGATTACCACAGCTGA-3' and 5'-GGAGTACCCTGATGAGATC-3', respectively. This
sequence was checked against the database to confirm specificity. As a negative control, a
scrambled siRNA sequence was used. The hairpin oligonucleotides were ligated into pSilencer
2.1-U6 vector (Ambion, Austin, TX). The constructs were transfected into A2780 cells by
Lipofectamine (Invitrogen, Carlsbad, CA) per the manufacturer’s instructions. G418 was added
to the culture to a final concentration of 500 µg/ml24 h after transfection. After two weeks of
selection, the resultant colonies were pooled and maintained in the medium containing 250
µg/ml of G418.

Transient Transfection and Luciferase Reporter Assay
The VEGF promoter reporter was constructed by inserting 47 bp of human VEGF promoter 5’flanking sequence (between -985 to -939) into the pGL2-basic luciferase vector (Promega) as
described previously (19). The dominant-negative HIF-1α expressing plasmid was described
previously (19). The cells were co-transfected with the reporter, pCMV-β-gal plasmid, and a
dominant-negative or wild-type HIF-1α expressing plasmid using lipofectomine reagent
(Invitrogen). An empty vector plasmid was used to adjust the equal amounts of plasmids used in
each experiment. Luciferase activity was measured 24 h after transfection using a luciferase
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assay reagent (Promega) and normalized to β-galactosidase activity. The data were mean ± SD
from three replicate experiments.

Statistical Analysis
Statistical significance was determined using one-way ANOVA or the Student’s t-test. SPSS
statistical software (SPSS, Chicago, IL) was employed.

Results

PI3K/Akt signaling in endothelial cells is important for cancer cell conditioned mediuminduced endothelial cell tube formation
Numerous studies have shown that activation of PI3K/AKT signaling pathway in ECs is crucial
for endothelial proliferation, migration, survival, and differentiation induced by the prototypical
angiogenic factors, including basic fibroblast growth factor (bFGF), VEGF, and angiopoietin-1
(11-15). Akt activity was found to be up-regulated in tumor-derived ECs (35). Here we wanted
to determine the specific roles of PI3K and Akt activities in endothelial cells in tumor-induced
angiogenesis. As shown in Fig 1A, conditioned medium (CM) generated from human ovarian
cancer cell A2780 was able to dramatically induce Akt activation in human microvascular
endothelial cells (HMVECs), which was completely blocked by PI3K inhibitor LY294002. To
more specifically inhibit PI3K activity in ECs, we constructed adenovirus vector expressing the
tumor suppressor PTEN (Ad-PTEN), which is the natural antagonist of PI3K. We also generated
adenovirus expressing a dominant-negative Akt (Ad-Akt DN) to inhibit Akt activity, which is a
downstream target of PI3K. To determine the roles of PI3K and Akt in tumor-induced
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angiogenesis, we first performed endothelial cell tube formation assay. As shown in Fig. 1B,
pretreatment of HMVECs with LY294002 or transduction of the cells with Ad-PTEN or Ad-Akt
DN significantly inhibited ovarian cancer cell CM-induced endothelial cell capillary formation,
indicating that activation of PI3K and Akt in ECs is required for tumor-induced angiogenesis in
vitro. Then we asked whether overexpession of active forms of PI3K or Akt enhanced tumorinduced angiogenesis. We upregulated PI3K or Akt activity in HMVECs by infecting the cells
with adenovirus expressing active form of PI3K (Ad-p110) or Akt (Ad-mAkt). As expected,
overexpression of p110 and Akt induced the phosphorylation of the corresponding downstream
kinase Akt and GSK-3β, respectively (Fig. 1F). Expression of p110α or the active Akt was
sufficient to induce endothelial cell tube formation, and enhanced the effects of cancer cell CM
on tube formation as compared with the mock-infected and vector-infected cells (Fig. 1D, E).
Taken together, these data demonstrate that PI3K and Akt activities in human endothelial cells
are important for EC function in response to the stimulation of cancer cell secreted-angiogenic
factors, suggesting an important role of endothelial PI3K/Akt signaling in tumor-induced
angiogenesis.

Modulation of PI3K activity in endothelial cells affects tumor growth and angiogenesis in
vivo
We next wanted to determine the role of PI3K in endothelial cells in tumor-induced angiogenesis
in vivo. We utilized a recently established animal model to study tumor-induced angiogenesis. In
this model, human cancer cells are co-transplanted with human microvascular ECs into nude
mice by using a biodegradable PLGA sponge as a scaffold (31). The implanted human ECs will
form microvessels that anastomose with the host vasculature and transport mouse blood to
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support tumor growth (31). By using this unique model, we were able to specifically modulate
the PI3K and Akt activities in ECs, and evaluate the contribution of endothelial PI3K/Akt
signaling to tumor neovascularization. We implanted adenovirus-transduced HMVECs along
with human ovarian cancer cell A2780 into nude mice. As shown in Fig 2A-C, co-transplantation
of HMVECs facilitated tumor growth compared with implantation of tumor cell alone.
Overexpression of p110α in HMVECs (EC/Ad-p110) significantly increased the weight and
volume of tumors when compared with tumors formed from co-transplantation of A2780 with
parental HMVECs and adenoviral vector-infected HMVECs (Fig 2A-C). In contrast, tumors
developed by the implantation of A2780 and HMVECs expressing with PTEN (EC/Ad-PTEN)
were much smaller (Fig 2A-C). Implantation of HMVECs expressing p110α did not form tumors,
suggesting that the primary HMVECs overexpressing PI3K were not transformed to develop
tumors by themselves. We modified the above-mentioned nude mice model to establish a new
animal system in our laboratory for studying tumor angiogenesis—the chicken chorioallantoic
membrane (CAM) tumor model. Compared with the nude mouse model, the CAM model has the
advantages of easy manipulation, low cost, and allowing large–scale treatments in a relatively
short time. We modified PI3K activity in HMVECs and performed similar tumor assays in the
CAM model. We observed similar results by using the CAM tumor model when compared to the
nude mice model (Fig 2D-E). These results demonstrated that PI3K activity in endothelial cells
is important for tumor growth in vivo.
The development and growth of solid tumors is dependent on tumor-induced
angiogenesis. To determine whether the modulation of endothelial PI3K activity affected tumor
angiogenesis, we visualized tumor microvessels by immunohistochemical staining using a
monoclonal anti-human CD31 antibody, and determined the microvessel density in the tumor
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sections. The implanted human ECs contributed to the formation of functional blood vessels in
the tumors (Fig. 2F, 2I). As shown in Fig. 2F-K, tumors formed from co-transplantation of
EC/Ad-p110 and A2780 were significantly more vascularized than those induced by
implantation of EC/Ad-GFP and A2780. Tumors developed from implantation of EC/Ad-PTEN
and A2780 were less vascularized (Fig. 2F-K). These data indicate that endothelial PI3K activity
plays an important role in tumor-induced angiogenesis, which in turn affects tumor growth in
vivo.

The activity of Akt, the key downstream target of PI3K, in ECs is important for tumor
growth and angiogenesis in vivo
The serine/threonine kinase Akt is a key transducer of PI3K signal. We showed that endothelial
Akt activity was important for cancer cell CM-induced endothelial cell tube formation (Fig. 1).
Here, we wanted to further determine the role of Akt activity endothelial cells in tumor growth
and angiogenesis in vivo. To modify the Akt activity in HMVECs, the cultured cells were either
infected with Ad-mAkt (EC/Ad-mAkt) to express constitutively active Akt, or infected with AdAkt DN (EC/Ad-Akt DN) to inhibit endogenous Akt activity. The transduced HMVECs were
then mixed with A2780 ovarian cancer cells, and transplanted into nude mice or the CAM. As
shown in Fig 3A-E, tumors that developed by the implantation of A2780 and EC/Ad-mAkt were
significantly larger when compared to tumors formed from co-transplantation of A2780 with
parental HMVECs and HMVECs infected with Ad-GFP (EC/Ad-GFP), whereas tumors
developed by implantation of A2780 and EC/Ad-Akt DN were significantly smaller than those in
the A2780 plus EC/Ad-mAkt, and A2780 plus EC/Ad-GFP groups. Implantation of endothelial
cells infected by Ad-mAKt alone did not form tumors. These results demonstrate that Akt
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activity in ECs is important for tumor growth in vivo, which is similar to PI3K in the cells.
We next examined whether the effect of Akt in ECs on tumor growth correlated with
changes in tumor-induced angiogenesis in vivo. As shown in Figs. 3F-I, significantly more robust
angiogenesis was observed in tumors generated from the co-transplantation of EC/Ad-mAkt and
A2780 when compared with the control group (EC/Ad-GFP and A2780). Conversely, much less
neovascularization was observed in tumors developed from implantation of EC/Ad-Akt DN and
A2780 (Fig. 3F-I). These experiments demonstrate that endothelial Akt activity is important for
tumor-induced angiogenesis in vivo.

PI3K/Akt signaling pathway regulates HIF-1α-mediated VEGF expression in human
ovarian cancer cells; Inhibition of PI3K and Akt activity in the cells compromises tumorinduced in vitro angiogenesis
Tumor angiogenesis is a complex process that is regulated by many angiogenic factors. One of
these key factors is VEGF, which is a potent and EC-specific mitogen that plays a crucial role
during the process of tumor angiogenesis. VEGF expression by tumor cells directly correlates
with angiogenesis within the tumors (16). Previous studies showed that PI3K/Akt signaling
pathway is crucial for VEGF expression in response to hypoxia, growth factors, and oncogenic
proteins (19;20;23-25;36). Consistent with these findings, we showed here that PI3K selective
inhibitor LY294002 significantly reduced VEGF production by human ovarian cancer cell line
A2780 (Fig. 4A). Similar effects were observed in experiments where we utilized Ad-PTEN or
Ad-Akt DN to more specifically inhibit PI3K or Akt activity in the cells (Fig. 4A). Inhibition of
PI3K and Akt activity by LY294002 or adenoviral constructs markedly suppressed the
expression of HIF-1α, which is one of the major transcriptional regulators of the VEGF gene
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(Fig. 4B). Transfection of the cells with a plasmid expressing a dominant-negative HIF-1α
inhibited the expression of the luciferase reporter driven by the full-length promoter of human
VGEF gene in a dose-dependent manner (Fig. 4C). LY294002, Ad-PTEN, or Ad-Akt DN also
inhibited VEGF luciferase reporter activity, and these inhibitory effects could be completely
reversed by overexpression of wild-type HIF-1α (Fig. 4C). Collectively, these data indicate that
HIF-1α-mediated VEGF expression is regulated by PI3K/Akt signaling pathway in human
ovarian cancer cells. Because HIF-1α-mediated VEGF expression is important for tumor
angiogenesis, these results suggest that inhibition of PI3K/Akt signaling in cancer cells may have
an inhibitory effect on tumor angiogenesis. To directly test this hypothesis, we first performed
endothelial cell tube formation assay. As shown in Fig. 4D, conditioned medium collected from
A2780 cells infected with Ad-PTEN or Ad-Akt-DN had much weaker effects on endothelial cell
capillary formation when compared to the effects of CM collected from parental A2780 and AdGFP-infected A2780 cell. These results indicate that PI3K and Akt activities in cancer cells,
which regulate VEGF expression, are important for tumor-induced angiogenesis in vitro.

Inhibition of PI3K or Akt activity in cancer cells suppresses tumor growth and tumor in
vivo
We wanted to further determine whether inhibition of PI3K or Akt activity in cancer cells had
any inhibitory effects on tumor growth and angiogenesis in vivo. PI3K and Akt activity in A2780
cells was inhibited by adenoviral vector-mediated expression of PTEN and a dominant-negative
Akt, respectively. The transduced cells were then mixed with normal HMVECs, and implanted
onto the chicken CAM to allow tumor formation. We found that tumors developed from the
implantation of HMVECs and A2780 overexpressing PTEN or dominant-negative Akt were
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significantly smaller when compared to tumors formed from the co-implantation of HMVECs
and parental A2780, or adenoviral vector-infected A2780 (Fig 5A). We next examined the
microvessel density in tumor tissue sections to determine whether the inhibitory effects on tumor
growth correlated with the decrease in tumor-induced angiogenesis in vivo. As shown in Fig. 5B,
tumors developed from co-implantation of HMVECs and A2780/Ad-PTEN and A2780/Ad-Akt
DN were significantly less vascularized than those from the implantation of HMVECs and
A2780/Ad-GFP. We also showed that expression of HIF-1α and VEGF was much lower in
tumors developed from co-implantation of HMVECs and A2780/Ad-PTEN and A2780/Ad-Akt
DN when compared to the control groups (Fig 5C). These data demonstrate that PI3K and Akt
activities in cancer cells are important for tumor growth in vivo, which is due in part to the
regulation of HIF-1α and VEGF expression in the process of tumor-induced angiogenesis.

Knockdown of HIF-1α and VEGF expression by Si-RNA in human ovarian cancer cells
inhibit tumor growth and angiogenesis in vivo
To determine whether inhibition of HIF-1α and VEGF expression in cancer cells has similar
inhibitory effects on tumor growth and angiogenesis, we specifically inhibited HIF-1α and
VEGF expression using the siRNAs against HIF-1α and VEGF, respectively. The cells were
transfected with constructs expressing HIF-1α or VEGF si-RNA, and selected with G418 to
obtain stable cell clones. A2780 cells stably expressing si-RNA against HIF-1α decreased HIF1α protein expression, which correlated with suppression of VEGF transcriptional activation and
VEGF protein secretion (Fig 6A).

A2780 cells stably expressing si-RNA against VEGF

effectively inhibited VEGF mRNA and protein expression (Fig 6B). The conditioned medium
generated from A2780 cells stably expressing si-RNA against HIF-1α or VEGF induced
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significantly less endothelial cell capillary formation when compared to those in the control
group (Fig 6C). To test whether inhibition of HIF-1α or VEGF expression in cancer cells
decreases tumor angiogenesis and tumor growth in vivo, A2780 cells stably expressing si-RNA
against HIF-1α or VEGF were mixed with normal HMVECs, and implanted onto the chicken
CAM to allow the tumor formation. We found that tumors developed by the implantation of
HMVECs and A2780 cells stably expressing si-RNA against HIF-1α or VEGF were
significantly smaller when compared to tumors formed from co-implantation of HMVECs and
parental A2780 cells or A2780 cells expressing the scramble siRNA sequence (Fig 7A). When
compared to the control group, tumors developed from the implantation of HMVECs and A2780
cells stably expressing si-RNA against HIF-1α or VEGF had significantly less levels of
angiogenesis response (Fig 7B). Expression of VEGF was much lower in tumors developed
from the co-implantation of HMVEC and A2780 cells stably expressing si-RNA against HIF-1α
or VEGF when compared to the control group (Fig 7C). These data demonstrate that HIF-1α or
VEGF expression in cancer cells is important for tumor growth and angiogenesis in vivo.

Discussion

Angiogenesis is a vital process during tumor progression because it supports rapid growth of
tumor cells and facilitates metastases (1;2). The study of the molecular mechanisms involved in
tumor angiogenesis will identify potential therapeutic targets for treatment of cancer by the new
antiangiogenic strategy. Multiple cell types and a variety of proteins are involved in the
regulation of tumor angiogenesis. Cancer and vascular endothelial cells are the key cell types for
tumor angiogenesis. The angiogenic cytokines secreted by tumor cells are the primary stimuli to
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initiate tumor angiogenesis. VEGF is one of the key cytokines that plays an important role for
tumor angiogenesis, which has been considered as one of the primary targets for anti-angiogenic
therapy because inhibition of VEGF function has potent anti-tumor activities in experimental and
clinical studies (3). HIF-1 is the principal transcription factor that regulates VEGF expression
under both hypoxic and normoxic conditions (19;20;23-25;37). Vascular endothelial cells in the
tumor microenvironment respond to the proangiogenic stimuli, become activated, and
differentiate into new capillaries. Multiple signaling pathways are involved in the induction of
angiogenic factors in tumor cells and the functional responses of ECs to these stimuli.
Accumulating evidence suggests that PI3K/Akt signaling pathway plays a key role in both
cancer cells and endothelial cells (29). In this study, we aimed to specifically modulate PI3K and
Akt activities in either EC or cancer cells, and to define their roles in the regulation of
angiogenesis and tumor growth in vivo.
To specifically modify PI3K/Akt signaling in either endothelial cells or cancer cells, and
examine their effects on tumor angiogenesis, we developed a chicken CAM model system. In
this model, human microvascular endothelial cells (HMVECs) were mixed with human ovarian
cancer cell A2780, absorbed into a biodegradable PLGA sponge in vitro, and implanted onto the
chicken CAM. The porous biodegradable sponges function as temporary scaffolds that maintain
implanted cells in a defined space and guide the organization and differentiation of the
transplanted human ECs into functional microvessels that anastomose with the host vasculature
and transport blood to support tumor growth (31;33;38). In this model system, co-implantation of
human ECs and cancer cells resulted in the development of human tumors supported by
microvessels developed from the implanted human endothelial cells in the chicken CAM. The
development of tumors in the implants was primarily determined by the direct interaction of the
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implanted human ECs and cancer cells. This unique model system allowed us to genetically
modify PI3K and Akt activities in either ECs or cancer cells in vitro, and evaluate their
contributions to tumor neovascularization and tumor growth in vivo. Our chicken CAM model
system was modified from a recently reported nude mouse model (31). Eleven days after
transplantation, just before the hatching of the chicks, we observed the formation of large tumors
in the sponge implants in the chicken CAM. The overall sizes of tumors generated in the CAM
were smaller compared to those generated in the nude mouse model, which usually took 3
weeks. However, we observed similar changes in tumor sizes and tumor angiogenesis in both
model systems in response to PI3K/Akt signaling. Therefore, we have successfully established a
novel chicken CAM model system to study tumor angiogenesis that can substitute for the nude
mouse model. The CAM model has the advantages of easy manipulation, low cost, and allowing
large–scale treatments in a relatively short time.
Considerable evidence suggests that PI3K/Akt signaling pathway in ECs is crucial for the
functional responses of ECs to a variety of prototypical angiogenic factors including bFGF,
VEGF and angiopoietin-1 (11-15). Akt activity was found to be constitutively activated in
tumor-derived ECs which showed enhanced survival, proadhesive, and angiogenic properties
(35). Therefore, we hypothesized that endothelial PI3K/Akt signaling is important for
angiogenesis and tumor growth in vivo. We first demonstrated that PI3K/Akt signaling pathway
was significantly activated in normal human microvascular endothelial cells upon the stimulation
by conditioned medium (CM) generated from human ovarian cancer cells A2780. The activation
of PI3K/Akt signaling correlated with enhanced capillary formation of HMVEC in vitro induced
by cancer cell CM, suggesting that PI3K/Akt pathway may be important for the angiogenic
responses of ECs to cancer cell-secreted soluble factors. This was confirmed by subsequent
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experiments, in which we showed that blockade of PI3K-Akt signaling in HMVECs completely
inhibited cancer cell CM-induced endothelial cell tube formation, and overexpression of wildtype PI3K or active Akt in HMVECs enhanced cancer cell CM-induced angiogenesis in vitro.
These observations strongly suggest that endothelial PI3K/Akt signaling may play a critical role
in tumor-induced angiogenesis in vivo. To test this, we genetically modified PI3K or Akt activity
in HMEVCs by adenoviral vector-mediated transduction, followed by co-implantation with
normal A2780 cancer cells into nude mice or onto the chicken CAM. We found that inhibition of
PI3K/Akt signaling in HMVECs had dramatic inhibitory effects, whereas upregulation of PI3K
or Akt activity in HMVECs had significant stimulatory effects on angiogenesis and tumor
growth in vivo. In these experiments, we selectively modulated PI3K/Akt signaling in ECs so
that only the endothelial functioning would be changed during tumor angiogenesis and
development in vivo. Therefore, our data clearly demonstrate that endothelial PI3K/Akt signaling
is crucial for tumor-induced angiogenesis, which further controls tumor growth in vivo.
Malignant tumor cells can secrete a variety of angiogenic factors such as bFGF, VEGF, TGF-β,
PDGF, and endothelin-1 (39), and many of these factors can induce activation of PI3K/Akt
signaling in ECs. Thus, these results suggest that it might be quite effective to suppress tumor
angiogenesis by inhibiting endothelial PI3K/Akt signaling, which appears to be a converging
signaling cascade harnessed by many angiogenic factors secreted by tumor cells.
In this study, we showed that in human ovarian cancer cells, PI3K/Akt signaling pathway
was required for HIF-1α expression and VEGF production. Previous studies showed that
PI3K/Akt signaling pathway regulates VEGF expression in cancer cells in response to hypoxia,
growth factors, and oncogenic proteins (19;20;23-25;40). Consistent with these reports, we
showed that inhibition of PI3K or Akt activity significantly suppressed VEGF production in
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human ovarian cancer cell A2780. We further showed that blockade of PI3K or Akt activity
inhibited HIF-1α expression, which is one of the major transcriptional regulators of the VEGF
gene expression under both hypoxic and normoxic conditions, and overexpression of wild-type
HIF-1α reversed the inhibitory effects on VEGF transcriptional activation by blockade of PI3K
and Akt activation. These results indicate that PI3K/Akt signaling controls HIF-1α-mediated
VEGF expression in human ovarian cancer cells. VEGF gene transcription can also be regulated
by other transcriptional factors such as AP-1, Sp1, and NF-κB (41;42), and Akt-mediated
induction of VEGF expression may be independent of HIF-1α expression under certain
circumstances (42). In this study we did not rule out the involvement of other transcriptional
factors in PI3K/Akt-regulated VEGF expression, but the data demonstrate a significant role of
HIF-1α in the PI3K and Akt-regulated VEGF expression. VEGF is one of the key angiogenic
factors secreted by tumor cells. The role of PI3K/Akt signaling in regulating VEGF expression
suggests that PI3K and Akt activities in cancer cells may be important for tumor angiogenesis.
Indeed, we found that inhibition of PI3K or Akt activity in cancer cells substantially suppressed
tumor-induced angiogenesis in vitro and in vivo, which correlated with retarded tumor growth in
vivo. Blockade of PI3K or Akt activity in cancer cells may affect tumor growth independent of
angiogenesis since PI3K/Akt signaling also plays important roles in regulating tumor cell
proliferation and survival. Our data indicate that PI3K and Akt activities in cancer cells are
important for tumor growth in vivo, which is due at least in part to its regulation of tumorinduced angiogenesis via HIF-1α and VEGF expression in cancer cells.
We showed that PI3K and Akt activity in cancer cells regulated HIF-1α and VEGF
expression in vitro and in vivo, and inhibition of PI3K or Akt activation suppressed tumor growth
and angiogenesis in vivo. These results suggest that HIF-1α and VEGF are important
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downstream effectors of PI3K/Akt signaling in cancer cells during the process of tumor
angiogenesis. Previous work showed that loss of either HIF-1α or HIF-1β retarded tumor growth,
accompanied by decreased vascularization (43;44). It has been well documented that VEGF
expression correlated with microvessel density of tumor tissues, and was associated with poor
prognosis in several tumor types (3). Experimental and clinical studies have shown that
inhibition of VEGF functioning inhibits tumor growth, and improves the responsiveness of
cancer patients to conventional chemotherapy (3;45;46). In this study, we wanted to determine
whether inhibition of HIF-1α or VEGF expression in cancer cells was able to inhibit tumor
growth and angiogenesis in vivo. We used Si-RNA constructs to specifically knock-down HIF1α or VEGF expression in A2780 cells. The A2780 cells stably expressing Si-RNA against HIF1α or VEGF were then mixed with HMVECs, and transplanted onto the chicken CAM. We
found that inhibition of HIF-1α or VEGF expression in cancer cells markedly inhibited tumorinduced angiogenesis, and suppressed tumor growth in vivo, which was similar to the effects of
inhibition of PI3K/Akt signaling in cancer cells. These data demonstrate that HIF-1α or VEGF
expression in cancer cells is important for tumor growth and angiogenesis in vivo. Interestingly, a
previous study showed that although loss of HIF-1α inhibited VEGF expression, the growth of
tumors was not retarded (20). Another study showed that loss of HIF-1α inhibited tumor growth,
however, vascular density was similar in wild-type and HIF-1α-null tumors (47). In both of the
studies, tumors were generated by subcutaneous injection of tumor cells into nude mice. In these
endothelial and cancer cells co-implantation model systems, tumor angiogenesis and growth
were primarily determined by the direct interactions between cancer cells and endothelial cells.
The discrepancies between these previous reports and ours may result from the different model
systems used to generate tumors.
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In summary, we demonstrate that modulation of endothelial PI3K or Akt activity
significantly affected tumor-induced angiogenesis and tumor growth. Blockade of PI3K or Akt
activation in tumor cells inhibited HIF-1-mediated VEGF expression, and resulted in dramatic
inhibition of tumor growth and angiogenesis in vivo. Similarly, downregulation of HIF-1α or
VEGF expression in cancer cells inhibited tumor growth and angiogenesis in vivo. Our results
thus demonstrate the important role of PI3K/Akt signaling pathway in both endothelial cells and
cancer cells for tumor angiogenesis, suggesting that the targeting of PI3K/Akt signaling in both
endothelial cells and cacer cells may be more effective to control tumor growth and angiogenesis.
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Figures and figure legends:
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Fig. 1. PI3K/Akt signaling in human microvascular endothelial cells (HMVEC) is critical
for tumor conditioned medium-induced endothelial cell tube formation.

A: conditioned

medium (CM) from A2780 cell culture activates PI3K/Akt signaling in HMVEC. A2780 CM
was added into serum-starved endothelial cells for 30 min, which were pretreated or not with
PI3K specific inhibitor LY94002 for 1 h. Cell lysates were subjected to immunoblotting analysis
using antibodies against phospho-Akt, total Akt, or β-actin, respectively. B: PI3K and Akt are
required for A2780 CM-induced endothelial tube formation. HMVEC cells were either
uninfected (mock) or infected with Ad-GFP, Ad-PTEN, Ad-PTEN C/S, or Ad-Akt DN for 24 h.
The cells were then serum-starved, and then incubated in the absence or presence of LY94002
for 30 min. Tube formation assay was performed on growth factor-reduced Matrigel in the
presence or absence of A2780 conditioned medium. Shown are representative tube-like
structures photographed 24 h after the assay under a phase contrast microscope. C: quantification
of tube length from the experiments described in Fig 1B. (*indicates significant difference when
compared to RPMI-treated control, p<0.01; #indicates significant difference when compared to
CM-treated control, p<0.01). D: expression of active forms of PI3K or Akt enhances tumorinduced angiogenesis in vitro. HMVEC cells were either uninfected (mock) or infected with AdGFP, Ad-p110, or Ad-mAkt (active Akt) for 24 h. The cells were then serum-starved, and tube
formation assay was performed and the tube structures were photographed as described above. E:
summary of tube length from the experiments described in Fig 1D. (*indicates significant
difference when compared to Mock and Ad-GFP groups, p<0.05). F: Left panel, HMVEC were
either uninfected (Mock) or infected with Ad-GFP or Ad-p110 for 24 h. The cells were serum
starved overnight, cell lysates were subjected to immunobloting analysis using antibodies against
phospho-Akt, total Akt, p110, and β-actin, respectively. Right panel, cell lysates from mock-
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infected endothelial cells or cells infected with Ad-GFP or Ad-mAkt were analysed by
immunobloting using antibodies against phospho-GSK3β, total GSK3β, total Akt, or β-actin,
respectively.
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Fig. 2. PI3K activity in human endothelial cells is important for tumor growth and tumor
angiogenesis in vivo. A: Results generated from nude mice tumor model. Shown are
macroscopic views of representative tumors. A2780 ovarian cancer cells (0.1×106) were mixed
with 0.9×106 HMVECs uninfected or infected with Ad-GFP, Ad-p110 or Ad-PTEN. The cell
mixture was absorbed into PLGA sponges and implanted subcutaneously into nude mice. Mice
were euthanized 21 days after transplantation, and the implants were retrieved and photographed.
B: Summary of tumor weight from the experiments described in Fig 2A. Tumor weight was
measured by an electronic balance. Data represent mean values ± SE from 4 replicates. C:
Summary of tumor volume from the experiments described in Fig 2A. The three dimensions of
tumors were measured with a caliper and tumor volume was calculated by the formula: length ×
width × depth. Data represent mean values ± SE from 4 replicates. (*indicates significant
difference when compared to A2780 group, p < 0.05; ** indicates significant difference when
compared to A2780 + EC group, p < 0.05; #indicates significant difference when compared to
A2780 + EC and A2780 + EC/Ad-GFP groups, p<0.05 compared with). D: Results generated
from the chicken chorioallantoic membrane (CAM) model. Shown are macroscopic views of
representative tumors from the CAM model. A2780 and HMVEC cell mixtures as described
above were absorbed into PLGA sponges, and implanted onto the CAM of day 8 chicken
embryos. Tumors were removed from the CAM 12 days after implantation, and photographed
under an anatomical microscope. E: Summary of tumor weight from the experiments described
in Fig 2D. Tumor weight was measured by an electronic balance. Data represent mean values ±
SE from 5 replicates. (*indicates significant difference when compared to A2780 group, p < 0.05;
**indicates significant difference when compared to A2780 + EC group, p < 0.05; #indicates
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significant difference when compared to A2780 + EC and A2780 + EC/Ad-GFP groups, p<0.05).
F-K: Modulation of PI3K activity in human endothelial cells affects tumor induced-angiogenesis.
F: Implanted human endothelial cells form functional blood vessels inside the tumors generated
in the nude mouse model. Tumor sections at 5 µM were stained using a monoclonal anti-human
CD31 antibody to visualize the microvessels inside the tumors. 2nd IgG: negative control. G:
Representative CD31 staining (brown color) of tissue sections of tumors generated in the nude
mouse model. Original magnification of the microphotographs: 200×. H: Quantitation of CD31positive microvessels within tumor tissues generated in the nude mouse model. Data represent
the mean number of microvessels obtained from five 200× field (mean± SE). (*indicates
significant difference when compared to A2780+EC and A2780+EC/Ad-GFP groups, p < 0.05).
I: Implanted human endothelial cells form functional blood vessels inside the tumors generated
in the CAM model. Microvessels inside the tumors were visualized by immunohistochemical
staining using a monoclonal anti-human CD31 antibody. 2nd IgG: negative control. J: CD31
staining (brown color) of tissue sections of tumors generated from the CAM model. Original
magnification of the microphotographs: 400×. K: Quantitation of CD31-positive microvessels
within tumor tissues generated from the CAM model. Data represent the mean number of
microvessels obtained from five 400× field (mean± SE). (*indicates significant difference when
compared to A2780+EC and A2780+EC/Ad-GFP groups, p < 0.05).
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Fig. 3. Modulation of Akt activity in human endothelial cells affects tumor growth and
tumor induced-angiogenesis in vivo. A: Macroscopic views of representative tumors generated
from nude mouse tumor model. A2780 ovarian cancer cells (0.1×106) were mixed with 0.9×106
HMVEC uninfected or infected with Ad-GFP, Ad-mAkt or Ad-Akt DN. The cell mixture was
absorbed into PLGA sponges, and implanted subcutaneously into nude mice. Mice were
euthanized21 days after transplantation, and the implants were retrieved and photographed. B:
Summary of tumor weight from the experiments described in Fig 3A. Data represent mean
values ± SE from 4 replicates. C: Summary of tumor volume from the experiments described in
Fig 3A. Data represent mean values ± SE from 4 replicates. (*indicates significant difference
when compared to A2780 group, p < 0.05; **indicates significant difference when compared to
A2780 + EC group, p < 0.05; # indicates significant difference when compared to A2780 + EC
and A2780 + EC/Ad-GFP groups, p<0.05). D: Macroscopic view of representative tumors
generated from the CAM tumor model. The A2780 and HMVEC cell mixtures as describes
above were absorbed into PLGA sponges, and implanted onto the CAM of day 8 chicken
embryos. Tumors were removed from the CAM12 days after implantation, and photographed
under an anatomical microscope. E: Summary of tumor weight from the experiments described
in Fig 3D. Data represent mean values ± SE from 6 replicates. (*indicates significant difference
when compared to A2780 group, p<0.05; ** indicates significant difference when compared to
A2780+EC and A2780+EC/Ad-GFP groups, p<0.05; #indicates significant difference when
compared to A2780+EC/Ad-p110 group, p<0.05). F: Modulation of Akt activity in human
endothelial cells affects tumor induced-angiogenesis in the nude mice model. Shown are
representative CD31 staining (brown color) of tissue sections of tumors from nude mice.
Original magnification of the microphotographs: 200×. G: Quantification of CD31-positive
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microvessels within tumor tissues from the nude mice model. Data represent the mean number of
microvessels obtained from five 200× field (mean± SE). (*indicates significant difference when
compared to A2780+EC and A2780+EC/Ad-GFP groups, p<0.05; #indicates significant
difference when compared to A2780 + EC/Ad-p110 group, p<0.05). H: Modulation of Akt
activity in human endothelial cells affects tumor induced-angiogenesis in the CAM model.
Shown are representative CD31 staining (brown color) of tissue sections of the tumors. Original
magnification of the microphotographs: 400×. I: Quantification of CD31-positive microvessels
within tumor tissues generated in the CAM model. Data represent the mean number of
microvessels obtained from five 400× field (mean± SE). (*indicates significant difference when
compared to A2780+EC and A2780+EC/Ad-GFP groups, p < 0.05; #indicates significant
difference when compared to A2780 + EC/Ad-mAkt group, p < 0.05).
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Fig. 4. PI3K-Akt signaling regulates VEGF expression through HIF-1α in human ovarian
cancer cells; inhibition of PI3K or Akt activity in the cells inhibits tumor CM-induced EC
tube formation. A: Inhibition of PI3K and Akt activity reduces VEGF production by A2780
cells. Left panel, 2780 cells were treated with the indicated doses of LY294002 for 12 h, and
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VEGF levels in the conditioned medium were measured by ELISA. Right panel, A2780 cells
infected by Ad-GFP, Ad-PTEN, or Ad-Akt DN have reduced VEGF expression. B: Inhibition of
PI3K and Akt activity inhibits HIF-1α expression. Left panel, A2780 cells were treated with the
indicated doses of LY294002 or solvent DMSO for 6 h. Western blotting was performed to
detect the levels of HIF-1α, phosphor-Akt, total Akt, and β–actin, respectively. Right panel, cell
lysates were prepared from parental A2780 cells, A2780 cells infected by Ad-GFP, Ad-PTEN, or
Ad-Akt DN. Immunoblotting was performed as described above. C: PI3K and Akt activities
regulate HIF-1α-mediated transcriptional activation of VEGF. Left panel, A2780 cells were cotransfected with a luciferase reporter construct driven by the full-length promoter of VEGF gene
and a plasmid expressing a dominant-negative HIF-1α. Luciferase activity was measured 24 h
after transfection. Middle panel, A2780 cells were co-transfected with the VEGF luciferase
reporter construct and a plasmid expressing wild-type HIF-1α. The cells were then treated with
LY294002. Luciferase activity was measured 12 h after the treatment. Right panel, A2780 cells
infected by Ad-GFP, Ad-PTEN, or Ad-Akt DN were co-transfected with the VEGF luciferase
reporter construct and a plasmid expressing wild-type HIF-1α. Luciferase activity was measured
24 h after transfection. D: Expression of PTEN and dominant-negative Akt in A2780 cells
inhibited tumor CM-induced endothelial cell tube formation. Upper panel, EC tube formation
assay was performed on growth factor-reduced Matrigel in the presence or absence of
conditioned medium collected from A2780 cells, A2780 cells infected by Ad-GFP, Ad-PTEN, or
Ad-Akt DN. Tube-like structures were photographed 24 h later under a phase contrast
microscope. Lower panel, quantification of tube length by calculating the length of the tubular
network in five randomly selected fields under 200× magnification. (*, p<0.05 compared with
RPMI-treated group; #, p<0.05 compared with CM-treated A2780 and A2780/Ad-GFP groups).

147

Fig. 5

A

A2780

A2780+EC

3 mm

A2780/Ad-GFP

3 mm

3 mm

3 mm

3 mm

A2780/Ad-PTEN

A2780/Ad-Akt DN

100
A2780

Tumor weight (mg)

80

*

*

A2780+EC
A2780/Ad-GFP+EC
A2780/Ad-PTEN+EC
A2780/Ad-Akt DN+EC

60

#

40
20
0

148

#

Fig. 5

B

A2780

Negative control

A2780+EC

A2780/Ad-GFP+EC

A2780/Ad-PTEN+EC

A2780/Ad-Akt DN+EC

A2780+EC

400

# Microvessels/HP Field

A2780/Ad-GFP+EC
A2780/Ad-PTEN+EC

300

A2780/Ad-Akt-DN

*

200

100

0

149

*

Fig. 5

C

anti-HIF-1 α Ab
A2780/Ad-GFP+EC

A2780/Ad-PTEN+EC

A2780/Ad-Akt DN+EC

Negative control

anti-VEGF Ab
A2780/Ad-PTEN+EC

A2780/Ad-GFP+EC

A2780/Ad-Akt DN+EC

Negative control

150

Fig. 5. Overexpression of PTEN or dominant-negative Akt in human ovarian cancer cells
inhibits tumor growth and tumor-induced angiogenesis in vivo. A: Inhibition of PI3K or Akt
activity in cancer cells inhibits tumor growth. Upper panel, Shown are macroscopic views of
representative tumors from the CAM. HMVECs (0.9×106) were mixed with 0.1×106 A2780
ovarian cancer cells uninfected or infected by Ad-GFP, Ad-PTEN or Ad-Akt DN. The cell
mixture was absorbed into PLGA sponges and implanted onto the CAM of day-8 chicken
embryos. Tumors were removed from the CAM 12 days after implantation, and photographed
under an anatomical microscope. Lower panel, Tumor weight. Data represent mean values ± SE
from 6 replicates. (*indicates significant difference when compared to A2780+EC and
A2780/Ad-GFP+EC groups, p<0.05; #indicates significant difference when compared to
A2780/Ad-GFP+EC group, p<0.05). B: Inhibition of PI3K or Akt activity in cancer cells inhibits
tumor-induced angiogenesis in vivo. Upper panel, Representative CD31 staining (brown color)
of tissue sections of tumors from the CAM. Original magnification of the microphotographs:
200×. Lower panel, Quantification of CD31-positive microvessels within tumor tissues. Data
represent the mean number of microvessels in a 200× field (mean± SE). (*indicates significant
difference when compared to A2780+EC and A2780/Ad-GFP+EC groups, p<0.05). C:
Overexpression of PTEN or dominant-negative Akt in human ovarian cancer cells inhibits HIF1α and VEGF expression in vivo. Upper panel, HIF-1α expression in tumors tissues was
analyzed by immunohistochemcal staining using an anti-HIF-1α antibody. Original
magnification of the microphotographs: 200×. Lower panel, VEGF expression in tumors tissues
was analyzed by immunohistochemcal staining using an anti-VEGF antibody. Original
magnification of the microphotographs: 200×.
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Fig. 6. Conditioned medium collected from ovarian cancer cells stably expressing HIF-1α
or VEGF siRNAs have reduced ability to induce EC tube formation. A: Knockdown of HIF1α expression suppresses HIF-1α and VEGF expression in human ovarian cancer cells. Upper
panel, Total protein samples prepared from A2780 cells stably expressing SiRNA against HIF1α were analyzed by immunobloting using antibodies against HIF-1α and β-actin, respectively.
Lower left panel, HIF-1α regulates transcriptional activation of VEGF. Parental A2780 cells,
A2780 cells stably expressing SiRNA against HIF-1α or a scramble (SCR) sequence were
transfected with the VEGF luciferase reporter construct. Luciferase activity was measured 24 h
after transfection. (*indicates significant difference when compared to the controls, p<0.05).
Lower right panel, expression of HIF-1α siRNA reduces VEGF secretion in A2780 cells. ELISA
assays were performed to detect VEGF levels in the conditioned medium collected from parental
A2780 cells, A2780 cells stably expressing HIF-1α siRNA or a scramble siRNA sequence.
(*indicates significant difference when compared to the controls, p<0.05). B: Inhibition of
VEGF expression by VEGF siRNA. Left panel RT-PCR was carried out to detect VEGF mRNA
levels in parental A2780 cells, A2780 cells stably expressing siRNA against VEGF or a scramble
siRNA sequence. Right panel, levels of VEGF protein secretion were determined by ELISA in
the conditioned medium collected from parental A2780 cells, A2780 cells stably expressing
siRNA against VEGF or a scramble siRNA sequence. (*indicates significant difference when
compared to the controls, p<0.05). C: Conditioned medium collected from ovarian cancer cells
stably expressing HIF-1α or VEGF siRNAs have reduced ability to induce EC tube formation.
Upper panel, tube formation assay was performed on growth factor-reduced Matrigel in the
presence or absence of conditioned medium collected from A2780 cells, A2780 cells stably
expressing siRNA against HIF-1α, VEGF or a scramble siRNA sequence. Tube structures were
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photographed 24 h later under a phase contrast microscope. Lower panel, quantification of tube
length by calculating the length of the tubular network in five randomly selected fields under
200× magnification. (*indicates significant difference when compared to RPMI-treated group,
p<0.05; # indicates significant difference when compared to A2780-CM and A2780/Si-SCRCM-treated groups, p<0.05).
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Fig. 7. Knockdown of HIF-1α and VEGF expression in ovarian cancer cells inhibits tumor
growth and angiogenesis in vivo. A: Knockdown of HIF-1α and VEGF expression in ovarian
cancer cells inhibits tumor growth in vivo. Upper panel, macroscopic view of representative
tumors from the CAM. HMVEC (0.9×106) were mixed with 0.1×106 A2780 ovarian cancer
cells, or A2780 cells stably expressing siRNA against HIF-1α, VEGF or a scramble sequence.
The cell mixture was absorbed into PLGA sponges, and implanted onto the CAM of day-8
chicken embryos. Tumors were removed from the CAM 12 days after implantation, and
photographed under an anatomical microscope. Lower panel, Tumor weight. Data represent
mean values ± SE from 6 replicates. (*indicates significant difference when compared to A2780
group, p<0.05; #indicates significant difference when compared to A2780+EC and
A2780+EC/Si-SCR groups, p<0.05). B: Inhibition of HIF-1α or VEGF expression in cancer
cells inhibits tumor-induced angiogenesis in vivo. Upper panel, Representative CD31 staining
(brown color) of tissue sections of tumors from the CAM. Original magnification of the
microphotographs: 200×. Lower panel, quantification of CD31-positive microvessels within
tumor tissues. Data represent the mean number of microvessels obtained in a 200x field.
(*indicates significant difference when compared to A2780+EC and A2780+EC/Si-SCR groups,
p<0.05). C: Knockdown of HIF-1α and VEGF expression in ovarian cancer cells inhibits HIF1α and VEGF expression in vivo. Upper panel, HIF-1α expression in tumors tissues was
analyzed by immunohistochemcal staining using an anti-HIF-1α antibody. Original
magnification of the microphotographs: 200×. Lower panel, VEGF expression in tumors tissues
was analyzed by immunohistochemcal staining using an anti-VEGF antibody. Original
magnification of the microphotographs: 200×.
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Abstract
trans-3,4,5'-Trihydroxystibene (resveratrol) is a natural product commonly found in the human
diet and has been shown recently to have anticancer effects on various human cancer cells.
However, the molecular basis for its anticancer action remains to be elucidated. In this study, we
investigated the effect of resveratrol on hypoxia-inducible factor 1α (HIF-1α) and vascular
endothelial growth factor (VEGF) expression in human ovarian cancer cells A2780/CP70 and
OVCAR-3. We found that although resveratrol did not affect HIF-1α mRNA levels, it did
dramatically inhibit both basal-level and growth factor-induced HIF-1α protein expression in the
cells. Resveratrol also greatly inhibited VEGF expression. Mechanistically, we demonstrated that
resveratrol inhibited HIF-1α and VEGF expression through multiple mechanisms. First,
resveratrol inhibited AKT and mitogen-activated protein kinase activation, which played a partial
role in the down-regulation of HIF-1α expression. Second, resveratrol inhibited insulin-like
growth factor 1-induced HIF-1α expression through the inhibition of protein translational
regulators, including Mr 70,000 ribosomal protein S6 kinase 1, S6 ribosomal protein, eukaryotic
initiation factor 4E-binding protein 1, and eukaryotic initiation factor 4E. Finally, we showed that
resveratrol substantially induced HIF-1α protein degradation through the proteasome pathway.
Our data suggested that resveratrol may inhibit human ovarian cancer progression and
angiogenesis by inhibiting HIF-1α and VEGF expression and thus provide a novel potential
mechanism for the anticancer action of resveratrol.
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Introduction
trans-3,4,5'-Trihydroxystibene (resveratrol), a polyphenolic, was identified originally as a
phytoalexin produced by plants in response to injury, UV irradiation, and insect or fungal attack
(1) . Resveratrol is present in more than 70 plant species and is especially abundant in food
products such as grapes, peanuts, and mulberries (2) . During the past few years, resveratrol has
attracted considerable attention as one of the most promising cancer chemopreventive agents.
Resveratrol was shown to affect diverse cellular events associated with each step of
carcinogenesis, i.e., tumor initiation, promotion, and progression (2) . At the molecular level,
these effects corresponded with the inhibition of free radical formation, cyclooxygenase, and
cytochrome P450 activity, as well as the inhibition of protein kinase C activity (3, 4) .
Additionally, resveratrol inhibited cell proliferation by decreasing DNA synthesis through its
inhibitory effects on ribonucleotide reductase, DNA polymerase, and ornithine decarboxylase
activities (3, 4) . Resveratrol induces apoptosis in various malignant cells through multiple
mechanisms, such as up-regulation of CD95L expression, enhancement of p53 expression and
activity, induction of B-cell CLL/lymphoma 2-associated X protein expression, suppression of Bcell CLL/lymphoma 2 expression, and inhibition of nuclear factor κB activity (3, 4) . Therefore,
resveratrol possesses therapeutic potential based on its suppression of tumor cell growth by
inducing cell cycle arrest and apoptosis. For example, in a rat ascetic hepatoma model, i.p.
administration of resveratrol caused apoptosis in the tumor cell population and significantly
decreased tumor cell numbers (5) . Despite these findings, however, the molecular mechanisms
by which resveratrol exerts its anticancer effects remain largely unknown.
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Ovarian cancer represents the fourth leading cause of cancer-related death for women and
is the most common cause of death from gynecologic cancer in the Western world (6) . The
overall 5-year survival rate of ovarian cancer is 50% and about 30% for advanced stage disease
(7) . The symptoms of the disease are observed only after it has spread to the surfaces of the
peritoneal cavity. At this stage, it is impossible to remove all apparent lesions by surgical
operations, and this accounts for the high rate of cancer recurrence after surgery. Consequently,
the majority of ovarian cancer patients require chemotherapy. However, the major challenge in
ovarian cancer treatment is the broad resistance to available chemotherapeutic drugs (6) . The
combination of cisplatin and paclitaxel as a chemotherapy regimen has improved the survival rate
of ovarian cancer patients (8) , but in the majority of cases, the cancer ultimately progresses, and
the ovarian cancer patient dies from chemotherapy-refractory cancer (6) .
It has been well established that solid tumor growth is angiogenesis dependent (9) .
Advanced solid tumors have a characteristic property of intratumoral hypoxia, which is caused
by the structural and functional abnormalities of the tumor microvasculature, rapid expansion of
tumor mass, and tumor-associated anemia (10). Hypoxia condition is a strong stimulus for
angiogenesis, and this is predominantly accomplished by hypoxia-inducible factor 1 (HIF-1)mediated up-regulation of vascular endothelial growth factor (VEGF) expression (11, 12, 13) .
VEGF, also known as the vascular permeability factor, is a potent and endothelial cell-specific
mitogen that plays a crucial role during the process of tumor angiogenesis. VEGF expression is
elevated in many human cancers, including ovarian carcinoma (14, 15) . HIF-1 is a heterodimeric
transcriptional factor composed of HIF-1α and HIF-1ß subunits (16) . HIF-1 binds to the
hypoxia-responsive element in the promoter region of the VEGF gene and up-regulates VEGF
expression (16) . HIF-1 -deficient cells have reduced VEGF production under hypoxia (17, 18) .
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VEGF expression levels in vivo are also much lower in HIF-1α null tumors (17) . HIF-1α
expression increases dramatically under hypoxia. However, under normoxic conditions, HIF-1α
protein is expressed at a very low level due to rapid degradation via the ubiqitin-proteasomal
pathway. Certain oncogenic proteins and growth factors have been shown to up-regulate HIF-1α
expression in normoxic cells (19, 20, 21, 22, 23) . HIF-1 was also shown to be elevated in
various human tumors, including ovarian cancer (24) . The effect of VEGF on vascular
permeability has been implicated in the pathogenesis of ovarian cysts and malignant ascites (25 ,
26) . In addition, increased levels of VEGF expression and the microvessel density in ovarian
cancer directly correlate with poor prognosis (27, 28) . Therefore, an anti-angiogenic therapy that
targets the HIF-1α/VEGF system would be a rational strategy for the treatment of ovarian cancer.
In this study, we have demonstrated for the first time that resveratrol has a strong
inhibitory effect on HIF-1α and VEGF expression in human ovarian cancer cells. Our data
showed that resveratrol did not affect HIF-1α mRNA levels; rather, it interfered with the protein
translational machinery and promoted HIF-1α protein degradation. These unique actions of
resveratrol provide important clues to the molecular basis for its anticancer effects.

MATERIALS AND METHODS
Cell Culture and Reagents
A2780/CP70 and OVCAR-3 human ovarian cancer cells were cultured in RPMI 1640 (Life
Technologies, Inc., Grand Island, NY), supplemented with 10% fetal bovine serum, 50 nM insulin
(Sigma), 100 units/ml penicillin, and 100 µg/ml streptomycin. The cells were maintained at 37°C
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and 5% CO2 in a humid environment. Resveratrol was purchased from ICN Biomedicals, Inc.
(Aurora, OH). Cycloheximide was obtained from EMD Biosciences, Inc. (San Diego, CA).
Recombinant human insulin and insulin-like growth factor 1 (IGF-1) were obtained from Sigma.
LY294002, rapamycin, and PD98059 were purchased from Calbiochem (La Jolla, CA).
Monoclonal HIF-1 antibody was obtained from BD Transduction Laboratories (Lexington,
KY). Antibodies specific for phosphorylated (Thr-202/Tyr-204) or total p44/p42 mitogenactivated protein kinase (MAPK) were from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies against phosphorylated (Ser-473) or total AKT, phosphorylated (Thr-421/Ser-424) or
total Mr 70,000 ribosomal protein S6 kinase 1 (p70S6K1), phosphorylated (Ser-235/236) S6
ribosomal protein, phosphorylated (Ser-65) eukaryotic initiation factor 4E (eIF4E)-binding
protein 1 (4E-BP1), and phosphorylated (Ser-209) eIF4E were obtained from Cell Signaling
Technology (Beverly, MA). Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
monoclonal antibody was from R&D Systems (Minneapolis, MN).
Treatment of the Cells with Resveratrol
Exponentially growing cells (about 80% confluence) were treated with resveratrol at 12.5, 25,
37.5, 50, 75, 100, and 150 µM for 6 h in complete medium. For time-dependent studies, cells were
treated with 50 µM resveratrol from 0 to 24 h. The control cells were incubated with the highest
amount of solvent (DMSO) used for dissolving corresponding doses of resveratrol in the dosedependent studies. For experiments in which cells received growth factor stimulation, cells were
starved in serum-free and insulin-free medium overnight and then pretreated with resveratrol for
30 min, followed by incubation with growth factors for 6 h.
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Western Blotting
Cells were washed with ice-cold PBS [140 mM NaCl, 3 mM KCl, 6 mM Na2HPO4, and 1 mM
KH2PO4 (pH 7.4)], scraped, and pelleted by centrifugation. Whole-cell extracts were prepared
using modified radioimmune precipitation buffer [100 mM Tris, 5 mM EDTA, 1% Triton X-100,
1% deoxycholate acid, 0.1% SDS, 2 mM phenylmethylsulfonyl fluoride, 1 mM sodium
orthovanadate, 2 mM DTT, 20 µg/ml leupeptin, and 20 µg/ml pepstatin (pH 7.4)]. Protein
concentrations of the lysates were assayed using a protein assay reagent (Bio-Rad). Aliquots (50
µg) of protein samples were fractionated by 8% SDS-PAGE, transferred to a nitrocellulose
membrane (Schleicher & Schuell Biosciences, Keene, NH), and subjected to immunoblotting
analysis. Monoclonal HIF-1 antibody was used at a dilution of 1:3,000 in blocking buffer [1x
Tris-buffered saline plus Tween 20: 20 mM Tris (pH 7.4), 137 mM NaCl, and 0.1% Tween 20]
containing 5% nonfat dry milk. Anti-GAPDH antibody was used at a dilution of 1:10,000. All
other polyclonal antibodies were diluted at 1:2,000 in 1x Tris-buffered saline plus Tween 20
containing 5% BSA. The blots were blocked in 1x Tris-buffered saline plus Tween 20 containing
5% nonfat dry milk for 2 h at room temperature, followed by incubation with the appropriately
diluted primary antibodies overnight at 4°C. Immunoreactivity was visualized with appropriate
horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence
(Perkin-Elmer Life Sciences, Boston, MA).
Northern Blotting
Total cellular RNA was extracted from the cells using Trizol reagent (Invitrogen) according to
the manufacturer’s instructions. Aliquots (15 µg) of total RNA were fractionated by
electrophoresis in 1% agarose gel with 2.2

M

formaldehyde, transferred to a Nytron supercharge
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membrane (Schleicher & Schuell) by capillary transfer with a downward transfer system
(Schleicher & Schuell), and cross-linked to the membrane by UV irradiation. The blot was
prehybridized for 1 h at 42°C in 10 ml of Ultrahyb buffer (Ambion). Human VEGF, HIF-1 , and
ß-actin cDNA probes were labeled with [α-32P]dATP by random priming using the RadPrime
DNA labeling system (Invitrogen) and purified with the ProbeQuant G-50 Micro Columns
(Amersham Biosciences, Piscataway, NJ). Heat-denatured probes were added to the
hybridization buffer to a final concentration of 1 x 106 cpm/ml, and hybridization was continued
overnight at 42°C. The membrane was washed twice for 15 min in 2x SSC/0.1% SDS at 42°C,
and 2 x 15 min in 0.1x SSC/0.1% SDS at 60°C. The membrane was wrapped and overlaid with a
Kodak Biomax MS film, and an intensifying screen. Autoradiography was performed overnight
at –80°C.
Enzyme-Linked Immunosorbent Assay
The levels of VEGF protein secreted by the cells in the medium were determined by a VEGF
ELISA kit (R&D Systems). In brief, subconfluent cells were changed into fresh medium in the
presence of solvent or various concentrations of resveratrol for 12 h, or the cells were cultured in
serum-free and insulin-free medium overnight, followed by incubation with IGF-1 in the absence
or presence of various concentrations of resveratrol for 12 h. The medium was collected, and
VEGF protein concentrations were measured by ELISA according to the manufacturer’s
instructions. The results were normalized to the number of cells per plate. The data were
presented as mean ± SD from three replicate experiments.
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Transient Transfection and Luciferase Reporter Assays
The VEGF promoter reporter was constructed by inserting 47 bp of human VEGF promoter 5'flanking sequence between –985 and –939, which contains the HIF-1 binding site, into the pGL2basic luciferase vector (Promega) as described previously (11) . The dominant-negative HIF-1
expressing plasmid was described previously (11) . The cells were cotransfected with the
reporter, pCMV-ß-gal plasmid, and a dominant-negative or wild-type HIF-1 -expressing plasmid
using LipofectAMINE reagent (Invitrogen). An empty vector plasmid was used to adjust the
equal amounts of plasmids used in each experiment. The cells were cultured overnight after
transfection. The cells were then treated with resveratrol for 12 h. Luciferase activity was
measured using a luciferase assay reagent (Promega) and normalized to ß-galactosidase activity.
The data were mean ± SD from three replicate experiments.
Cell Viability Assays
Cell viability was assayed by the trypan blue dye exclusion method. A2780/CP70 and OVCAR-3
cells were seeded into 6-well plate at a density of 1 x 105/well. The cells were treated with 50 or
100 µM resveratrol for 12 h and then trypsinized and resuspended. A 1:1 dilution of the cell
suspension using 0.4% trypan blue was loaded into the counting chambers of a hemocytometer,
and the number of stained cells and the total number of cells were counted. Cell viability was the
percentage of unstained cells. The data were mean ± SD from three replicate experiments.
Statistical Analysis
When applicable, the data were analyzed by Student’s t test using SPSS statistical software
(SPSS, Inc., Chicago, IL).
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RESULTS
Resveratrol Inhibited HIF-1α Expression in Human Ovarian Cancer Cells
In our preliminary studies, human ovarian cancer cell lines A2780/CP70 and OVCAR-3 were
shown to express high steady-state levels of HIF-1α. Initial experiments were performed to
determine the effect of resveratrol on HIF-1α expression in these cells. Both cell lines expressed
high levels of HIF-1α protein under normal culture conditions (Fig. 1). Treatment of the cells
with resveratrol for 6 h resulted in a dose-dependent reduction of HIF-1α protein levels (Fig. 1, A
and B). The concentrations of resveratrol required for 50% inhibition of HIF-1α in A2780/CP70
and OVCAR-3 cells were 20 and 30 µM, respectively. In the presence of 50 µM resveratrol, HIF1 protein levels decreased significantly at 1 h and were almost undetectable at 6 h and thereafter
(Fig. 1, C and D). It was known that prolonged treatment of resveratrol inhibited tumor cell
growth and induced apoptosis (3 , 4) . To determine whether the effect of resveratrol on HIF-1α
expression might be due to the cellular cytotoxic effect, we performed cell viability assays
following treatment with 50 and 100 µM resveratrol for 6 h. The resveratrol treatment did not
affect cell viability (Fig. 1E), suggesting that the decrease of HIF-1α expression by resveratrol
was not due to cell death.
Resveratrol Prevented HIF-1α Expression Induced by Growth Factors
Growth factors and hormones play important roles in malignant transformation and tumor cell
growth (29) . Furthermore, previous work by our laboratory and others showed that stimulation
by serum or specific growth factors induces HIF-1α expression in several cultured cells (19 , 23 ,
30) . Here, we investigated whether certain growth factors can up-regulate HIF-1α expression in
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human ovarian cancer cells, and whether resveratrol can inhibit the induction. A2780/CP70 and
OVCAR-3 cells were cultured in serum-free and insulin-free medium for 18 h and then exposed
to serum in the absence or presence of various doses of resveratrol for 6 h. Serum markedly
induced HIF-1α protein expression in both A2780/CP70 and OVCAR-3 cells (Fig. 2A). Seruminduced HIF-1α expression was inhibited by resveratrol in a dose-dependent manner (Fig. 2A).
To examine the effects of specific growth factors that are reportedly relevant to ovarian cancer
progression (26) , the cells were exposed to 200 nM insulin or 200 ng/ml IGF-1. Both insulin and
IGF-1 significantly increased HIF-1α expression in ovarian cancer cells, whereas pretreatment
with resveratrol effectively inhibited the HIF-1 induction (Fig. 2, B and C). At concentrations of
50 µM and higher, resveratrol inhibited both basal-level and growth factor-induced HIF-1α
expression to almost undetectable levels (Fig. 2). Overall, these results demonstrated that while
specific growth factors such as insulin and IGF-1 up-regulated HIF-1α expression in human
ovarian cancer cells, resveratrol strongly inhibited the growth factor-induced HIF-1α expression
in the cells.
Resveratrol Did Not Affect HIF-1α mRNA Levels
To examine whether inhibition of HIF-1α protein levels by resveratrol was caused by a decrease
in its mRNA level, HIF-1α mRNA levels were measured by Northern blotting. As shown in Fig.
3, A and B, IGF-1 did not induce HIF-1α mRNA expression in A2780/CP70 and OVCAR-3 cells,
which corresponds with previous observations that IGF-1 did not increase HIF-1α mRNA levels
in other cell lines (31). Resveratrol treatment did not have any effect on HIF-1α mRNA levels in
A2780/CP70 and OVCAR-3 cells (Fig. 3). These results indicated that inhibition of HIF-1α
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expression by resveratrol was not through the inhibition of its mRNA level, suggesting
posttranscriptional mechanisms of resveratrol action on HIF-1α expression.

Resveratrol Inhibited Vascular Endothelial Growth Factor Expression in A2780/CP70 and
OVCAR-3 Cells

VEGF is one of the target genes of HIF-1, which plays a crucial role in tumor angiogenesis (11,
12, 13 , 16) . HIF-1 regulates the expression of VEGF at the transcriptional level (11, 12, 13 , 16) .
To determine whether resveratrol inhibits VEGF expression in human ovarian cancer cells,
VEGF mRNA levels were measured by Northern blot analysis. A2780/CP70 and OVCAR-3 cells
expressed high levels of VEGF mRNA under normal culture conditions (Fig. 4A), which
correlated with high levels of HIF-1α expression in the cells (Fig. 1). Treatment of the cells with
resveratrol resulted in a dose-dependent inhibition of VEGF mRNA expression (Fig. 4A). IGF-1
treatment significantly increased VEGF mRNA expression, and resveratrol inhibited IGF-1induced VEGF mRNA expression in a dose-dependent manner (Fig. 4B). To determine whether
down-regulation of VEGF mRNA levels by resveratrol subsequently leads to a decrease in
VEGF protein expression, we assayed VEGF protein levels by ELISA. Treatment of the cells
with resveratrol inhibited VEGF protein levels in a dose-dependent manner (Fig. 5A). Resveratrol
also inhibited IGF-1-induced VEGF protein expression in the cells (Fig. 5B). No apparent
cytotoxic effects were observed in the experiments when cells were treated with 50 and 100 µM
resveratrol for 12 h (Fig. 5C).
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Resveratrol Inhibited Vascular Endothelial Growth Factor Transcriptional Activation
through HIF-1α
To determine whether resveratrol inhibited VEGF transcriptional activation, we tested the effect
of resveratrol on the expression of a VEGF promoter reporter plasmid containing HIF-1 binding
site, which was an indicator of VEGF transcriptional activation. Resveratrol treatment inhibited
the VEGF reporter activity, and cotransfection of HIF-1α wild-type plasmid reversed resveratrolinhibited reporter activity to an even higher level (Fig. 6A). This result suggested that reveratrol
inhibited VEGF transcriptional activation through HIF-1α expression in the ovarian cancer cells.
The expression of a dominant-negative HIF-1 plasmid inhibited the reporter activity in a dosedependent manner (Fig. 6B). This result indicated that HIF-1α expression was required for VEGF
transcriptional activation in the cells. Thus, these data further confirmed that HIF-1α expression
was important for resveratrol-inhibited VEGF expression.

Resveratrol Inhibited AKT and Mitogen-Activated Protein Kinase Activation
Next, we investigated the signaling pathways involved in resveratrol-induced inhibition of HIF1α protein expression in the cells. As shown in Fig. 3, resveratrol did not affect HIF-1α mRNA
levels, suggesting that resveratrol may either decrease HIF-1α protein synthesis, and/or increase
HIF-1α protein degradation. Previously, we and others have shown that specific growth factors,
such as insulin and IGF-1, induce HIF-1α protein expression via the phosphatidylinositol 3'kinase (PI3K)/AKT and MAPK signaling pathways in several cell types (23, 31, 32) . Previous
studies further showed that growth factor-induced activation of PI3K/AKT and MAPK signaling
mediates HIF-1α expression by increasing HIF-1α protein synthesis but not decreasing HIF-1α
protein degradation (19, 31, 33) . In this study, we found that serum and specific growth factors
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such as insulin and IGF-1 induced high levels of HIF-1α protein expression in human ovarian
cancer cells (Fig. 2). Thus, we examined whether resveratrol treatment affected IGF-1-induced
activation of the PI3K/AKT and MAPK signaling pathways. Phosphorylation levels of AKT and
MAPK, which correspond with their activation, were analyzed by immunoblotting. IGF-1 greatly
increased AKT and MAPK phosphorylation in both cell lines (Fig. 7). Treatment of the cells with
PI3K-specific inhibitor LY294002 completely blocked IGF-1-induced AKT phosphorylation and
inhibited IGF-1-induced HIF-1α expression (data not shown), which was consistent with the
effect of LY294002 on HIF-1α expression in other cell lines (23, 31, 32) . MAPK/extracellular
signal-regulated kinase1 inhibitor PD98059 inhibited MAPK activation and prevented HIF-1α
expression induced by IGF-1 (Fig. 7, C and D). Although resveratrol could inhibit HIF-1α
expression completely, it only partly reduced both AKT and MAPK phosphorylation induced by
IGF-1 in the cells (Fig. 7). These results indicated that inhibition of AKT and MAPK activation
by resveratrol played a partial role in its down-regulation of HIF-1 expression.

Resveratrol Interfered with Protein Translational Machinery
Growth factor-induced activation of PI3K/AKT and MAPK pathways has been shown to regulate
HIF-1α protein synthesis via phosphorylation of protein translational regulators, including
p70S6K1 and 4E-BP1 (31, 32, 33, 34, 35) . We next examined whether resveratrol affected the
protein translational machinery. We investigated the effect of resveratrol on the phosphorylation
of the components of protein translational apparatus, including p70S6K1, S6 ribosomal protein,
4E-BP1, and eIF4E. In A2780/CP70 and OVCAR-3 cells, the phosphorylation of p70S6K1
induced by IGF-1 was blocked by LY294002, rapamycin, and PD98059 (Fig. 8A). Similarly,
resveratrol inhibited IGF-1-induced p70S6K1 phosphorylation at 50 and 100 µM (Fig. 8A).
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Strikingly, treatment of the cells with resveratrol at as low as10 µM dramatically inhibited IGF-1induced phosphorylation of S6 ribosomal protein, comparable with the effect of LY294002,
rapamycin, and PD98059 (Fig. 8B). Phosphorylation of the S6 ribosomal protein by p70S6K1
and other kinases is involved in the initiation of protein synthesis (36). Resveratrol also reduced
phosphorylation of 4E-BP1 and, to a much greater extent, the mRNA cap-binding protein eIF4E
(Fig. 8C), which is the key enzyme for cap-dependent initiation of protein translation. Expression
of eIF4E was shown recently to be sufficient to elevate HIF-1α protein levels (21). In this study,
we found that treatment of the cells with rapamycin also inhibited IGF-1-induced HIF-1α
expression in the cells (Fig. 8D). Rapamycin is a specific inhibitor of the mammalian target of
rapamycin (mTOR), which is the upstream kinase for 4E-BP1 and p70S6K1. These results
indicated that resveratrol interfered with protein translational regulation, which contributed to its
inhibitory effect on HIF-1α protein expression.

Resveratrol Promoted HIF-1α Protein Degradation via the Proteasomal Pathway
HIF-1α protein levels are regulated by a balance between HIF-1α protein synthesis and
degradation in the cells. Hypoxia or hypoxia-mimetic agent CoCl2 can rapidly induce HIF-1α
protein accumulation due to a marked decrease in HIF-1α protein degradation (37) . Based on the
results presented above, we found that resveratrol could inhibit completely both growth factorinduced and basal-level HIF-1α expression (Fig. 1; Fig. 2). These observations suggested that, in
addition to inhibiting the HIF-1α protein synthesis, resveratrol may also promote HIF-1α protein
degradation. Thus, we examined the effect of resveratrol on the stability of HIF-1α protein in the
cells. A2780/CP70 cells were cultured in complete medium to subconfluence and then pretreated
with solvent alone or resveratrol for 1 h, followed by incubation with cycloheximide to block
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ongoing protein synthesis. The cells were collected at various time intervals, and HIF-1α protein
levels were examined. In the presence of cycloheximide, the half-life of HIF-1α protein in the
cells pretreated with 50 µM resveratrol was 2.55 min, which was significantly shorter than that for
cells treated with solvent alone (7.5 min; p<0.05. Fig. 9). This result demonstrated that
resveratrol increased HIF-1α protein degradation. To examine whether resveratrol-induced HIF1α degradation is mediated by the proteasome degradation pathway, we treated the cells with
proteasome inhibitor MG132 in the presence or absence of resveratrol, and analyzed HIF-1α
protein levels. As shown in Fig. 10, treatment of the cells with MG132 increased HIF-1α protein
ubiquitination and total HIF-1α protein levels. Resveratrol-induced HIF-1α inhibition was
prevented completely by MG132 (Fig. 10). These data indicated that resveratrol induced HIF-1α
protein degradation through the proteasome degradation pathway.

DISCUSSION

Angiogenesis, the development of new blood vessels from the pre-existing vasculature, is
essential for tumor growth and metastasis (9, 38) . HIF-1-mediated VEGF expression plays a
pivotal role during the process of tumor angiogenesis (38) . In this study, we demonstrated for
the first time that resveratrol, a natural product with cancer chemopreventive effects, markedly
inhibited HIF-1α and VEGF expression in human ovarian cancer cells. Resveratrol was shown to
affect PI3K/AKT and MAPK-signaling pathways, to interfere with protein translational
machinery, and to enhance HIF-1α protein degradation. The data presented here suggested that
resveratrol may inhibit human ovarian cancer progression by interfering with tumor angiogenesis
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mediated by HIF-1α and VEGF, thereby providing a novel mechanism for the anticancer action
of resveratrol.
Numerous studies have implicated the role of IGFs in the development and progression of
human malignancies such as ovarian carcinoma (29) . In addition, IGF-1 has been shown to
induce HIF-1α expression in several cultured cells (30, 31) . IGF-1 is a growth factor commonly
used to up-regulate the PI3K/AKT and MAPK signaling pathways in various cell types. In this
study, we used IGF-1 as a stimulus to investigate the mechanism of resveratrol on HIF-1α
expression in human ovarian cancer cells. IGF-1 treatment significantly increased HIF-1α protein
levels in human ovarian cancer cells, which is consistent with previous findings that IGF-1
stimulates HIF-1α expression in other cell lines (30, 31) . Moreover, IGF-1 also markedly upregulated HIF-1α target gene VEGF expression in human ovarian cancer cells. These results
correspond with previous reports that IGF-1 is involved in tumor-induced angiogenesis
associated with the up-regulation of VEGF expression in human colon cancer and pancreatic
cancer (39 , 40) . Several studies have shown that growth factors including IGF-1 do not induce
HIF-1α mRNA expression but increase HIF-1α protein synthesis (31, 32) . Similarly, we did not
observe the induction of HIF-1α mRNA expression by IGF-1 in the ovarian cancer cells.
Resveratrol treatment did not have any effect on HIF-1α mRNA levels in the cells, suggesting
that resveratrol inhibited HIF-1α protein expression through post-transcriptional mechanisms, for
example, by influencing HIF-1α protein synthesis and/or degradation.
To further define the molecular mechanisms by which resveratrol inhibited HIF-1α
expression, we next examined whether resveratrol affected HIF-1α protein synthesis. Recently, it
was reported that IGF-1-induced expression of HIF-1α and VEGF in HCT116 colon cancer cells
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can be blocked by the PI3K inhibitor wortmannin, MAPK/extracellular signal-regulated kinase
kinase inhibitor PD98095, or mTOR inhibitor rapamycin and that these inhibitors also blocked
the phosphorylation of the translational regulatory protein 4E-BP1, p70S6K1, and eIF4E (31) .
Epidermal growth factor and HERneu were also shown to induce HIF-1α expression through
similar signaling pathways in breast cancer and prostate cancer cells, respectively (19, 33) .
Induction of HIF-1α expression by these growth factors and oncogenes was due to an increase in
HIF-1α protein synthesis but was not due to a decrease in HIF-1α protein degradation (19, 31,
33). In this study, we found that IGF-1 treatment induced HIF-1α and VEGF expression and
activation of AKT and MAPK in human ovarian cancer cells. Resveratrol treatment partly
reduced AKT and MAPK activation; however, resveratrol could dramatically inhibit HIF-1α
protein expression to undetectable levels. Thus, inhibition of AKT and MAPK activation by
resveratrol only played a partial role in its down-regulation of HIF-1α expression.
We next examined the effect of resveratrol on protein translational machinery, which has
been shown to regulate HIF-1α protein synthesis induced by growth factors. Regulation of
protein synthesis allows for a more rapid response to diverse stimuli in the absence of
transcription. Eukaryotic initiation factors (eIFs) and p70S6K1 play critical roles in protein
translational regulation. p70S6K1 phosphorylates the S6 ribosomal protein of the 40S subunit of
the ribosome, and stimulates the translation of mRNAs with a 5' oligopyrimidine tract that
encodes major components of the protein synthesis apparatus (41). p70S6K1 is a downstream
effector of PI3K; full activation of p70S6K1 also requires mTOR activity (36, 41, 42). The
activity of p70S6K1 is controlled by multiple phosphorylation events. Phosphorylation of Thr421 and Ser-424 on the COOH-terminal autoinhibitory domain is mediated by MAPK (41) . In
this study, we found that IGF-1-induced phosphorylation of p70S6K1 was inhibited by
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resveratrol at 50–100 µM. This effect was consistent with its inhibitory effects on AKT and
MAPK activation as shown in Fig. 9. Remarkably, phosphorylation of S6 ribosomal protein, a
downstream effector of p70S6K1, was dramatically inhibited by resveratrol treatment at as low
as 10 µM. Because other kinases including cAMP-dependent protein kinase and protein kinase C
are also known to phosphorylate S6 ribosomal protein (43), it is possible that resveratrol may also
inhibit some of these kinases in addition to p70S6K1. 4E-BP1 functions in the PI3K/AKT
pathway and is phosphorylated by mTOR and other unidentified kinases (36). 4E-BP1 binds to
eIF4E and inhibits eIF4E function. Hyperphosphorylation of 4E-BP1 disrupts this binding,
releasing eIF4E to be phosphorylated at Ser-209 by Mnk1 and to associate with eIF4G to initiate
cap-dependent translation (36). eIF4E is the key enzyme for cap-dependent initiation of protein
translation. Expression of eIF4E was shown recently to be sufficient to elevate HIF-1 protein
levels (21). In the present study, we found that resveratrol inhibited phosphorylation of 4E-BP1 at
Ser-65 and greatly inhibited phosphorylation of eIF4E at Ser-209. We showed that treatment of
the cells with mTOR inhibitor rapamycin completely inhibited IGF-1-induced HIF-1α expression.
Thus, these data indicated that resveratrol interfered with protein translational regulation, which
contributed to its inhibitory effect on HIF-1α protein expression.
HIF-1α protein levels are also subject to posttranslational regulation. Under normoxic
conditions, HIF-1α protein is expressed at very low levels due to rapid degradation via the
ubiqitin-proteasomal pathway. Conversely, under hypoxic conditions, HIF-1α protein levels are
increased dramatically due to a marked decrease in HIF-1 protein degradation (37). In this study,
we found that resveratrol could eliminate both growth factor-induced and basal-level HIF-1α
expression. These observations suggested that, in addition to inhibiting HIF-1α protein synthesis,
resveratrol may also promote HIF-1α protein degradation. Indeed, the half-life of HIF-1α protein
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was shortened significantly in the presence of resveratrol, demonstrating that resveratrol induced
HIF-1α protein degradation (Fig. 9). We further showed that resveratrol-induced HIF-1α protein
degradation was through the proteasome pathway. HIF-1α protein degradation is mediated by the
oxygen-dependent HIF-prolyl hydroxylases. Prolyl hydroxylation of HIF-1α by HIF-prolyl
hydroxylase is required for the binding of HIF-1α to the von Hippel Lindau tumor suppressor
protein, which serves as the E3 ubiquitin-protein ligase that targets HIF-1α for proteasomal
degradation (37). HIF-prolyl hydroxylases are hydroxygenases requiring oxygen and 2oxoglutarate as cosubstrates. The binding of oxygen to the iron-containing central moiety of HIFprolyl hydroxylase requires the vitamin C-dependent maintenance of iron in its ferrous state (37).
Recently, vitamin C was shown to abrogate efficiently HIF-1α protein levels in several human
cancer cell lines by increasing HIF-prolyl hydroxylase activity (44). Both vitamin C and
resveratrol have multiple hydroxyl groups, which are essential for their antioxidant activities. In
addition, resveratrol was shown to be a much more potent antioxidant than vitamin C and can
enhance the activity of vitamin C when used together (45). We speculate that the effect of
resveratrol on HIF-1α degradation could possibly result from its interference with HIF-prolyl
hydroxylase activity, which requires additional investigation.
The distinct ability of resveratrol to inhibit HIF-1α and VEGF expression observed in this
study raises the possibility of its usefulness in the therapy of human ovarian cancer. Tumor
angiogenesis triggered by HIF-1α and VEGF is a vital process for tumor progression because it
nourishes tumor cell growth and facilitates metastases (38). In addition, tumor cell-derived VEGF
was also shown to have an autocrine stimulatory effect on tumor cell growth because various
human tumor cells, including ovarian cancer cells, express VEGF receptors (14, 38, 46) .
Therefore, resveratrol may potentially inhibit ovarian cancer progression based on its remarkable
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inhibitory effect on HIF-1α and VEGF expression. Furthermore, the A2780/CP70 human ovarian
cancer cell line used in this study is cisplatin resistant. A2780/CP70 was developed by chronic
exposure of the parent cisplatin-sensitive A2780 cell line to increasing concentrations of cisplatin
in culture (47). OVCAR-3 was derived from the malignant ascites of a patient with progressive
ovarian cancer resistant to clinically relevant concentrations of cisplatin (48). Therefore, our data
suggest that resveratrol may exert anticancer effects even in cisplatin-resistant ovarian cancer
patients. Indeed, resveratrol recently has been shown to have synergistic cytotoxic activity when
used in combination with chemotherapeutic drugs or cytotoxic factors in the treatment of drug
refractory tumor cells (49). Finally, based on its effects on protein translational regulation and
HIF-1 protein degradation, two processes that are not cell-type specific, resveratrol may inhibit
expression of HIF-1 and VEGF in other human malignancies with high levels of HIF-1α
expression. This may also explain, at least in part, the broad spectrum of anticancer effects of
resveratrol observed previously in various human cancer cell lines.
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Fig. 1. Resveratrol (RES) decreased HIF-1α protein levels in A2780/CP70 and OVCAR-3
cells. A and B, A2780/CP70 and OVCAR-3 cells were cultured to 80% confluence and then
treated with solvent alone or various concentrations of resveratrol for 6 h. Cell lysates were
subjected to immunoblotting analysis using an anti-HIF-1α monoclonal antibody. The blot was
stripped off and rehybridized with an anti-GAPDH antibody as a control for protein loading and
transfer efficiency. C and D, A2780/CP70 and OVCAR-3 cells were cultured to 80% confluence
and then treated with 50 µM resveratrol for 0–24 h as indicated. The HIF-1α and GAPDH
proteins were analyzed by immunoblotting as described above. E, A2780/CP70 and OVCAR-3
cells were treated with 50 and 100 µM resveratrol for 6 h. Cell viability was assayed by the trypan
blue dye exclusion method. The percentage of viable cells represented the mean ± SD from three
replicate experiments.
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Fig. 2. Resveratrol (RES) inhibited serum-induced, insulin-induced, and IGF-1-induced
HIF-1α expression. Serum-starved A2780/CP70 and OVCAR-3 cells were pretreated with
solvent alone (lane 1, 2) or various doses of resveratrol for 30 min, followed by stimulation with
10% fetal bovine serum (A), 200 µM of insulin (INS; B), or 200 ng/ml IGF-1 (C) for 6 h. Whole
cell extracts were subjected to immunoblotting analysis using antibodies specific for HIF-1α or
GAPDH.
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Fig. 3. Effect of resveratrol (RES) on HIF-1α mRNA levels. Serum-starved A2780/CP70 and
OVCAR-3 cells were pretreated with solvent alone (Lanes 1 and 2) or various doses of
resveratrol for 30 min, followed by incubation with 200 ng/ml IGF-1 for 6 h. Total RNA was
extracted and subjected to Northern blot analysis using a human HIF-1α cDNA probe. The blot
was stripped off and reprobed with ß-actin cDNA probe as an internal control.
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Fig. 4. Effect of resveratrol (RES) on VEGF mRNA expression in the cells. A, A2780/CP70
and OVCAR-3 cells cultured in complete medium were treated with solvent alone (Lane 1) or
various doses of resveratrol for 6 h. Total RNA was extracted and analyzed by Northern blotting
using a VEGF cDNA probe. The blot was stripped off and reprobed with ß-actin cDNA probe as
an internal control. B, serum-starved A2780/CP70 and OVCAR-3 cells were pretreated with
solvent alone (Lanes 1 and 2) or various doses of resveratrol for 30 min, followed by incubation
with 200 ng/ml IGF-1 for 6 h. Total RNA was extracted and analyzed by Northern blotting using
VEGF or ß-actin cDNA probe.
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Fig. 5. Effect of resveratrol (RES) on VEGF protein levels. A, A2780/CP70 and OVCAR-3
cells cultured in complete medium were treated with solvent alone or various doses of resveratrol
for 12 h. VEGF protein concentrations in the medium were measured by ELISA assays. The
results were normalized to the number of cells per plate, and data were presented as mean ± SD
from three replicate experiments. *, significant difference when compared with the solvent
treatment (P < 0.01). B, cells were cultured in serum-free and insulin-free medium overnight,
followed by the addition of IGF-1 in the absence or presence of various concentrations of
resveratrol for 12 h. VEGF protein concentrations in the medium were measured by ELISA
assay. #, significant difference when compared with the unstimulated control (P < 0.01); *,
significant difference when compared with IGF-1-treated cells (P < 0.01). C, cells were cultured
in serum-free and insulin-free medium overnight, followed by exposure to IGF-1 in the absence
or presence of 50 or 100 µM resveratrol for 12 h. Cell viability was assayed by the trypan blue
dye exclusion method. The percentage of cell viability represented mean ± SD from three
triplicate experiments.
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Fig. 6. HIF-1α-mediated VEGF transcriptional activation in human ovarian cancer cells. A,
A2780/CP70 cells were cultured in normal growth medium. HIF-1α-expressing plasmid was
cotransfected into the cells with the reporter plasmid and the pCMV-ß-gal plasmid. An empty
vector plasmid was used to adjust to the same amounts of plasmids used in each transfection.
After overnight recovery, the cells were treated with solvent or 50 µM resveratrol (RES) for 12 h.
Luciferase activity was measured and normalized to ß-galactosidase activity. Assays were
performed in triplicate, and data were presented as mean ± SD. *, significant difference
compared with the solvent control; #, significant difference compared with the vector control (P
< 0.01). B, cells were cotransfected with the indicated amount of a dominant-negative HIF-1
plasmid, pCMV-ß-gal plasmid, and a VEGF promoter reporter plasmid. Luciferase activity was
measured 24 h after transfection and normalized to ß-galactosidase activity. Assays were
performed in triplicate, and data were presented as mean ± SD. *, significant difference when
compared with the control (P < 0.01).
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Fig. 7. Effect of resveratrol (RES) on AKT and MAPK activation. A and B, effects of
resveratrol on AKT activation and HIF-1α expression in ovarian cancer cells. Serum-starved
A2780/CP70 and OVCAR-3 cells were pretreated with solvent alone or various doses of
resveratrol for 30 min, followed by incubation with 200 ng/ml IGF-1 for 6 h as indicated. Cell
lysates were subjected to immunoblotting analysis using antibodies against phospho-AKT (pAKT; Ser-473), total AKT (AKT), HIF-1 , and GAPDH, respectively. C and D, effects of
resveratrol and PD98059 on MAPK activation and HIF-1α expression. Serum-starved
A2780/CP70 and OVCAR-3 cells were pretreated with solvent alone, various doses of
resveratrol, or 50 µM PD98059 for 30 min, followed by incubation with 200 ng/ml IGF-1 for 6 h
as indicated. Cell lysates were subjected to immunoblotting analysis using antibodies against
phospho-p42/p44 MAPK (p-MAPK; extracellular signal-regulated kinase 1/2), total MAPK
(MAPK), HIF-1 , and GAPDH, respectively.
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Fig. 8. Effect of resveratrol on phosphorylation of p70S6K1, S6 ribosomal protein, 4E-BP1,
and eIF4E. A, serum-starved A2780/CP70 and OVCAR-3 cells were pretreated with solvent
alone (Lanes 1 and 2) or various doses of resveratrol (RES), 20 µM LY294002 (LY), 25 nM
rapamycin (RAP), or 50 µM PD98059 (PD) for 30 min, followed by incubation with 200 ng/ml
IGF-1 for 6 h. Cell lysates were analyzed by immunoblotting using antibodies specific for
phospho-p70S6K1 (p-p70S6K1; Thr-421/Ser-424) and total p70S6K1. B, protein samples from
cells treated as described above were analyzed by immunoblotting using specific antibodies
against phospho-S6 ribosomal protein (Ser-235/236) and GAPDH. C, serum-starved
A2780/CP70 and OVCAR-3 cells were pretreated with solvent alone or various doses of
resveratrol for 30 min, followed by incubation with 200 ng/ml IGF-1 for 6 h. Cell lysates were
analyzed by immunoblotting using antibodies specific for phospho-4E-BP1 (p-4E-BP1; Ser-65),
phospho-eIF4E (p-eIF4E; Ser-209), and GAPDH. D, A2780/CP70 and OVCAR-3 cells were
serum-starved overnight and then pretreated with 20 nM rapamycin for 30 min, followed by
exposure to 200 ng/ml IGF-1 for 6 h. Immunoblotting analysis was performed using anti-HIF-1α
and GAPDH, respectively.
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Fig. 9. Effect of resveratrol on HIF-1α protein stability. A, A2780/CP70 cells were cultured in
normal growth medium to 80% confluence. The cells were treated with solvent alone (CHX; top
panel) or 50 µM resveratrol (CHX + RES; bottom panel) for 1 h, followed by incubation with 100
µM cycloheximide from 0 to 30 min. Cell lysates were subjected to immunoblotting using
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antibodies against HIF-1α or GAPDH. B, intensity of HIF-1α protein signals obtained in A was
quantified using EagleSight densitometry software (Version 3.21; Stratagene). The HIF-1α
densitometry data were normalized to that of the control (Lane 1) and GAPDH levels. The plots
represented mean ± SD from three independent experiments. Calculation of HIF-1α half-life was
performed by the Regression program of Microsoft Excel 2000.
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Fig. 10. Resveratrol-induced HIF-1α protein degradation is mediated by the proteasome
pathway. A2780/CP70 and OVCAR-3 cells were pretreated with vehicle or 10 µM MG132 (MG)
for 30 min, followed by treatment with 25 or 50 µM resveratrol (RES) for 6 h. Whole-cell lysates
were subjected to immunoblotting analysis using antibodies against HIF-1α and GAPDH.
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Chapter 6

Summary and Conclusions
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This dissertation research focuses on the role of PI3K/Akt pathway in the regulation of both
physiological angiogenesis and tumor-induced angiogenesis. Ang1 is the second known factor
specific for endothelial cells that plays a distinct role in angiogenesis as compared to VEGF.
PI3K/Akt signaling has been recognized as the key signaling event modulating Ang1-induced
various angiogenic responses in endothelial cells, such as cell survival, migration, sprouting, and
tube formation (1-6). However, it remains unclear about the downstream targets of PI3K/Akt
pathway involved in regulating the function of Ang1. We found that the serine/thrionine kinase
p70S6K1 was potently activated by Ang1 treatment of human endothelial cells in a PI3Kdependent manner. To determine whether p70S6K1 modulates the angiogenic effects of Ang1,
p70S6K1 activity in HUVECs was modified by adenovirus-mediated expression of either a
dominant negative or a constitutively active mutant of p70S6K1. By performing multiple
classical in vitro angiogenesis assays, we clearly demonstrated that p70S6K1 is a novel
angiogenic mediator for Ang1-induced endothelial responses. Notably, modulation of p70S6K1
activity has significant effects on basal endothelial cell behaviors in addition to the effects on
Ang1-induced responses. Furthermore, Ang1 induces p70S6K1 activation through PI3K and
MAPK signaling pathways, which can also be initiated by many other angiogenic factors, such
as basic fibroblast growth factor (bFGF) and VEGF. Therefore, p70S6K1 may influence
angiogenesis induced by other angiogenic factors as well. To the best of our knowledge, this is
the first direct evidence that p70S6K1 is a mediator of angiogenesis. Limited recent studies
suggested that p70S6K1 might regulate angiogenesis because rapamycin inhibits VEGFstimulated HUVEC proliferation (7), and suppresses tumor angiogenesis in animal models(8).
However, rapamycin targets the p70S6K1 upstream kinase mTOR, which has other downstream
effectors such as 4EBP1(9). The rapamycin analog CCI-779 has been evaluated in phase I phase
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II studies for cancer treatment (10). Inhibition of mTOR showed very evident anti-cancer activity,
but the noticeable toxic effects remain a problem (9;10). The toxicity of mTOR inhibitors may be
due to the inhibition of multiple mTOR downstream effectors. Based on our findings, we
propose that selective targeting of p70S6K1 might be a more attractive strategy for anti-cancer
and anti-angiogenic therapy, because it may achieve similar therapeutic effects with less serious
toxicity as compared to mTOR inhibitors.
Another important focus of this dissertation research is tumor angiogenesis. Compelling
evidence has implicated COX-2 as a critical mediator of tumor development and progression,
primarily by inducing tumor angiogenesis (11;12). Increased COX-2 expression is frequently
detected in many human cancers especially colorectal cancer (11;13). However, the precise
factors and molecular mechanisms regulating COX-2 gene expression in human ovarian cancer
remain largely unknown. In this study, we showed that IGF-1 significantly upregulates COX-2
expression and PGE2 biosynthesis in human ovarian cancer cells. We further demonstrated that
IGF-1 activates PI3K, MAPK, and PKC signaling cascades, which were differentially involved
in the transcriptional and posttranscriptional regulation of COX-2 expression induced by IGF-1.
The significance of this finding is highlighted by recent epidemiological observations that
elevated levels of IGF-1 are associated with the risk of ovarian cancer development (14-17). Our
data suggest that the role of IGF-1 in ovarian carcinogenesis and progression may depend on the
activation of COX-2-related events.
Tumor angiogenesis involves complex interactions between multiple types of cells,
including cancer cells, endothelial cells, fibroblasts, inflammatory cells, and immune cells.
Among these cells, cancer cells and vascular endothelial cells are the key players in tumor
angiogenesis. Recently, PI3K/Akt pathway was found to be up-regulated in tumor-derived
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endothelial cells (18). However, there is no direct evidence about the functional significance of
endothelial PI3K/Akt signaling in tumor angiogenesis in vivo. To address this question, we
developed a chicken chorioallantoic membrane (CAM) tumor model system based on a recently
reported nude mouse model (19), in which human cancer cells were co-transplanted with human
microvascular endothelial cells by using a biodegradable sponge as a scaffold. In this model
system, tumor angiogenesis and growth will be predominantly determined by the direct
interactions between cancer cells and the implanted human endothelial cells within the defined
space of the biodegradable sponge. We found that while inhibition of PI3K or Akt activity in
endothelial cells had significantly inhibitory effects, upregulation of endothelial PI3K or Akt
activity exerted stimulatory effects on tumor angiogenesis and tumor growth in vivo. These data
suggest that PI3K/Akt pathway in tumor associated endothelial cells might be a good target for
designing novel anti-angiogenic therapy of cancer. By using the same model, we showed that
PI3K/Akt signaling in tumor cells is similarly important for angiogenesis and tumor growth in
vivo. Taken together, we demonstrated the important roles of PI3K/Akt signaling pathway in the
two key cellular compartments for tumor angiogenesis, suggesting that targeting PI3K/Akt
signaling in both tumor cells and endothelial cells may be more effective to control tumor
angiogenesis and tumor progression.
Cancer chemoprevention is defined as the use of natural or synthetic compounds to
prevent, suppress, or reverse the development of human cancer (20). Natural products from
plants have been expected to be the major sources for developing safer and more effective
chemopreventive agents. Resveratrol (trans-3,4,5'-Trihydroxystibene) is a representative of such
products that has been shown recently to function as a cancer chemopreventive agent by
influencing various aspects of carcinogenesis (21). It is noteworthy that no toxicity reports have
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been published with respect to resveratrol in animals even at very high doses (3,000 mg/kg diet
for 120 days in rats) (21). In this study, we demonstrated for the first time that resveratrol
dramatically inhibited HIF-1α and VEGF expression in human ovarian cancer cells (22),
providing a novel molecular mechanism for the anticancer effects of resveratrol. This finding
suggests a potential anti-angiogenic activity of resveratrol. Indeed, several recent studies clearly
showed that inhibition of tumor growth by resveratrol was associated with significant
suppression of tumor angiogenesis in animal models (23;24).
In summary, the work presented in this dissertation investigated the role of PI3K/Akt
pathway in various aspects of angiogenesis. The data from this research provide direct evidence
that the PI3K/Akt downstream target p70S6K1 is a novel angiogenic mediator in Ang1-induced
angiogenesis. The work also demonstrated that, in human ovarian cancer cells, PI3K/Akt
pathway, along with other parallel signaling events, regulates IGF-1-induced expression of
COX-2, which is an important player in tumor-induced angiogenesis. We developed a novel
chicken chorioallantoic membrane (CAM) tumor model system in which human cancer cells
were co-transplanted with microvascular endothelial cells by using a biodegradable sponge as a
scaffold. By utilizing this model, we demonstrated that PI3K and Akt activities in both
endothelial and tumor cells contribute equally to tumor angiogenesis and tumor growth. Finally,
we showed that the chemopreventive agent resveratrol potently inhibits HIF-1-mediated VEGF
expression in human ovarian cancer cells, which is partly due to its inhibitory effect on PI3K/Akt
pathway. These findings confirm the pivotal roles of PI3K/Akt pathway in various aspects of
angiogenesis, suggesting that the PI3K/Akt pathway might be a potential target for angiogenesisbased therapy.
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Appendix: Detailed Methods

1. Adenovirus preparation

Recombinant adenoviruses were made by using the AdEasy system (generously provided
by Dr. Bert Vogelstein at Johns Hopkins University). Briefly, the cDNA constructs were
subcloned into the shuttle vector pAdTrack-CMV, the shuttle plasmids was then
linearized with Pme I. The Pme I-digested shuttle plasmid was transformed into
electrocompetent Adeasier-1 cells (E. coli BJ5183 cells pretransformed with adenoviral
backbone vector) by electroporation. Pick up smallest colonies that potentially contain
the recombinant adenoviral plasmid. Perform minipreps using the conventional alkaline
lysis method, and restriction digest DNA with Pac I to confirm correct recombinants. Retransform of the correct recombinant miniprep DNA into DH10B E Coli cells. Plasmids
are purified by CsCl-banding. Linearize the recombinant adenoviral plasmids with Pac I,
perform standard transfection of 293 cells with Lipofectamine. Virus production was
monitored by checking GFP expression. Scrape cells off flasks with a rubber policeman
about one week post-transfection. Release viruses by performing four cycles of
freeze/thaw/vortex. Use the crude virus supernatant to infect 293 cells, collect cells and
prepare virus as described above. Perform two more rounds of infection to amplify the
virus. Infect the cells of interest with the virus, and perform Western blotting to confirm
the effectiveness of the recombinant adenoviruses. To prepare high titer viral stock,
Infect 15 to 20 10-cm plates of 293 cells with the virus sup at a multiplicity of infection
(MOI) of 5 to 10 PFU per cell. When all cells have rounded up and about half of the cells
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are detached (usually at 3 to 4 days post infection), harvest and combine all the cells.
Prepare virus and purify the virus stock by cesium chloride gradient centrifugation. Viral
titers were determined by using the BD Adeno-X™ Rapid Titer Kit (BD Biosciences
Clontech, Mountain View, CA) per the manufacturer’s instructions. Briefly, 293 cells
were infected with serial dilutions of viral supernatant for 24 h, and virus infection was
determined by monitoring the expression of Adenoviral protein hexon with
immunohistochemical staining.

2. Endothelial tube formation assay

Matrigel (Becton Dickinson) capillary-tube-formation assay was performed to study in
vitro angiogenesis. Briefly, human endothelial cells (HUVEC or HMVEC cells) were
grown to about 80% confluence. The cells washed twice with 1×PBS and serum-starved
in basal medium overnight (about 16 h). Cells were trypsinized and resuspended in basal
medium at a concentration of 1 ×105 cells/ml. 100 µl (10,000 cells/well) of the cell
suspension was seeded in a 96-well tissue culture plate which had been evenly coated
with growth factor-reduced Matrigel (BD Labware, Bedford, MA). Seeded cells were
incubated at 37 °C in a 5% CO2 incubator for 12~24 h. Tube structures was examined
under phase-contrast microscopy and photographed using an Olympus imaging system
(Olympus, Thornwood, NY, USA). Tube formation was quantified by calculating the
average tube length per high power field (200×) from five randomly selected fields.
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3. Biodegradable sponge fabrication

The bioabsorbable polymer scaffolds were prepared following a particulate leaching
technique. Briefly, PLGA (85% d,l-lactide/15%glycolide, Medisorb, Cincinnati, Ohio)
was dissolved in chloroform to yield a solution of 5% polymer. The solution was loaded
into a Teflon dishes packed with sodium chloride particles which was sieved to a size
between 250 and 500 μm. The solvent was allowed to evaporate and the salt was leached
by immersing the films in distilled water with several changes.

Sponges were

subsequently coated with polyvinyl alcohol (PVA, Aldrich Chem. Co., Milwaukee, WI)
by immersing them for 16 h in an aqueous solution containing 10 mg/mL of PVA in PBS.
The sponges were removed from the solution, dried, and were cut to 6 ×6 ×1 mm in size.
The day before transplantation, sponges were disinfected by soaking in 100% ethanol for
2 hours, followed by washing twice in PBS.

4. Survival surgery to co-transplant human endothelial and cancer cells in nude mice
to study tumor angiogenesis

Just before transplantation, 0.9 x 106 endothelial cells were mixed with 0.1 x 106 A2780
ovarian cancer cells by resuspending in a 1:1 mixture of basal medium and growth factorreduced Matrigel (BD Labware, Bedford, MA). The cell mixture was absorbed into a
piece of PLGA sponge. The sponge was incubated for 30 minutes at 37° C to allow for
gelation of the Matrigel. Female nude mice (3 to 4 weeks old, CB.17. nude, Taconic,
Germantown, NY) were anesthetized with pentobarbital (0.05 mg/g body weight). A 0.5
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cm-long dorsal incision was made, and two sponges were implanted subcutaneously on
the right and left flank regions of each mouse. 21 days after transplantation, mice were
euthanized and the implants were retrieved, immediately measured with calipers, and
weighed in an electronic balance. The tumor tissues were fixed overnight in Bouin’s
solution and processed for histological examination. The care and treatment of
experimental animals was in accordance with West Virginia University Animal Care and
Use Committee Policy for Survival Surgery on Rodents.

5. Co-transplantation of human endothelial and cancer cells in chicken chorioallantoic
membrane (CAM) to study tumor angiogenesis

Fertilized chicken eggs (standard pathogen free grade; SPAFAS, Preston, CT) were
incubated for 7 d at 37°C in a humidified atmosphere. An artificial air sac was created
over the well-formed chicken chorioallantoic membrane (CAM). A 1.0 × 1.0-cm square
window was cut in the shell over the artificial air sac and sealed with Scotch® tape. On
the next day, a piece of PLGA sponge loaded with cell mixture was put on the exposed
CAM. The eggshell window was resealed and the embryo was maintained at 37°C in a
humidified atmosphere. 11 days after implantation, the eggshell window was opened and
the remaining eggshell was removed to retrieve the implants. The tumor was trimmed to
remove attached CAM tissues and was immediately measured with calipers, and weighed
in an electronic balance. The tumor tissues were fixed overnight in Bouin’s solution and
processed for histological examination.
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6. Immuonohistochemical Staining of CD31 and quantification of tumor angiogenesis
Microvessels inside tumor tissues were visualized by immuonohistochemical staining of
the vascular endothelial marker CD31. Tissue sections were deparaffinized and
rehydrated following standard protocol. Antigen retrieval was performed by heating the
tissue section in a microwave oven to 89ºC for 10 min in BD PharmingenTM Retrievagen
A solution (pH 6.5). The sections were then incubated at 4ºC overnight with a 1:40
diluted monoclonal mouse antihuman CD31 antibody (Clone JC/70A, DakoCytomation
California Inc., Carpinteria, CA). Sections were incubated with appropriate secondary
antibodies, and visualization of the complex was accomplished using an ABC staining kit
(Santa Cruz Biotechnology, Santa Cruz, CA). The sections were counterstained with
haematoxylin, dehydrated and mounted. The same procedure without primary antibody
was included as a negative control.
Tumor angiogenesis was quantified by calculating the microvessel density
(MVD). Since microvessels are distributed heterogeneously throughout the tumor, two to
four sections from each tumor were scanned under low-power magnification (x40) to
identify areas of highest CD31-positive vessel density (hot-spots). Then 5 high-power
fields (400x) were randomly chosen from each section to count for the number of CD31positive microvessels. All of the areas in which cells were stained with the endothelial
cell marker CD31 were considered as a microvessel in spite of their size or morphology.
Data were collected by two independent observers without knowledge of which tumors
were viewed. MVD was defined as the total number of microvessels per 200x field
(mean± SE).
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7. Immunoblotting

The cells were washed once with ice-cold phosphate-buffered saline (140 mM NaCl, 3
mM KCl, 6 mM Na2HPO4, 1 mM KH2PO4, PH 7.4), scrapped and pelleted by
centrifugation. Whole cell extracts were prepared by incubating the cells on ice for 15
min in a modified radioimmune precipitation buffer (100 mM Tris, 100mM NaCl, 5 mM
EDTA, 1% Triton X-100, 1% deoxycholate acid, 0.1% SDS, 2 mM phenylmethylsulfonyl
fluoride, 1 mM sodium orthovanadate, 2 mM DTT, 20 μg/ml leupeptin 20 μg/ml
pepstatin 20 μg/ml, PH 7.4). Cell lysates were clarified by centrifugation at 15000 rpm
for 15 min. Protein concentrations of the lysates were determined using a protein assay
reagent (Bio-Rad). 25~50 μg of protein samples were fractionated by 8-10% SDS-PAGE,
transferred to a nitrocellulose membrane (Schleicher & Schuell Bisciences, Keene, NH),
and subjected to immunoblotting analysis. Primary antibodies were appropriately diluted
in a blocking buffer (1× TBS-T: 20 mM Tris, PH 7.4, 137 mM NaCl, 0.1% Tween-20)
containing 5% nonfat dry milk or 5% bovine serum albumin. The blots were blocked in
1× TBS-T buffer containing 5% nonfat dry milk for 2 h at room temperature, followed by
incubation with the appropriately diluted primary antibodies overnight at 4°C.
Immunoreactivity was visualized with horseradish peroxidase-conjugated secondary
antibodies and enhanced chemiluminescence (PerkinElmer Life Sciences, Boston, MA).
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8. PKC kinase activity assay

Protein samples were prepared by lysing the cells in a PKC extraction buffer (50 mM
HEPES, pH 7.5, 150 mM NaCl, 0.1% Tween 20, 1 mM EDTA, 2.5 mM EGTA, 10%
glycerol) supplemented with protease inhibitors (10 µg/ml of aprotinin, 10 µg/ml of
leupeptin, 0.1 mM phenylmethylsulfonyl fluoride) and phosphatase inhibitors (1 mM NaF,
0.1 mM Na3VO4). 200 µg of the cellular extracts was diluted to 500 µl in 1×PBS. PKC
proteins were immunoprecipitated with 2 µg of the anti-phospho-PKC (pan) antibody
(beta II, Ser660, Cell Signaling Technology, Beverly, MA). The kinase activity assay was
performed in 40 µl of PKC reaction buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2,
1 mM dithiothreitol, 2.5 mM EGTA, 1 mM NaF, 0.1 mM Na3VO4, 10 µM ATP)
containing 1 µg of the substrate myelin basic protein and 5 µCi of [γ-32P]ATP. The
reactions were performed at 30°C for 20 min, and terminated by adding SDS-PAGE
sample buffer. Reaction products were analyzed by SDS-PAGE and visualized by
autoradiography. The radioactive bands were excised and quantified by liquid
scintillation counting. The activity of PKC is expressed as counts per min per 200 µg of
protein.
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